

UNITEDHEALTHCARE® COMMUNITY PLAN: RADIOLOGY IMAGING COVERAGE DETERMINATION GUIDELINE

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only)

V2.0.2024

Guideline Number: CSRAD013OH.C

Effective Date: November 15, 2024

Application (for Ohio Only)

This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.CPage 1 of 162UnitedHealthcare Community Plan Coverage Determination GuidelineEffective: November 15, 2024

Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Table of Contents

Guideline

**Related Community Plan Policies Application (For Ohio Only)** Guideline Development (Preface-1) Benefits, Coverage Policies, and Eligibility Issues (Preface-2) **Clinical Information (Preface-3)** Coding Issues (Preface-4) Whole-Body Imaging (Preface-5) **References (Preface-6) Copyright Information (Preface-7) Trademarks (Preface-8) General Information Genetic Predisposition to Arterial Disease Cerebrovascular Imaging Aortic Imaging Peripheral Arterial Imaging** Venous Imaging **Policy History and Instructions for Use** 

V2.0.2024

# Related Community Plan Policies

#### Guideline

**Related Community Plan Policies** 

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 3 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Related Community Plan Policies**

## Related Community Plan Policies v2.0.2024

**General Policies** 

Cardiac Imaging Guidelines

**Pediatric Policies** 

- Pediatric Peripheral Vascular Disease (PVD) Imaging Guidelines
- Pediatric Cardiac Imaging Guidelines

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 4 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Application (For Ohio Only)

#### Guideline

Application (For Ohio Only)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 5 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Application (For Ohio Only)**

## **Application for Ohio OH UHC**

### v2.0.2024

• This Medical Policy only applies to the state of Ohio. Any requests for services that are stated as unproven or services for which there is a coverage or quantity limit will be evaluated for medical necessity using Ohio Administrative Code 5160-1-01.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 6 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Guideline Development (Preface-1)

#### Guideline

Guideline Development (Preface-1.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 7 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Guideline Development (Preface-1.1)**

## PRF.GG.0001.1.UOH

#### v2.0.2024

- The UnitedHealthcare's evidence-based, proprietary clinical guidelines evaluate a range of advanced imaging and procedures, including NM, US, CT, MRI, PET, Radiation Oncology, Sleep Studies, as well as Cardiac, musculoskeletal and Spine interventions.
- UnitedHealthcare reserves the right to change and update the guidelines. The guidelines undergo a formal review annually. UnitedHealthcare's guidelines are based on current evidence supported by major national and international association and society guidelines and criteria, peer-reviewed literature, major treatises as well as, input from health plans, and practicing academic and community-based physicians.
- These guidelines are not intended to supersede or replace sound medical judgment, but instead, should facilitate the identification of the most appropriate imaging or other designated procedure given the individual's clinical condition. These guidelines are written to cover medical conditions as experienced by the majority of individuals. However, these guidelines may not be applicable in certain clinical circumstances, and physician judgment can override the guidelines.
- These guidelines provide evidence-based, clinical benefits with a focus on health care quality and patient safety.
- Clinical decisions, including treatment decisions, are the responsibility of the individual and his/her provider. Clinicians are expected to use independent medical judgment, which takes into account the clinical circumstances to determine individual management decisions.
- UnitedHealthcare supports the Choosing Wisely initiative (https:// www.choosingwisely.org/) by the American Board of Internal Medicine (ABIM) Foundation and many national physician organizations, to reduce the overuse of diagnostic tests that are low value, no value, or whose risks are greater than the benefits.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 8 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Benefits, Coverage Policies, and Eligibility Issues (Preface-2)

Guideline

Benefits, Coverage Policies, and Eligibility Issues (Preface-2.1) References (Preface-2)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 9 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Benefits, Coverage Policies, and Eligibility Issues (Preface-2.1)

PRF.BC.0002.1.UOH v2.0.2024

#### Investigational and Experimental Studies

- Certain studies, treatments, procedures, or devices may be considered experimental, investigational, or unproven for any condition, illness, disease, injury being treated if one of the following is present:
  - if there is a paucity of supporting evidence;
  - if the evidence has not matured to exhibit improved health parameters;
  - if clinical utility has not been demonstrated in any condition; OR
  - if the study, treatment, procedure, or device lacks a collective opinion of support
- Supporting evidence includes standards that are based on credible scientific evidence
  published in peer-reviewed medical literature (such as well conducted randomized
  clinical trials or cohort studies with a sample size of sufficient statistical power)
  generally recognized by the relevant medical community. Collective opinion of
  support includes physician specialty society recommendations and the views of
  physicians practicing in relevant clinical areas when physician specialty society
  recommendations are not available.

#### **Clinical and Research Trials**

- Similar to investigational and experimental studies, clinical trial imaging requests will be considered to determine whether they meet UnitedHealthcare's evidence-based guidelines.
- Imaging studies which are inconsistent with established clinical standards, or are requested for data collection and not used in direct clinical management are not supported.

#### **Legislative Mandate**

• State and federal legislations may need to be considered in the review of advanced imaging requests.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 10 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **References (Preface-2)**

#### v2.0.2024

1. Coverage of Clinical Trials under the Patient Protection and Affordable Care Act; 42 U.S.C.A. § 300gg-8.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 11 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Clinical Information (Preface-3)

Guideline

Clinical Information (Preface-3.1) References (Preface-3)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 12 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Clinical Information (Preface-3.1)**

## PRF.CL.0003.1.UOH v2.0.2024

#### **Clinical Documentation and Age Considerations**

- UnitedHealthcare's guidelines use an evidence-based approach to determine the most appropriate procedure for each individual, at the most appropriate time in the diagnostic and treatment cycle. UnitedHealthcare's guidelines are framed by:
  - · Clinical presentation of the individual, rather than the studies requested
  - Adequate clinical information that must be submitted to UnitedHealthcare in order to establish medical necessity for advanced imaging or other designated procedures includes, but is not limited to, the following:
    - Pertinent clinical evaluation should include a recent detailed history, physical examination<sup>20</sup> since the onset or change in symptoms, and/or laboratory and prior imaging studies.
      - Condition-specific guideline sections may describe additional clinical information which is required for a pertinent clinical evaluation.
      - The Spine and Musculoskeletal guidelines require x-ray studies from when the current episode of symptoms has started or changed; x-ray imaging does not have to be within the past 60 days.
      - Advanced imaging or other designated procedures should not be ordered prior to clinical evaluation of an individual by the physician treating the individual. This may include referral to a consultant specialist who will make further treatment decisions.
      - Other meaningful technological contact (telehealth visit, telephone or video call, electronic mail or messaging) since the onset or change in symptoms by an established individual can serve as a pertinent clinical evaluation.
        - Some conditions may require a face-to-face evaluation as discussed in the applicable condition-specific guideline sections.
    - A recent clinical evaluation may be unnecessary if the individual is undergoing a guideline-supported, scheduled follow-up imaging or other designated procedural evaluation. Exceptions due to routine surveillance indications are addressed in the applicable condition-specific guideline sections.
  - UnitedHealthcare's evidence-based approach to determine the most appropriate procedure for each individual requires submission of medical records pertinent to the requested imaging or other designated procedures.
- Many conditions affecting the pediatric population are different diagnoses than those occurring in the adult population. For those diseases which occur in both pediatric and adult populations, minor differences may exist in management due to individual

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 13 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

age, comorbidities, and differences in disease natural history between children and adults.

- Individuals who are 18 years old or younger<sup>19</sup> should be imaged according to the Pediatric Imaging Guidelines if discussed in the condition-specific guideline sections. Any conditions not specifically discussed in the Pediatric Imaging Guidelines should be imaged according to the General Imaging Guidelines. Individuals who are >18 years old should be imaged according to the General Imaging Guidelines, except where directed otherwise by a specific guideline section.
- The terms "male" and "female" used in these guidelines refer to anatomic-specific diseases and disease predispositions associated with the individual's sex assigned at birth rather than their gender identity. It should be noted that gender identity and anatomic-specific diseases as well as disease predispositions are not always linked. As such, these guidelines should be applied to the individual's corresponding known or suspected anatomic-specific disease or disease predisposition. At UnitedHealthcare, we believe that it is important to understand how all individuals, including those who are gender-diverse, choose to identify themselves. To ensure that gender-diverse individuals are treated with respect and that decisions impacting their healthcare are made correctly and with sensitivity, UnitedHealthcare recognizes all individuals with the following gender marker options: Male, Female, Transgender Male, Transgender Female, "X", and "Not Specified."

### **General Imaging Information**

- "Standard" or "conventional" imaging is most often performed in the initial and subsequent evaluations of malignancy. Standard or conventional imaging includes plain film, CT, MRI, or US.
  - Often, further advanced imaging is needed when initial imaging, such as ultrasound, CT, or MRI does not answer the clinical question. Uncertain, indeterminate, inconclusive, or equivocal may describe these situations.
- Appropriate use of contrast is a very important component of evidence-based advanced imaging use.
  - The appropriate levels of contrast for an examination (i.e., without contrast, with contrast, without and with contrast) is determined by the evidence-based guidance reflected in the condition-specific guideline sections.
  - If, during the performance of a non-contrast imaging study, there is the unexpected need to use contrast in order to evaluate a possible abnormality, then that is appropriate.<sup>1</sup>

### Ultrasound

- Diagnostic ultrasound uses high-frequency sound waves to evaluate soft tissue structures and vascular structures utilizing grey scale and Doppler techniques.
- Ultrasound allows for dynamic real-time imaging at the bedside.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 14 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- Ultrasound is limited in areas where there is dense bone or other calcification.
- Ultrasound also has a relatively limited imaging window so may be of limited value in evaluating very large abnormalities.
- In general, ultrasound is highly operator-dependent, and proper training and experience are required to perform consistent, high-quality evaluations.
- Indications for ultrasound may include, but are not limited to, the following:
  - Obstetric and gynecologic imaging
  - Soft tissue and visceral imaging of the chest, abdomen, pelvis, and extremities
  - Brain and spine imaging when not obscured by dense bony structures
  - Vascular imaging when not obscured by dense bony structures
  - Procedural guidance when not obscured by dense bony structures
  - Initial evaluation of ill-defined soft tissue masses or fullness and differentiating adenopathy from mass or cyst. Prior to advanced imaging, ultrasound can be very beneficial in selecting the proper modality, body area, image sequences, and contrast level that will provide the most definitive information for the individual.
- More specific guidance for ultrasound usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

## Computed Tomography (CT)

- The AMA CPT<sup>®</sup> manual does not describe nor assign any minimum or maximum number of sequences for any CT study. CT imaging protocols are often influenced by the individual's clinical situation and additional sequences are not uncommon. There are numerous CT protocols that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
- CT utilizes ionizing radiation to create cross-sectional and volumetric images of the body.
  - Advantages over ultrasound include a much larger field of view and faster completion time in general. Disadvantages compared to ultrasound include lack of portability and exposure to ionizing radiation.
  - Advantages over MRI include faster imaging and a more spacious scanner area limiting claustrophobia. Disadvantages compared to MRI include decreased soft tissue definition, especially with non-contrast imaging, and exposure to ionizing radiation.
- CT can be performed without, with, or without and with intravenous (IV) contrast depending on the clinical indication and body area.
  - In general, non-contrast imaging is appropriate for evaluating structures with significant tissue density differences such as lung parenchyma and bony structures, or when there is a contraindication to contrast.
  - In general, CT with contrast is the most common level of contrast and can be used when there is need for improved vascular or soft tissue resolution, including better

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 15 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
0, 0, 0	

characterization of known or suspected malignancy, as well as infectious and inflammatory conditions.

- CT without and with contrast has a limited role as the risks of doubling the ionizing radiation exposure rarely outweigh the benefits of multiphasic imaging, though there are some exceptions which include, but are not limited to, the following:
  - Characterization of a mass
  - Characterization of arterial and venous anatomy
  - CT with contrast may be used to better characterize findings on a very recent (within two weeks) inconclusive non-contrast CT where the guidelines would support CT without and with contrast.
- More specific guidance for CT contrast usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.
- Shellfish allergy:
  - It is commonly assumed that an allergy to shellfish indicates iodine allergy, and that this implies an allergy to iodinated contrast media used with CT. However, this is NOT true. Shellfish allergy is due to tropomyosins. Iodine plays no role in these allergic reactions. Allergies to shellfish do not increase the risk of reaction to iodinated contrast media any more than that of other allergens.<sup>1</sup>
- Enteric contrast (oral or rectal) is sometimes used in abdominal imaging. There is no specific CPT<sup>®</sup> code which refers to enteric contrast.
- The appropriate contrast level and anatomic region in CT imaging is specific to the clinical indication, as listed in the condition-specific guideline sections.
- CT should not be used to replace MRI in an attempt to avoid sedation unless it is listed as a recommended study the appropriate condition-specific guideline.
- There are significant potential adverse effects associated with the use of iodinated contrast media. These include hypersensitivity reactions, thyroid dysfunction, and contrast-induced nephropathy (CIN). Individuals with impaired renal function are at increased risk for CIN.<sup>2</sup>
- Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR <30 mL/min).
- The use of CT contrast should proceed with caution in pregnant and breastfeeding individuals. There is a theoretical risk of contrast toxicity to the fetal and infant thyroid. The procedure can be performed if the specific need for that contrast-enhanced procedure outweighs risk to the fetus. Breastfeeding individuals may reduce this risk by choosing to pump and discard breast milk for 12-24 hours after the contrast injection.
- CT without contrast may be appropriate if clinical criteria for CT with contrast are met AND the individual has:
  - Elevated blood urea nitrogen (BUN) and/or creatinine
  - Renal insufficiency
  - Allergies to iodinated contrast

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 16 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024

- Thyroid disease which could be treated with I-131
- Diabetes
- Very elderly
- Urgent or emergent settings due to availability
- Trauma
- CT is superior to other imaging modalities in certain conditions including, but not limited to, the following:
  - Screening following trauma
  - Imaging pulmonary disease
  - Imaging abdominal and pelvic viscera
  - Imaging of complex fractures
  - Evaluation of inconclusive findings on Ultrasound or MRI, or if there is a contraindication to MRI
- More specific guidance for CT usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

### Magnetic Resonance Imaging (MRI)

- The AMA CPT<sup>®</sup> manual does not describe nor assign any minimum or maximum number of sequences for any MRI study. MRI protocols are often influenced by the individual's clinical situation and additional sequences are not uncommon. There are numerous MRI sequences that may be performed to evaluate specific clinical questions, and this technology is constantly undergoing development.
- Magnetic Resonance Imaging (MRI) utilizes the interaction between the intrinsic radiofrequency of certain molecules in the body (hydrogen in most cases) and a strong external magnetic field.
  - MRI is often superior for advanced imaging of soft tissues and can also define physiological processes in some instances (e.g., edema, loss of circulation [AVN], and increased vascularity [tumors]).
  - MRI does not use ionizing radiation and even non-contrast images have much higher soft tissue definition than CT or Ultrasound.
  - MRI typically takes much longer than either CT or Ultrasound, and for some individuals may require sedation. It is also much more sensitive to individual motion that can degrade image quality than either CT or Ultrasound.
- MRI Breast and MRI Chest are not interchangeable, as they focus detailed sequences on different adjacent body parts.
- MRI may be utilized either as the primary advanced imaging modality, or when further definition is needed based on CT or ultrasound imaging.
- Most orthopedic and dental implants are not magnetic. These include hip and knee replacements; plates, screws, and rods used to treat fractures; and cavity fillings. Yet,

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 17 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

<ul> <li>all of these metal implants can distort the MRI image if near the part of the body beir scanned.</li> <li>Other implants, however, may have contraindications to MRI. These include the following: <ul> <li>Pacemakers</li> <li>ICD or heart valves</li> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> </ul> </li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> </ul> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolin</li>	Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
<ul> <li>all of these metal implants can distort the MRI image if near the part of the body beir scanned.</li> <li>Other implants, however, may have contraindications to MRI. These include the following: <ul> <li>Pacemakers</li> <li>ICD or heart valves</li> <li>Metal implants in the brain</li> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> </ul> </li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in ind</li></ul>		
<ul> <li>Other implants, however, may have contraindications to MRI. These include the following:         <ul> <li>Pacemakers</li> <li>ICD or heart valves</li> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> </ul> </li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL</li></ul>	all of these metal implants can distort the MRI image if near the pa scanned.	art of the body being
<ul> <li>Pacemakers</li> <li>ICD or heart valves</li> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (EDA) has noted that there is currently not</li></ul>	<ul> <li>Other implants, however, may have contraindications to MRI. The following:</li> </ul>	hese include the
<ul> <li>ICD or heart valves</li> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of in</li></ul>	<ul> <li>Pacemakers</li> </ul>	
<ul> <li>Metal implants in the brain</li> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition foll</li></ul>	<ul> <li>ICD or heart valves</li> </ul>	
<ul> <li>Metal implants in the eyes or ears</li> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contras</li></ul>	<ul> <li>Metal implants in the brain</li> </ul>	
<ul> <li>Infusion catheters and bullets or shrapnel</li> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following th</li></ul>	<ul> <li>Metal implants in the eyes or ears</li> </ul>	
<ul> <li>CT can therefore be an alternative study to MRI in these scenarios.</li> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MR</li></ul>	<ul> <li>Infusion catheters and bullets or shrapnel</li> </ul>	
<ul> <li>The contrast level and anatomic region in MRI imaging is specific to the clinical indication, as listed in the specific guideline sections.</li> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies. <sup>3,4,5,6,7</sup></li> </ul>	<ul> <li>CT can therefore be an alternative study to MRI in these scenar</li> </ul>	rios.
<ul> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigational and experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup></li> <li>The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that cardinium certain in the brain is brancful and restriction</li> </ul>	<ul> <li>The contrast level and anatomic region in MRI imaging is specific t indication, as listed in the specific guideline sections.</li> </ul>	to the clinical
<ul> <li>experimental at this time. MRI with or with and without contrast in these guidelines refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup></li> <li>The U.S. Food and Drug Administration (FDA) has noted that there is currently no exidence to tha cardinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>MRI utilizing Xenon Xe 129 for contrast is considered investigation</li> </ul>	nal and
<ul> <li>refers to MRI utilizing gadolinium for contrast.</li> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>34,5,6,7</sup></li> <li>The U.S. Food and Drug Administration (FDA) has noted that there is currently not evidence to accordinium the prain is harmful and restricting the studies.</li> </ul>	experimental at this time. MRI with or with and without contrast in f	these guidelines
<ul> <li>MRI is commonly performed without, without and with contrast.</li> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup></li> </ul>	refers to MRI utilizing gadolinium for contrast.	
<ul> <li>Non-contrast imaging offers excellent tissue definition.</li> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently and restriction.</li> </ul>	<ul> <li>MRI is commonly performed without, without and with contrast.</li> </ul>	
<ul> <li>Imaging without and with contrast is commonly used when needed to better characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to surgeet that gadolinium retention in the brain is harmful and restriction.</li> </ul>	<ul> <li>Non-contrast imaging offers excellent tissue definition.</li> </ul>	
<ul> <li>characterize tissue perfusion and vascularization.</li> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>Imaging without and with contrast is commonly used when need</li> </ul>	ded to better
<ul> <li>Most contrast is gadolinium based and causes T2 brightening of the vascular and extracellular spaces.</li> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup></li> <li>The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that candolinium retention in the brain is harmful and restriction</li> </ul>	characterize tissue perfusion and vascularization.	
<ul> <li>Some specialized gadolinium and non-gadolinium contrast agents are available and most commonly used for characterizing liver lesions.</li> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium reaction in the brain is harmful and restricting of the use of suggest that gadolinium reaction in the brain is harmful and restriction.</li> </ul>	<ul> <li>Most contrast is gadolinium based and causes T2 brightening and extracellular spaces.</li> </ul>	g of the vascular
<ul> <li>MRI with contrast only is rarely appropriate and is usually used to better characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently not exvidence to suggest that gadolinium retention in the brain is harmful and restriction.</li> </ul>	<ul> <li>Some specialized gadolinium and non-gadolinium contrast ag and most commonly used for characterizing liver lesions.</li> </ul>	gents are available,
<ul> <li>characterize findings on a recent inconclusive non-contrast MRI, commonly called a completion study.</li> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restriction.</li> </ul>	<ul> <li>MRI with contrast only is rarely appropriate and is usually used</li> </ul>	to better
<ul> <li>MRI contrast is contraindicated in pregnant individuals.</li> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is barmful and restriction</li> </ul>	characterize findings on a recent inconclusive non-contrast MRI a completion study.	l, commonly called
<ul> <li>More specific guidance for MRI contrast usage, including exceptions to this gener guidance, can be found throughout the condition-specific guidelines.</li> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>MRI contrast is contraindicated in pregnant individuals.</li> </ul>	
<ul> <li>MRI may be preferred in individuals with renal failure and in individuals allergic to intravenous CT contrast.</li> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently not evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>More specific guidance for MRI contrast usage, including excep guidance, can be found throughout the condition-specific guidel</li> </ul>	itions to this general lines.
<ul> <li>Both contrast CT and MRI may be considered to have the same risk profile with renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently not evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>MRI may be preferred in individuals with renal failure and in individ intravenous CT contrast.</li> </ul>	luals allergic to
<ul> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). The greater the exposure to gadolinium in individuals with a low GFR (especially if on dialysis), th greater the chance of individuals developing NSF.</li> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>Both contrast CT and MRI may be considered to have the same renal failure (GFR &lt;30 mL/min).<sup>2</sup></li> </ul>	erisk profile with
<ul> <li>Multiple studies have demonstrated potential for gadolinium deposition following the use of gadolinium-based contrast agents (GBCAs) for MRI studies.<sup>3,4,5,6,7</sup> The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restriction</li> </ul>	<ul> <li>Gadolinium can cause Nephrogenic Systemic Fibrosis (NSF). T exposure to gadolinium in individuals with a low GFR (especially greater the chance of individuals developing NSF.</li> </ul>	he greater the y if on dialysis), the
The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadelinium retention in the brain is harmful and restriction	<ul> <li>Multiple studies have demonstrated potential for gadolinium dep the use of gadolinium-based contrast agents (GBCAs) for MRI st</li> </ul>	oosition following studies. <sup>3,4,5,6,7</sup>
evidence to suggest that gadelinium retention in the brain is harmful and restriction	The U.S. Food and Drug Administration (FDA) has noted that the	nere is currently no
	evidence to suggest that gadolinium retention in the brain is har	mful and restricting

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Onio Only): CSRAD013OH.C Page 18 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

gadolinium-based contrast agents (GBCAs) use is not warranted at this time. It has been recommended that GBCA use should be limited to circumstances in which additional information provided by the contrast agent is necessary and the necessity of repetitive MRIs with GBCAs should be assessed.<sup>8</sup>

- A CT may be approved in place of an MRI when clinical criteria are met for MRI AND there is a contraindication to having an MRI (pacemaker, ICD, insulin pump, neurostimulator, etc.).
  - When replacing MRI with CT, contrast level matching should occur as follows:
    - MRI without contrast  $\rightarrow$  CT without contrast
    - MRI without and with contrast  $\rightarrow$  CT with contrast or CT without and with contrast
- The following situations may impact the appropriateness for MRI and or MR contrast:
  - Caution should be taken in the use of gadolinium in individuals with renal failure.
  - The use of gadolinium contrast agents is contraindicated during pregnancy unless the specific need for that procedure outweighs risk to the fetus.
  - MRI can be performed for non-ferromagnetic body metals (i.e., titanium), although some imaging facilities will consider it contraindicated if recent surgery, regardless of the metal type.
- MRI should not be used as a replacement for CT for the sole reason of avoidance of ionizing radiation when MRI is not supported in the condition-based guidelines, since it does not solve the problem of overutilization.
- MRI is superior to other imaging modalities in certain conditions including, but not limited to, the following:
  - Imaging the brain and spinal cord
  - · Characterizing visceral and musculoskeletal soft tissue masses
  - · Evaluating musculoskeletal soft tissues including ligaments and tendons
  - Evaluating inconclusive findings on ultrasound or CT
  - Individuals who are pregnant or have high radiation sensitivity
  - Suspicion, diagnosis, or surveillance of infections
- More specific guidance for MRI usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

## Positron Emission Tomography (PET)

- PET is a nuclear medicine study that uses a positron emitting radiotracer to create cross-sectional and volumetric images based on tissue metabolism.
- Conventional imaging (frequently CT, sometimes MRI or bone scan) of the affected area(s) drives much of initial and restaging and surveillance imaging for malignancy and other chronic conditions. PET is not indicated for surveillance imaging unless specifically stated in the condition-specific guideline sections.
- PET/MRI is generally not supported, see **PET-MRI (Preface-5.3)**.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 19 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- PET is rarely performed as a single modality, but is typically performed as a combined PET/CT.
  - The unbundling of PET/CT into separate PET and diagnostic CT CPT<sup>®</sup> codes is not supported, because PET/CT is done as a single study.
- PET/CT lacks the tissue definition of CT or MRI, but is fairly specific for metabolic activity based on the radiotracer used.
- Indications for PET/CT may include the following:
  - Oncologic Imaging for evaluation of tumor metabolic activity
  - · Cardiac Imaging for evaluation of myocardial metabolic activity
  - Brain Imaging for evaluation of metabolic activity for procedural planning
- More specific guidance for PET usage, including exceptions to this general guidance, can be found throughout the condition-specific guidelines.

## **Overutilization of Advanced Imaging**

- A number of recent reports describe overutilization in many areas of advanced imaging and other procedures, which may include the following:
  - High-level testing without consideration of less invasive, lower cost options which may adequately address the clinical question at hand
  - Excessive radiation and costs with unnecessary testing
  - Defensive medical practice
  - CT without and with contrast (so called "double contrast studies") requests, which have few current indications
  - MRI requested in place of CT to avoid radiation without considering the primary indication for imaging
  - Adult CT settings and protocols used for smaller people and children
  - Unnecessary imaging procedures when the same or similar studies have already been conducted
- A review of the imaging or other relevant procedural histories of all individuals
  presenting for studies has been recognized as one of the more important processes
  that can be significantly improved. By recognizing that a duplicate or questionably
  indicated examination has been ordered for individuals, it may be possible to avoid
  exposing them to unnecessary risks.<sup>9,10</sup> To avoid these unnecessary risks, the
  precautions below should be considered:
  - The results of initial diagnostic tests or radiologic studies to narrow the differential diagnosis should be obtained prior to performing further tests or radiologic studies.
  - The clinical history should include a potential indication such as a known or suspected abnormality involving the body part for which the imaging study is being requested. These potential indications are addressed in greater detail within the applicable guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 20 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology	/ Imaging Guidelines	
------------------------------	----------------------	--

- The results of the requested imaging procedures should be expected to have an impact on individual management or treatment decisions.
- Repeat imaging studies are not generally necessary unless there is evidence of disease progression, recurrence of disease, and/or the repeat imaging will affect an individual's clinical management.
- Pre-operative imaging/pre-surgical planning imaging/pre-procedure imaging is not indicated if the surgery/procedure is not indicated. Once the procedure has been approved or if the procedure does not require prior authorization, the appropriate preprocedural imaging may be approved.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 21 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **References (Preface-3)**

#### v2.0.2024

- 1. Bettmann MA. Frequently Asked Questions: Iodinated Contrast Agents. *RadioGraphics*. 2004;24(suppl\_1):S3-S10. doi: 10.1148/rg.24si045519.
- 2. Andreucci M, Solomon R, Tasanarong A. Side Effects of Radiographic Contrast Media: Pathogenesis, Risk Factors, and Prevention. *BioMed Res Int*. 2014;2014:1-20. doi: 10.1155/2014/741018.
- McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. *Radiology*. 2015;275(3):772-782. doi: 10.1148/radiol.15150025.
- Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material. *Radiology*. 2014;270(3):834-841. doi: 10.1148/radiol.13131669.
- Olchowy C, Cebulski K, Łasecki M, et al. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review. Mohapatra S, ed. *PLOS ONE*. 2017;12(2):e0171704. doi: 10.1371/journal.pone.0171704.
- Ramalho J, Castillo M, AlObaidy M, et al. High Signal Intensity in Globus Pallidus and Dentate Nucleus on Unenhanced T1-weighted MR Images: Evaluation of Two Linear Gadolinium-based Contrast Agents. *Radiology*. 2015;276(3):836-844. doi:10.1148/radiol.2015150872.
- Radbruch A, Weberling LD, Kieslich PJ, et al. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents. *Invest Radiol.* 2016;51(11):683-690. doi: 10.1097/rli.00000000000308.
- 8. FDA Warns That Gadolinium-Based Contrast Agents (GBCAs) Are Retained in the Body; Requires New Class Warnings. https://www.fda.gov/media/109825/download.
- 9. Amis ES, Butler PF, Applegate KE, et al. American College of Radiology White Paper on Radiation Dose in Medicine. *J Am Coll Radiol.* 2007;4(5):272-284. doi: 10.1016/j.jacr.2007.03.002.
- 10. Powell AC, Long JW, Kren EM, Gupta AK, Levin DC. Evaluation of a Program for Improving Advanced Imaging Interpretation. *J Patient Saf.* 2019;15(1):69-75. doi: 10.1097/PTS.000000000034.5.
- 11. FDA. White Paper: Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging. Page Last Updated: 06/14/2019. https://www.fda.gov/Radiation-EmittingProducts/RadiationSafety/ RadiationDoseReduction/ucm199994.htm.
- 12. Update on FDA approach to safety issue of gadolinium retention after administration of gadolinium-based contrast agents. https://www.fda.gov/media/116492/download.
- Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. *Pediatr Radiol.* 2019;49(4):448-457. doi: 10.1007/s00247-018-4304-8.
- 14. American College of Radiology. ACR SPR SRU Practice Parameter for the Performing and Interpreting Diagnostic Ultrasound Examinations. Revised 2017. (Resolution 32). Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/US-Perf-Interpret.pdf.
- American College of Radiology. ACR–SPR Practice Parameter for Performing FDG-PET/CT in Oncology. Revised 2021. (Resolution 20). Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/FDG-PET-CT.pdf.
- 16. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Magnetic Resonance Imaging (MRI). Revised 2017. (Resolution 10). Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Perf-Interpret.pdf.
- 17. American College of Radiology. ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography (CT). Revised 2017. (Resolution 22). Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Perf-Interpret.pdf.
- 18. Lohrke J, Frenzel T, Endrikat J, et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. *Adv Ther*. 2016;33(1):1-28. doi: 10.1007/s12325-015-0275-4.
- Implementation Guide: Medicaid State Plan Eligibility Eligibility Groups Mandatory Coverage Infants and Children under Age 19. Available at: https://www.hhs.gov/guidance/document/implementation-guide-medicaidstate-plan-eligibility-eligibility-groups-aeu-mandatory-2.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 22 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelin	es
---	----

- 20. History and Physicals Understanding the Requirements. Available at: https://www.jointcommission.org/ standards/standard-faqs/hospital-and-hospital-clinics/provision-of-care-treatment-and-services-pc/000002272/.
- 21. Mammarappallil JG, Rankine L, Wild JM, Driehuys B. New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. *J Thorac Imaging*. 2019;34(2):136-150. doi: 10.1097/rti.00000000000392.
- 22. Wang JM, Robertson SH, Wang Z, et al. Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. *Thorax*. 2017;73(1):21-28. doi: 10.1136/thoraxjnl-2017-210070.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 23 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Coding Issues (Preface-4)

Guideline

3D Rendering (Preface-4.1) CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2) Unlisted Procedures/Therapy Treatment Planning (Preface-4.3) CPT<sup>®</sup> 76380 Limited or Follow-up CT (Preface-4.5) SPECT/CT Imaging (Preface-4.6) CPT<sup>®</sup> 76140 Interpretation of an Outside Study (Preface-4.7) Quantitative MR Analysis of Tissue Composition (Preface-4.8)

HCPCS Codes (Preface-4.9)

References (Preface-4)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 24 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# 3D Rendering (Preface-4.1)

## PRF.CD.0004.1.UOH v2.0.2024

## **CPT<sup>®</sup> 76376 and CPT<sup>®</sup> 76377**

- Both codes require concurrent supervision of the image post-processing 3D manipulation of the volumetric data set and image rendering.
  - Concurrent supervision is defined as active physician participation in and monitoring of the reconstruction process including design of the anatomic region that is to be reconstructed; determination of the tissue types and actual structures to be displayed (e.g., bone, organs, and vessels); determination of the images or cine loops that are to be archived; and, monitoring and adjustment of the 3D work product. The American College of Radiology (ACR) recommends that it is best to document the physician's supervision or participation in the 3D reconstruction of images.
- These two codes differ in the need for and use of an independent workstation for post-processing.
  - CPT<sup>®</sup> 76376 reports procedures not requiring image post-processing on an independent workstation.
  - CPT<sup>®</sup> 76377 reports procedures that require image post-processing on an independent workstation.
- These 3D rendering codes should not be used for 2D reformatting.
- Two-dimensional reconstruction (e.g., reformatting an axial scan into the coronal plane) is now included in all cross-sectional imaging base codes and is not separately reimbursable.
- The codes used to report 3D rendering for ultrasound and echocardiography are also used to report the 3D post processing work on CT, MRI, and other tomographic modalities.
- Providers may be required to obtain prior authorization on these 3D codes even if prior authorization is not required for the echocardiography and/or ultrasound procedure codes. It may appear that UnitedHealthcare pre-authorizes echocardiography and/or ultrasound when, in fact, it may only be the 3D code that needs the prior authorization.
- CPT<sup>®</sup> codes for 3D rendering should not be billed in conjunction with computeraided detection (CAD), MRA, CTA, nuclear medicine SPECT studies, PET, PET/ CT, Mammogram, MRI Breast, US Breast, CT Colonography (virtual colonoscopy), Cardiac MRI, Cardiac CT, or Coronary CTA studies.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 25 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- CPT<sup>®</sup> 76377 (3D rendering requiring image post-processing on an independent workstation) or CPT<sup>®</sup> 76376 (3D rendering not requiring image post-processing on an independent workstation) can be considered in the following clinical scenarios:
  - Bony conditions:
    - Evaluation of congenital skull abnormalities in newborns, infants, and toddlers (usually for pre-operative planning)
    - Complex fractures (comminuted or displaced)/dislocations of any joint (for preoperative planning when conventional imaging is insufficient)
    - Spine fractures, pelvic/acetabulum fractures, intra-articular fractures (for preoperative planning when conventional imaging is insufficient)
    - Pre-operative planning for other complex surgical cases
    - Complex facial fractures
  - Pre-operative planning for other complex surgical cases
    - Cerebral angiography
  - Pelvis conditions:
    - Uterine intra-cavitary lesion when initial US is equivocal: See <u>Abnormal Uterine</u> <u>Bleeding (AUB) (PV-2.1)</u> and <u>Leiomyoma/Uterine Fibroids (PV-12.1)</u> in the Pelvis Imaging Guidelines.
    - Hydrosalpinxes or peritoneal cysts when initial US is indeterminate: See <u>Complex Adnexal Masses (PV-5.3)</u> in the Pelvis Imaging Guidelines.
    - Lost IUD (inability to feel or see IUD string) with initial US: See <u>Intrauterine</u> <u>Device (PV-10.1)</u> in the Pelvis Imaging Guidelines.
    - Uterine anomalies with initial US: See <u>Uterine Anomalies (PV-14.1)</u> in the Pelvis Imaging Guidelines.
    - Infertility: See <u>Initial Infertility Evaluation, Female (PV-9.1)</u> in the Pelvis Imaging Guidelines.
  - Abdomen conditions:
    - CT Urogram: See <u>Hematuria and Hydronephrosis (AB-39)</u> in the Abdomen Imaging Guidelines.
    - MRCP: See <u>MR Cholangiopancreatography (MRCP) (AB-27)</u> in the Abdomen Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 26 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# CT-, MR-, or Ultrasound-Guided Procedures (Preface-4.2)

### PRF.CD.0004.2.A

#### v2.0.2024

- CT-, MR-, and Ultrasound-guidance procedure codes contain all of the imaging necessary to guide a needle or catheter. It is inappropriate to routinely bill a diagnostic procedure code in conjunction with a guidance procedure code.
- Imaging studies performed as part of a CT-, MR-, or Ultrasound-guided procedure should be reported using the CPT<sup>®</sup> codes in the following table:

### **TABLE: Imaging Guidance Procedure Codes**

CPT®	Description
19085	Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance
19086	Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including MR guidance
75989	Imaging guidance for percutaneous drainage with placement of catheter (all modalities)
76942	Ultrasonic guidance for needle placement
77011	CT guidance for stereotactic localization
77012	CT guidance for needle placement
77013	CT guidance for, and monitoring of parenchymal tissue ablation
77021	MR guidance for needle placement
77022	MR guidance for, and monitoring of parenchymal tissue ablation

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 27 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## $CPT^{ earrow}$ 19085 and $CPT^{ earrow}$ 19086

- The proper way to bill an MRI-guided breast biopsy is CPT<sup>®</sup> 19085 (Biopsy, breast, with placement of breast localization device(s), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including MR guidance). Additional lesions should be billed using CPT<sup>®</sup> 19086.
  - **CPT**<sup>®</sup> **77021** (MR guidance for needle placement) is not an appropriate code for a breast biopsy.

## **CPT<sup>®</sup> 75989**

- This code is used to report imaging guidance for a percutaneous drainage procedure in which a catheter is left in place.
- This code can be used to report whether the drainage catheter is placed under fluoroscopy, Ultrasound-, CT-, or MR-guidance modality.

## CPT<sup>®</sup> 77011

- A stereotactic CT localization scan is frequently obtained prior to sinus surgery. The dataset is then loaded into the navigational workstation in the operating room for use during the surgical procedure. The information provides exact positioning of surgical instruments with regard to the individual's 3D CT images.<sup>3</sup>
- In most cases, the pre-operative CT is a technical-only service that does not require interpretation by a radiologist.
  - The imaging facility should report CPT<sup>®</sup> 77011 when performing a scan not requiring interpretation by a radiologist.
  - If a diagnostic scan is performed and interpreted by a radiologist, the appropriate diagnostic CT code (e.g., CPT<sup>®</sup> 70486) should be used.
  - It is not appropriate to report both CPT<sup>®</sup> 70486 and CPT<sup>®</sup> 77011 for the same CT stereotactic localization imaging session.
  - 3D Rendering (CPT<sup>®</sup> 76376 or CPT<sup>®</sup> 76377) should not be reported in conjunction with CPT<sup>®</sup> 77011 (or CPT<sup>®</sup> 70486 if used). The procedure inherently generates a 3D dataset.

## $\mbox{CPT}^{\mbox{\tiny B}}$ 77012 (CT) and $\mbox{CPT}^{\mbox{\tiny B}}$ 77021 (MR)

- These codes are used to report imaging guidance for needle placement during biopsy, aspiration, and other percutaneous procedures.
- They represent the radiological supervision and interpretation of the procedure and are often billed in conjunction with surgical procedure codes.
  - For example, CPT<sup>®</sup> 77012 is reported when CT guidance is used to place the needle for a conventional arthrogram.
  - Only codes representing percutaneous surgical procedures should be billed with CPT<sup>®</sup> 77012 and CPT<sup>®</sup> 77021. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 28 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- **CPT<sup>®</sup> 77021** (MR guidance for needle placement) is not an appropriate code for breast biopsy.
  - CPT<sup>®</sup> 19085 would be appropriate for the first breast biopsy site and CPT<sup>®</sup> 19086 would be appropriate for additional concurrent biopsies.

## CPT<sup>®</sup> 77013 (CT) and CPT<sup>®</sup> 77022 (MR)

- These codes include the initial guidance to direct a needle electrode to the tumor(s), monitoring for needle electrode repositioning within the lesion, and as necessary for multiple ablations to coagulate the lesion and confirmation of satisfactory coagulative necrosis of the lesion(s) and comparison to pre-ablation images.
  - **NOTE:** CPT<sup>®</sup> 77013 should only be used for non-bone ablation procedures.
    - CPT<sup>®</sup> 20982 includes CT guidance for bone tumor ablations.
  - Only codes representing percutaneous surgical procedures should be billed with CPT<sup>®</sup> 77013 and CPT<sup>®</sup> 77022. It is inappropriate to use with surgical codes for open, excisional, or incisional procedures.
- CPT<sup>®</sup> 77012 and CPT<sup>®</sup> 77021 (as well as guidance codes CPT<sup>®</sup> 76942 [US], and CPT<sup>®</sup> 77002 - CPT<sup>®</sup> 77003 [fluoroscopy]) describe radiologic guidance by different modalities.
  - Only one unit of any of these codes should be reported per individual encounter (date of service). The unit of service is considered to be the individual encounter, not the number of lesions, aspirations, biopsies, injections, or localizations.

# Unlisted Procedures/Therapy Treatment Planning (Preface-4.3)

## PRF.CD.0004.3.UOH

v2.0.2024

CPT ®	Description
76497	Unlisted CT procedure (e.g., diagnostic or interventional)
76498	Unlisted MR procedure (e.g., diagnostic or interventional)
78999	Unlisted procedure, diagnostic nuclear medicine

- These unlisted codes should be reported whenever a diagnostic or interventional CT or MR study is performed in which an appropriate anatomic site-specific code is not available.
  - A Category III code that describes the procedure performed must be reported rather than an unlisted code if one is available.
- CPT<sup>®</sup> 76497 or CPT<sup>®</sup> 76498 (Unlisted CT or MRI procedure) can be considered in the following clinical scenarios:
  - Studies done for navigation and planning for neurosurgical procedures (i.e., Stealth or Brain Lab Imaging)<sup>1,2</sup>
  - Custom joint arthroplasty planning (not as an alternative recommendation): See Osteoarthritis (MS-12.1) in the Musculoskeletal Imaging Guidelines.
  - Any procedure/surgical planning if thinner cuts or different positional acquisition (than those on the completed diagnostic study) are needed. These could include navigational bronchoscopy: See <u>Navigational Bronchoscopy (CH-1.7)</u> in the Chest Imaging Guidelines.

### Therapy Treatment Planning

 Radiation Therapy Treatment Planning: See <u>Unlisted Procedure Codes in</u> <u>Oncology (ONC-1.5)</u> in the Oncology Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 30 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# CPT<sup>®</sup> 76380 Limited or Follow-up CT (Preface-4.5)

## PRF.CD.0004.5.UOH

#### v2.0.2024

- CPT<sup>®</sup> 76380 describes a limited or follow-up CT scan. The code is used to report any CT scan, for any given area of the body, in which the work of a full diagnostic code is not performed.
- Common examples include, but are not limited to, the following:
  - Limited sinus CT imaging protocol
  - Limited or follow-up slices through a known pulmonary nodule
  - · Limited slices to assess a non-healing fracture (such as the clavicle)
- Limited CT (CPT<sup>®</sup> 76380) is not indicated for treatment planning purposes. See <u>Unlisted Procedure Codes in Oncology (ONC-1.5)</u> in the Oncology Imaging Guidelines.
- It is inappropriate to report CPT<sup>®</sup> 76380, in conjunction with other diagnostic CT codes, to cover 'extra slices' in certain imaging protocols.
  - There is no specific number of sequences or slices defined in any CT CPT<sup>®</sup> code definition.
  - The AMA, in *CPT*<sup>®</sup> 2019, does not describe nor assign any minimum or maximum number of sequences or slices for any CT study.
    - A few additional slices or sequences are not uncommon.
    - CT imaging protocols are often influenced by the individual's clinical situation. Sometimes the protocols require more time and sometimes less.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 31 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# SPECT/CT Imaging (Preface-4.6)

## PRF.CD.0004.6.A

#### v2.0.2024

- SPECT/CT involves SPECT (Single Photon Emission Computed Tomography) nuclear medicine imaging and CT for optimizing location, accuracy, and attenuation correction and combines functional and anatomic information.
  - Common studies using this modality include <sup>123</sup>I- or <sup>131</sup>I-Metaiodobenzylguanidine (MIBG) and octreotide scintigraphy for neuroendocrine tumors.
- Hybrid Nuclear/CT scan can be reported as CPT<sup>®</sup> 78830 (single area and single day), CPT<sup>®</sup> 78831 (2 or more days), or CPT<sup>®</sup> 78832 (2 areas with one day and 2-day study).
- CPT<sup>®</sup> 78072 became effective January 1, 2013 for SPECT/CT parathyroid nuclear imaging.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 32 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **CPT<sup>®</sup> 76140 Interpretation of an Outside** Study (Preface-4.7)

### PRF.CD.0004.7.UOH

#### v2.0.2024

- It is inappropriate to use diagnostic imaging codes for interpretation of a previously performed exam that was completed at another facility.
  - If the outside exam is being used for comparison with a current exam, the diagnostic code for the current examination includes comparison to the prior study.<sup>4</sup>
  - CPT<sup>®</sup> 76140 is the appropriate code to use for an exam which was completed elsewhere and a secondary interpretation of the images is requested.<sup>5</sup>

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 33 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Quantitative MR Analysis of Tissue Composition (Preface-4.8)

## PRF.CD.0004.8.A

v2.0.2024

- Category III CPT<sup>®</sup> codes for quantitative analysis of multiparametric-MR (mp-MRI) data with and without an associated diagnostic MRI have been established. Quantitative mp-MRI uses software to analyze tissue physiology of visceral organs and other anatomic structures non-invasively. At present, these procedures are primarily being used in clinical trials and there is no widely recommended indications in clinical practice. As such, these procedures are considered to be investigational and experimental for coverage purposes.
  - CPT<sup>®</sup> 0648T (without diagnostic MRI) and CPT<sup>®</sup> 0649T (with diagnostic MRI) refer to data analysis with and without associate imaging of a single organ, with its most common use being LiverMultiScan (LMS).
    - See <u>Fatty Liver (AB-29.2)</u> in the Abdomen Imaging Guidelines.
  - CPT<sup>®</sup> 0697T (without diagnostic MRI) and CPT<sup>®</sup> 0698T (with diagnostic MRI) refer to data analysis with and without associate imaging of a multiple organs, with its most common use being CoverScan.

# HCPCS Codes (Preface-4.9)

## PRF.CD.0004.9.UOH

#### v2.0.2024

- Healthcare Common Procedure Coding System (HCPCS) codes are utilized by some hospitals in favor of the typical Level-III CPT<sup>®</sup> codes. These codes are typically 4 digits preceded by a C or S.<sup>6</sup>
  - Many of these codes have similar code descriptions to Level-III CPT<sup>®</sup> codes (i.e., C8931 MRA with dye, Spinal Canal; and, CPT<sup>®</sup> 72159 MRA Spinal Canal).
  - If cases are submitted with HCPCS codes with similar code descriptions to the typical Level-III CPT<sup>®</sup> codes, those procedures should be managed in the same manner as the typical CPT<sup>®</sup> codes.
  - HCPCS code management is discussed further in the applicable guideline sections.
- Requests for many Healthcare Common Procedure Coding System (HCPCS) codes, including non-specific codes such as S8042 (Magnetic resonance imaging [MRI], lowfield), should be redirected to a more appropriate and specific CPT<sup>®</sup> code. Exceptions are noted in the applicable guideline sections.

# **References (Preface-4)**

#### v2.0.2024

- 1. Society of Nuclear Medicine and Molecular Imaging Coding Corner. Available at: http://www.snmmi.org/ ClinicalPractice/CodingCornerPT.aspx?ItemNumber=1786.
- 2. Intraoperative MR. Brainlab. Available at: https://www.brainlab.com/surgery-products/overview-neurosurgery-products/intraoperative-mr/
- 3. Experience the Advanced 3D Sinus Surgery Planning with Scopis Building Blocks planning software. Scopis Planning. Available at: http://planning.scopis.com/.
- 4. ACR Radiology Coding Source<sup>TM</sup> March-April 2007 Q and A. Available at: https://www.acr.org/Advocacy-and-Economics/Coding-Source/ACR-Radiology-Coding-Source-March-April-2007-Q-and-A.
- Chung CY, Alson MD, Duszak R, Degnan AJ. From imaging to reimbursement: what the pediatric radiologist needs to know about health care payers, documentation, coding and billing. *Pediatr Radiol.* 2018;48(7):904-914. doi: 10.1007/s00247-018-4104-1.
- 6. HCPCS General Information from CMS.gov. Available at: www.cms.gov/medicare/coding/medhcpcsgeninfo.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 36 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.
V2.0.2024

# Whole-Body Imaging (Preface-5)

#### Guideline

Whole-Body CT Imaging (Preface-5.1) Whole-Body MR Imaging (Preface-5.2) PET-MRI (Preface-5.3) References (Preface-5)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 37 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Whole-Body CT Imaging (Preface-5.1)

### PRF.WB.0005.1.UOH

#### v2.0.2024

- Whole-body CT or LifeScan (CT Brain, Chest, Abdomen, and Pelvis) for screening of asymptomatic individuals is not indicated. The performance of whole-body screening CT examinations in healthy individuals does not meet any of the current validity criteria for screening studies and there is no clear documentation of benefit versus radiation risk.
- Whole-body low-dose CT is supported for oncologic staging in Multiple Myeloma. See <u>Multiple Myeloma and Plasmacytomas (ONC-25)</u> in the Oncology Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 38 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Whole-Body MR Imaging (Preface-5.2)

### PRF.WB.0005.2.A

#### v2.0.2024

- Whole-body MRI (WBMRI) is, with the exception of select cancer predisposition syndromes and autoimmune conditions discussed below, generally not supported at this time due to lack of standardization in imaging technique and lack of evidence that WBMRI improves outcome for any individual disease state.
  - While WBMRI has the benefit of whole-body imaging and lack of radiation exposure, substantial variation still exists in the number of images, type of sequences (STIR vs. diffusion weighting, for example), and contrast agent(s) used.
- Coding considerations:
  - There are no established CPT<sup>®</sup> or HCPCS codes for reporting WBMRI.
  - WBMRI is at present only reportable using CPT<sup>®</sup> 76498. All other methods of reporting whole-body MRI are inappropriate including the following:
    - Separate diagnostic MRI codes for multiple individual body parts
    - MRI Bone Marrow Supply (CPT<sup>®</sup> 77084)
- Disease-specific considerations:
  - Cancer screening:
    - Interval WBMRI is recommended for cancer screening in individuals with select cancer predisposition syndromes. Otherwise, WBMRI has not been shown to improve outcomes for cancer screening.
      - For additional information, see <u>Li-Fraumeni Syndrome (LFS)</u> (PEDONC-2.2), <u>Hereditary Paraganglioma-Pheochromocytoma (HPP)</u> Syndromes (PEDONC-2.13), or <u>Constitutional Mismatch Repair</u> <u>Deficiency (CMMRD or Turcot Syndrome) (PEDONC-2.15)</u> in the Pediatric Oncology Imaging Guidelines.
  - Cancer staging and restaging:
    - While the feasibility of WBMRI has been established, data remain conflicting on whether WBMRI is of equivalent diagnostic accuracy compared with standard imaging modalities such as CT, scintigraphy, and PET imaging.
    - Evidence has not been published establishing WBMRI as a standard evaluation for any type of cancer.
  - Autoimmune disease:
    - WBMRI can be approved in some situations for individuals with chronic recurrent multifocal osteomyelitis.
      - For additional information, see <u>Chronic Recurrent Multifocal</u> <u>Osteomyelitis (PEDMS-10.2)</u> in the Pediatric Musculoskeletal Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 39 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **PET-MRI (Preface-5.3)**

### PRF.WB.0005.3.A

#### v2.0.2024

- PET-MRI is generally not supported for a vast majority of oncologic and neurologic conditions due to lack of standardization in imaging technique and interpretation. However, it may be appropriate in select circumstances when the following criteria are met:
  - The individual meets condition-specific guidelines for PET-MRI OR
  - The individual meets ALL of the following:
    - The individual is a pediatric patient or being treated under a pediatric guideline and treatment plan AND
    - The individual meets guideline criteria for PET-CT, AND
    - PET-CT is not available at the treating institution, AND
    - The provider requests PET-MRI in lieu of PET-CT
- When the above criteria are met, PET-MRI may be reported using the code combination of PET Whole-Body (CPT<sup>®</sup> 78813) and MRI Unlisted (CPT<sup>®</sup> 76498). All other methods of reporting PET-MRI are inappropriate.
  - When clinically appropriate, diagnostic MRI codes may be indicated at the same time as the PET-MRI code combination.
- For more information, see <u>PET Imaging in Pediatric Oncology (PEDONC-1.4)</u> in the Pediatric Oncology Imaging Guidelines, and <u>PET Brain Imaging (PEDHD-2.3)</u> and <u>Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)</u> in the Pediatric Head Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 40 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **References (Preface-5)**

#### v2.0.2024

- Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncol.* 2011;12(6):559-567. doi: 10.1016/ S1470-2045(11)70119-X.
- Siegel MJ, Acharyya S, Hoffer FA, et al. Whole-Body MR Imaging for Staging of Malignant Tumors in Pediatric Patients: Results of the American College of Radiology Imaging Network 6660 Trial. *Radiology*. 2013;266(2):599-609. doi: 10.1148/radiol.12112531.
- 3. Antoch G. Whole-Body Dual-Modality PET/CT and Whole-Body MRI for Tumor Staging in Oncology. *JAMA*. 2003;290(24):3199. doi: 10.1001/jama.290.24.3199.
- 4. Lauenstein TC, Semelka RC. Emerging techniques: Whole-body screening and staging with MRI. *J Magn Reson Imaging*. 2006;24(3):489-498. doi: 10.1002/jmri.20666.
- 5. Khanna G, Sato TSP, Ferguson P. Imaging of Chronic Recurrent Multifocal Osteomyelitis. *RadioGraphics*. 2009;29(4):1159-1177. doi: 10.1148/rg.294085244.
- 6. Ferguson PJ, Sandu M. Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis. *Curr Rheumatol Rep.* 2012;14(2):130-141. doi: 10.1007/s11926-012-0239-5.
- 7. National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>): Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2023. February 13, 2023. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2023. ©National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 10, 2023. The NCCN Guidelines<sup>®</sup> and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines<sup>®</sup>, go online to NCCN.org.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 41 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# References (Preface-6)

Guideline

References (Preface-6.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 42 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **References (Preface-6.1)**

### PRF.RF.0006.1.A

#### v2.0.2024

- Complete reference citations for the journal articles are embedded within the body of the guidelines and/or may be found on the Reference pages at the end of some guideline sections.
- The website addresses for certain references are included in the body of the guidelines but are not hyperlinked to the actual website.
- The website address for the American College of Radiology (ACR) Appropriateness Criteria<sup>®</sup> is http://www.acr.org.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 43 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Copyright Information (Preface-7)

Guideline

Copyright Information (Preface-7.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 44 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Copyright Information (Preface-7.1)**

### PRF.CI.0007.1.UOH

#### v2.0.2024

©2024 United HealthCare Services, Inc. All rights reserved. No part of these
materials may be changed, reproduced, or transmitted in any form or by any means,
electronic or mechanical, including photocopying or recording, or in any information
storage or retrieval system, without the prior express written permission of United
HealthCare Services, Inc.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 45 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Trademarks (Preface-8)

Guideline

Trademarks (Preface-8.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 46 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Trademarks (Preface-8.1)**

**PRF.TM.0008.1.A** 

#### v2.0.2024

 CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five-digit codes, nomenclature, and other data are copyright 2024 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 47 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# **General Information**

#### Guideline

Abbreviations and Glossary for the PVD Imaging Guidelines General Guidelines (PVD-1.0) General Information (PVD-1.1) Procedure Coding (PVD-1.2) General Guidelines – Imaging (PVD-1.3) Nuclear Medicine Imaging indications (PVD-10.1) References

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 48 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Abbreviations and Glossary for the PVD Imaging Guidelines

v1.0.2024

(See also: Cardiac Imaging Guidelines Glossary)

Abbreviation	Definition	
AAA	Abdominal aortic aneurysm	
ABI	Ankle brachial index: a noninvasive, non-imaging test for arterial insufficiency – (see toe-brachial index below). This testing can also be done after exercise if resting results are normal.	
Claudication	or <b>Intermittent claudication</b> : usually a painful cramping sensation of the legs with walking or severe leg fatigue	
CLI	Critical Limb Ischemia	
СТА	Computed tomography angiography	
СТV	Computed tomography venography	
DLCO	Diffusion capacity: defined as the volume of carbon monoxide transferred into the blood per minute per mmHg of carbon monoxide partial pressure	
DVT	Deep venous thrombosis	
ECG	Electrocardiogram	
ENT	Ears, Nose, Throat	
EVAR	Endovascular Aneurysm Repair	
HbA1C	Hemoglobin A1C: test used to determine blood sugar control for individuals with diabetes	
MRA	Magnetic resonance angiography	

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 49 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Abbreviation	Definition	
MRV	Magnetic resonance venography	
PAD	Peripheral artery disease	
PAH	ulmonary artery hypertension	
PFT	Pulmonary function tests	
PVD	<sup>&gt;</sup> eripheral vascular disease	
PSV ratio	Peak systolic velocities	
SVC	Superior vena cava	
TEVAR	Thoracic Endovascular Aortic Repair	
TIA	Transient ischemic attack	
TTE	Transthoracic echocardiogram	
Toe-Brachial Index	Useful in individuals with ABI above the normal range due to non- compressible posterior tibial or dorsalis pedis arteries	
V/Q Scan	Ventilation and perfusion scan	

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 50 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **General Guidelines (PVD-1.0)**

### PVD.GG.0001.0.A

#### v1.0.2024

- A pertinent clinical evaluation, or meaningful technological contact (telehealth visit, telephone call, electronic mail or messaging), is required prior to considering advanced imaging, including relevant medical treatments and a vascular history and physical that includes (when applicable):
  - Palpation of pulses
  - Evaluation of lower extremities for presence of non-healing wounds or gangrene
  - Associated skin changes such as thickened nails, absence of hair in the feet or calves, cool extremities
  - Evaluation for the presence of arterial bruits
  - Appropriate laboratory studies
  - Non-advanced imaging modalities, such as recent ABIs (within 60 days) after symptoms started or worsened
- ABI should be measured first:
  - If normal, then further vascular studies are generally not indicated.
  - If clinical suspicion for PAD remains high with normal ABI's, exercise ABI's (CPT<sup>®</sup> 93924) can be performed on a treadmill to elicit ischemia
  - The TBI (toe-brachial index) is used to establish the diagnosis of PAD in the setting of non-compressible arteries (ABI ≥1.40) and may also be used to assess perfusion in individuals with suspected CLI (rest pain and/or non-healing wound)
- If a prior imaging study (Ultrasound, MRA, CTA, Catheter angiogram, etc.) has been completed for a condition, a follow-up, additional, or repeat study for the same condition is generally not indicated unless there has been a change in the individual's condition, previous imaging showed an indeterminate finding, or eviCore healthcare guidelines support routine follow-up imaging.
- Runoff studies (CPT<sup>®</sup> 75635 for CTA or CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725, and CPT<sup>®</sup> 73725 for MRA) image from the umbilicus to the feet
  - CTA Abdomen and lower extremities should be reported as CPT<sup>®</sup> 75635, rather than using the individual CPT<sup>®</sup> codes for the abdomen, pelvis, and legs
  - MRA Abdomen, MRA Pelvis and MRA Lower extremities should be reported as CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725, and CPT<sup>®</sup> 73725. The CPT<sup>®</sup> code for MRA Pelvis (CPT<sup>®</sup> 72198) should not be included in this circumstance.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 51 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **General Information (PVD-1.1)**

PVD.GG.0001.1.A v1.0.2024

- Risk factors for vascular disease include:
  - Diabetes
  - Cigarette smoking
  - Hypertension
  - Hyperlipidemia
  - Age >50, with at least one risk factor, are considered "at risk" for vascular disease
  - See also: <u>Impotence/Erectile Dysfunction (PV-17)</u> in the Pelvis Imaging Guidelines.
- · Signs and symptoms of peripheral arterial disease
  - Claudication (Cramping pain in the legs, most notably back of the calves but can involve hips or thighs, after walking which is relieved with rest but recurs at a predictable distance)
    - Symptoms that are not consistent with claudication include
      - Generalized leg pain
      - Nocturnal cramps
      - Pain that is not easily relieved after a few minutes of rest
      - Burning pain in feet
  - Critical limb ischemia
    - Rest pain: Pain in the foot (not leg) at rest, particularly at night when the leg is elevated. Pain is relieved by dangling the leg off the bed or moving to an upright position
    - Non-healing wounds: Wounds present for >2 weeks with little to no evidence of healing
  - Erectile dysfunction can be associated with vascular disease
- Claudication and critical limb ischemia have different natural histories. Claudication generally follows a benign indolent course. 70% of individuals with claudication will have the same symptoms after five years with no progression. Critical limb ischemia, on the other hand, is associated with a high rate of limb loss (25%) and death (35%) one year after presentation
- Simultaneous venous and arterial systems evaluation are unusual but are occasionally needed
- Post-angioplasty/reconstruction: follow-up imaging is principally guided by symptoms. See also:
  - Post Aortic Endovascular/Open Surgery Surveillance Studies (PVD-6.8)
  - Post-Procedure Surveillance Studies (PVD-7.3)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 52 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Procedure Coding (PVD-1.2)**

## PVD.GG.0001.2.A

#### v1.0.2024

Non-Invasive Physiologic Studies of Extremity Arteries	CPT®	
<ul> <li>Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries.</li> <li>Non-invasive physiologic studies of upper or lower extremity arteries, single level, bilateral (e.g., ankle/brachial indices, Doppler waveform analysis, volume plethysmography, transcutaneous oxygen tension measurement).</li> </ul>	93922	
<ul> <li>Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels.</li> <li>Non-invasive physiologic studies of upper or lower extremity arteries, multiple levels or with provocative functional maneuvers, complete bilateral study (e.g., segmental blood pressure measurements, segmental Doppler waveform analysis, segmental volume plethysmography, segmental transcutaneous oxygen tension measurements, measurements with postural provocative tests, measurements with reactive hyperemia).</li> </ul>		
<ul> <li>CPT<sup>®</sup> 93922 and CPT<sup>®</sup> 93923 can be requested and reported only once for the upp extremities and once for the lower extremities.</li> <li>CPT<sup>®</sup> 93922 and CPT<sup>®</sup> 93923 should not be ordered on the same request nor billed together for the same date of service.</li> <li>CPT<sup>®</sup> 93924 and CPT<sup>®</sup> 93922 and/or CPT<sup>®</sup> 93923 should not be ordered on the same request and should not be billed together for the same date of service.</li> <li>ABI studies performed with handheld dopplers, where there is no hard copy output f evaluation of bidirectional blood flow, are not reportable by these codes.</li> </ul>		
Non-Invasive Physiologic Studies of Extremity Arteries		
Non-invasive physiologic studies of lower extremity arteries, at rest and following treadmill stress testing, complete bilateral study.	93924	
Arterial Duplex – Upper and Lower Extremities	CPT®	
Duplex scan of <b>lower</b> extremity arteries or arterial bypass grafts; complete bilateral.	93925	

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 53 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Arterial Duplex – Upper and Lower Extremities	CPT®	
<ul> <li>A complete duplex scan of the lower extremity arteries includes examination full length of the common femoral, superficial femoral and popliteal arteries.</li> <li>The iliac, deep femoral, and tibioperoneal arteries may also be examined.</li> </ul>	n of the	
Duplex scan of <b>lower</b> extremity arteries or arterial bypass grafts; unilateral or limited study.	93926	
• The limited study is reported when only one extremity is examined or when less than a full examination is performed (e.g. only one or two vessels or follow-up).		
Duplex scan of <b>upper</b> extremity arteries or arterial bypass grafts; complete <b>939</b> ; bilateral.		
<ul> <li>A complete duplex of the upper extremity arteries includes examination of the subclavian, axillary, and brachial arteries.</li> <li>The radial and ulnar arteries may also be included.</li> </ul>		
Duplex scan of <b>upper</b> extremity arteries or arterial bypass grafts; unilateral or limited study.		
• The limited study is reported when only one extremity is examined or when less than a full examination is performed (e.g. only one or two vessels or follow-up).		
Cerebrovascular Artery Studies		

Cerebrovascular Artery Studies	CPT®
Duplex scan of extracranial arteries; complete bilateral study.	93880
Duplex scan of extracranial arteries; unilateral or limited study.	93882

• This study is often referred to as a "carotid ultrasound" or "carotid duplex".

Typically, it includes evaluation of the common, internal, and external carotid arteries.

Transcranial Doppler Studies	CPT®	
Transcranial Doppler study of the intracranial arteries; complete study	93886	
Transcranial Doppler study of the intracranial arteries; limited study		
Transcranial Doppler vasoreactivity study		

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 54 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.202
Transcranial Doppler Studies	CPT®
Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection	93892
Transcranial Doppler study of the intracranial arteries; emboli detection with intravenous microbubble injection	93893
Venous Studies - Extremities	CPT®
Duplex scan of extremity veins, including responses to compression and other maneuvers; complete bilateral study.	93970
Duplex scan of extremity veins, including responses to compression and other maneuvers; unilateral or limited study.	93971
<ul> <li>These codes are used to report studies of lower <i>or</i> upper extremity veins.</li> <li>A complete bilateral study of the lower extremity veins includes examination common femoral, proximal deep femoral, great saphenous and popliteal ve veins may also be included.</li> <li>A complete bilateral study of upper extremity veins includes examination of subclavian, jugular, axillary, brachial, basilica, and cephalic veins. Forearm may also be included.</li> </ul>	ι of the ins. Calf the veins
Visceral Vascular Studies	CPT <sup>®</sup>
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study.	93975
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study	93976
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts;	93978

Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study 93979

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 55 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
---	-----------

Duplex for Hemodialysis Access	CPT®
Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow).	93990
Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete bilateral study	93985
Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete unilateral study	

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 56 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# General Guidelines – Imaging (PVD-1.3)

PVD.GG.0001.3.A v1.0.2024

- Imaging Studies:
  - Carotid studies MRA Neck (CPT<sup>®</sup> 70543) or CTA Neck (CPT<sup>®</sup> 70491) capture the area from the top of the aortic arch (includes the origin of the innominate artery, common carotid artery, and subclavian artery, which gives off the vertebral artery) to the base of the skull.
  - CTA or MRA Abdomen (CPT<sup>®</sup> 74175 or CPT<sup>®</sup> 74185) images from the diaphragm to the umbilicus or iliac crest
  - CTA or MRA Chest (CPT<sup>®</sup> 71275 or CPT<sup>®</sup> 71555) images from the base of the neck to the dome of the liver
  - Runoff studies (CPT<sup>®</sup> 75635 for CTA or CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725, and CPT<sup>®</sup> 73725 for MRA) image from the umbilicus to the feet
    - CTA Abdomen and lower extremities should be reported as CPT<sup>®</sup> 75635, rather than using the individual CPT<sup>®</sup> codes for the abdomen, pelvis, and legs
    - MRA Abdomen, MRA Pelvis and MRA Lower extremities should be reported as CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725, and CPT<sup>®</sup> 73725. The CPT<sup>®</sup> code for MRA Pelvis (CPT<sup>®</sup> 72198) should not be included in this circumstance
  - Studies used to quantify plaque morphology in noncoronary vessels (CPT<sup>®</sup> 0710T, CPT<sup>®</sup> 0711T, CPT<sup>®</sup> 0712T, CPT<sup>®</sup> 0713T) are considered experimental, investigational, or unproven.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 57 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Nuclear Medicine Imaging indications (PVD-10.1)

## PVD.GG.0010.1.A

#### v1.0.2024

- Nuclear medicine studies are rarely used in the evaluation of peripheral vascular disorders but are indicated in the following circumstances:
  - Lymphoscintigraphy (CPT<sup>®</sup> 78195) is indicated for evaluation of lower extremity lymphedema when recent Doppler ultrasound of the lower extremity and abdomen are negative for valvular insufficiency.
  - Vascular flow imaging (CPT<sup>®</sup> 78445) is an obsolete study that has been replaced by MRA, CTA, or Duplex ultrasonography, and is not supported for any indication at this time.
  - Venous thrombosis imaging (CPT<sup>®</sup> 78456, CPT<sup>®</sup> 78457, and CPT<sup>®</sup> 75458) are obsolete studies that have been replaced by MRA, CTA, or Duplex ultrasonography, and are not supported for any indication at this time.
  - Indium 111 (<sup>111</sup>In)–labeled white blood cell (WBC) or Gallium-67 citrate studies (CPT<sup>®</sup> 78800, CPT<sup>®</sup> 78801, CPT<sup>®</sup> 78802, or CPT<sup>®</sup> 78803) can be approved for evaluation of the following:
    - Mycotic aneurysms.
    - Vascular graft infection.
    - Infection of central venous catheter or other indwelling device.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 58 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardi	iovascular and Radiology Imaging Guidelines	V2.0.202
	Ref	erences
		v1.0.2024
1.	Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the manag	gement of patients
2.	Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for athered disease of the lower extremities: management of asymptomatic disease and claudication [ appears in J Vasc Surg. 2015 May;61(5):1382]. <i>J Vasc Surg.</i> 2015;61(3 Suppl):2S-41S. do j.jvs.2014.12.009.	osclerotic occlusive published correction pi:10.1016/
3.	Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brac scientific statement from the American Heart Association [published correction appears in 1;127(1):e264]. <i>Circulation</i> . 2012;126(24):2890-2909.	chial index: a Circulation. 2013 Jar
4.	Drachman DE, Beckman JA. The Exercise Ankle-Brachial Index: A Leap Forward in Nonir Prognosis. JACC Cardiovasc Interv. 2015;8(9):1245-1247. doi:10.1016/j.jcin.2015.06.006.	nvasive Diagnosis and
5.	Herraiz-Adillo Á, Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, Solera-Ma The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb arterial disease: A systematic review and meta-analysis. <i>Atherosclerosis</i> . 2020;315:81-92. j.atherosclerosis.2020.09.026.	artínez M. peripheral . doi:10.1016/

V2.0.2024

# Genetic Predisposition to Arterial Disease

#### Guideline

Screening for Suspected Peripheral Artery Disease/Aneurysmal Disease (PVD-2)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 60 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Screening for Suspected Peripheral Artery Disease/Aneurysmal Disease (PVD-2)

PVD.GP.0002.A v1.0.2024

## Asymptomatic Screening (PVD-2.1)

- Routine screening of asymptomatic individuals for PAD is not advised. Those with CVD risk factors should be placed on best medical management and should be questioned on symptoms of PAD at annual physicals.
- Currently, there is no evidence to demonstrate that screening all individuals with PAD for asymptomatic atherosclerosis in other arterial beds improves clinical outcome.
- Resting ABI's may be indicated in individuals with abnormal pulse exams.<sup>2,3</sup>

# Screening for Vascular related genetic connective tissue Disorders (PVD-2.2)

- Vascular related genetic connective tissue Disorders include:
  - Familial Aneurysm Syndromes
  - Fibromuscular Dysplasia
  - Spontaneous Coronary Artery Dissection (SCAD)
  - Ehlers-Danlos
  - Marfan
  - Loeys-Dietz
- Screening for Familial Syndromes in individuals with a positive family history (1<sup>st</sup> degree relative with dissection/TAA) but no known genetic syndrome/mutation, otherwise known as Suspected Familial Aneurysm Syndrome.
  - ECHO (CPT<sup>®</sup> 93306, CPT<sup>®</sup> 93307, or CPT<sup>®</sup> 93308) and chest x-ray for all First-degree relatives (parents, siblings, children) of individuals with TAA and/or dissection.
- <sup>1</sup> Andras A, Ferket B. Screening for peripheral arterial disease. Cochrane Database Syst Rev. 2014;(4):CD010835. Published 2014 Apr 7. doi:10.1002/14651858.CD010835.pub2
- <sup>2</sup> Firnhaber JM, Powell CS. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment [published correction appears in Am Fam Physician. 2019 Jul 15;100(2):74]. Am Fam Physician. 2019;99(6):362-369
- <sup>3</sup> US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment with the Ankle-Brachial Index:US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(2):177. doi:10.1001/jama.2018.8357

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 61 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024

 Any imaging listed in the Table of Thoracic Aorta Imaging Options can be performed if these studies identify a TAA or are equivocal or do not visualize the ascending or descending aorta adequately.

### **Table of Thoracic Aorta Imaging Options**

Description	CPT®
CT Chest without contrast	71250
CT Chest with contrast	71260
CTA Chest	71275
MRA Chest	71555
Transesophageal echocardiogram (TEE)	93312 or 93313 or 93314

• Studies can be repeated at 2 year intervals if prior results are negative

- Initial imaging for individuals with documented SCAD/fibromuscular dysplasia/Marfan/ Loeys-Dietz/Ehlers-Danlos type IV:
  - On initial diagnosis of Ehlers-Danlos, Loeys Deitz or Marfans or SCAD or suspicion of fibromuscular dysplasia, full vascular imaging should be performed from head to pelvis with:
    - CTA or MRA Head (CPT<sup>®</sup> 70496 or CPT<sup>®</sup> 70546 or CPT<sup>®</sup> 70545)
    - CTA or MRA Neck (CPT<sup>®</sup> 70498 or CPT<sup>®</sup> 70548 or CPT<sup>®</sup> 70549)
    - CTA or MRA Chest or CT Chest with contrast
    - CTA Abdomen/Pelvis or MRA Abdomen/Pelvis (CPT<sup>®</sup> 74174) or (CPT<sup>®</sup> 74185 and CPT<sup>®</sup> 72198)
  - If there are no identified aneurysms or dissections, repeat imaging can be obtained at two-year intervals
- Surveillance imaging
  - If an aneurysm is identified in individuals with fibromuscular dysplasia, then the aneurysm can be surveilled per the typical timeframe as described in <u>Thoracic</u> <u>Aortic Aneurysm (TAA) (PVD-6.2)</u>, <u>Abdominal Aortic Aneurysm (PVD-6.3)</u>, <u>Iliac Artery Aneurysm (PVD- 6.4)</u>, and <u>Visceral Artery Aneurysm (PVD-6.5)</u>.
  - Follow-Up of aneurysms in individuals with documented SCAD/Marfan's/Loeys-Dietz/Ehlers-Danlos type IV
    - Imaging can be performed every 6 months once an aneurysm has been identified until a decision has been made to repair.
      - Intracranial aneurysm CTA or MRA Head (CPT<sup>®</sup> 70496 or 70544)
      - Aneurysm of a cervical artery Carotid duplex or CTA or MRA neck if unable to fully visualize with carotid duplex

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 62 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- Thoracic aorta CTA Chest (CPT<sup>®</sup> 71275) or CT Chest with (CPT<sup>®</sup> 71260) or without (CPT<sup>®</sup> 71250), MRA chest (CPT<sup>®</sup> 71555)
- Abdominal aneurysm Abdominal duplex (CPT<sup>®</sup> 93975/93976/93978/93979/76770/76775)
- Visceral aneurysm These can be difficult to visualize on duplex. If not visible on duplex, can obtain a CTA or MRA Abdomen and Pelvis.

### Background and supporting information

Fibromuscular dysplasia and spontaneous coronary artery dissection is diagnosed radiographically. Loeys-Dietz, Marfans, Ehlers-Danlos type IV are diagnosed with genetic testing.

## Screening for TAA with bicuspid aortic valves (PVD-2.3)

- Screening in individuals with bicuspid aortic valve:
  - Screening, any requested imaging from the "Table of Thoracic Aorta Imaging Options" and/or ECHO (CPT<sup>®</sup> 93306, CPT<sup>®</sup> 93307, or CPT<sup>®</sup> 93308).

Description	CPT®
CT Chest without contrast	71250
CT Chest with contrast	71260
CTA Chest	71275
MRA Chest	71555
Transesophageal echocardiogram (TEE)	93312 or 93313 or 93314

### **Table of Thoracic Aorta Imaging Options**

- Additional imaging such as Cardiac MRI, Cardiac CT, or CCTA is NOT generally indicated.
- There is no evidence-based data to support screening relatives of individuals with bicuspid aortic valve for TAA except with echocardiogram.
- Follow-up per TAA Follow-Up guidelines in <u>Thoracic Aortic Aneurysm (TAA)</u> (PVD-6.2)
- If no dilatation of the aortic root or ascending thoracic aorta is found, there is no evidence-based data to support continued surveillance imaging.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 63 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

### Screening for Vascular Related Disorders in Multisystemic Smooth Muscle Syndrome (MSMS)/Smooth Muscle Dysfunction Syndrome (SMDS)/ACTA2 Mutations (PVD 2.4)

### Initial imaging

Upon initial genetic confirmation, all of the following studies can be approved:

- Transthoracic echocardiogram (TTE) (CPT<sup>®</sup> 93306)
- MRA Chest (CPT<sup>®</sup> 71555) or CTA Chest and CT Chest with contrast (CPT<sup>®</sup> 71275 and 71260)
- MRA Abdomen and Pelvis (CPT<sup>®</sup> 74185 and 72198) or CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174)
- MRI Perfusion study Brain CPT<sup>®</sup> 70553
- MRA Head and Neck (CPT<sup>®</sup> 70544 or 70545 AND 70548)
- Ultrasound Upper extremity(ies) (CPT<sup>®</sup> 93930 or 93931) or CTA Upper extremity (CPT<sup>®</sup> 73206) or MRA Upper extremity (CPT<sup>®</sup> 73225)

### **Repeat testing**

Repeat testing with any of the studies listed under initial imaging is indicated when there is documentation of new signs or symptoms.

### Surveillance imaging

Surveillance imaging with any of the studies listed in initial imaging is indicated according to the following:

- Transthoracic echocardiogram repeat every 6 months
- Chest imaging can be repeated every 12 months starting at age 10
- Abdomen and pelvis imaging can be repeated every 12 months starting age 10
- Upper extremity imaging can be repeated every 12 months starting age 10
- MRI perfusion study Brain see <u>Dysfunction Syndrome (SMDS)/ACTA2 Mutations</u> (PEDHD-12.8)
- MRA Head and Neck see <u>Dysfunction Syndrome (SMDS)/ACTA2 Mutations</u> (PEDHD-12.8)

### Background and supporting information

Smooth Muscle Dysfunction Syndrome presents as congenital mydriasis, a patent ductus arteriosus (PDA), pulmonary arterial hypertension (PAH) during infancy. Patients go on to developed aortic, peripheral arterial, and cerebrovascular disorders in childhood.

• Caused by heterozygous mutation of ACTA2. P.Arg179His

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 64 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024

- Cases mostly due to de novo mutations, so imaging screening based on family history without genetic confirmation is not supported.
- Because radiation is a known risk factor for moyamoya disease. MRI/MRA Head is recommended instead of Computed Tomography (CT)/CTA

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 65 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# **Cerebrovascular Imaging**

Guideline

Cerebrovascular and Carotid Disease - Initial Imaging (PVD-3.1) Surveillance Imaging with NO History of Carotid Surgery or Intervention (PVD-3.2) Surveillance Imaging WITH History of Carotid Surgery or Intervention (PVD-3.3) References

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 66 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Cerebrovascular and Carotid Disease -Initial Imaging (PVD-3.1)

### PVD.CV.0003.1.A

#### v1.0.2024

- Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) should generally be used to evaluate possible carotid artery disease, prior to considering advanced imaging, when ANY of the following apply:
  - Known or suspected retinal arterial emboli or Hollenhorst plaque
  - Pulsatile neck masses
  - Carotid or cervical bruit
  - Abnormal findings on physical exam of the carotid arteries (e.g., absent carotid pulses)
  - Preoperative evaluation of individuals with evidence of severe diffuse atherosclerosis, scheduled for major cardiovascular surgical procedures
  - Preoperative evaluation of individuals prior to elective cardiovascular surgery in individuals older than 65 years of age and in those with peripheral artery disease, history of cigarette smoking, history of stroke or TIA, or carotid bruit
  - Suspected Subclavian Steal Syndrome
    - See **Subclavian Steal Syndrome (CH-27)** in the Chest Imaging Guidelines
  - Blunt neck trauma in the absence of focal neurologic symptoms
  - Neurologic complaints after chiropractic neck manipulation
  - Vasculitis potentially involving carotid arteries, such as Takayasu's arteritis and fibromuscular dysplasia (FMD). In patients with neurologic symptoms and concern for cerebral vasculitis, see <u>Cerebral vasculitis (HD 22.1)</u>
  - Remote history of stroke or TIA (Greater than one month).
- Typical Symptoms of TIA/Stroke, see <u>Stroke/TIA (HD-21)</u> in the Head Imaging Guidelines
- CTA or MRA Neck is indicated for suspected internal carotid artery dissection, in individuals with ANY of the following mechanisms of injury or risk factors for arterial dissection:
  - Chiropractic manipulation of neck
  - Whiplash injury
  - Fibromuscular dysplasia/Marfan's
  - Stroke in the young (age  $\leq$ 50)
- CTA or MRA Neck can be approved for suspected vertebrobasilar pathology:
  - Symptoms include:
    - Vertigo associated with nausea and vomiting

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 67 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- Diplopia
- Loss of vision in one or both eyes
- Dysarthria
- Bifacial numbness
- Bilateral extremity weakness and/or numbness
- Acute changes in mental status
- Loss of consciousness
- Ataxia
- MRA or CTA of **both** Neck and Head are required to visualize the entire vertebralbasilar system for evaluation of posterior circulation disease. See <u>General</u> <u>Guidelines – CT and MR Angiography (HD-1.5)</u> in the Head Imaging Guidelines
- Surveillance imaging, post-stenting or known vertebrobasilar disease, interval determined by Vascular Specialist, Neurologist, or Neurosurgeon or any provider in consultation with a vascular specialist, neurologist, or neurosurgeon for ANY of the following:
  - Asymptomatic
  - Unchanged symptoms
  - New or worsening symptoms

### <u>After Intracranial Hemorrhage:</u>

- Initial Imaging see Head Trauma (HD-13.1) in the Head Imaging Guidelines
- Surveillance Imaging
  - Interval determined by neurosurgeon or neurologist or any provider in consultation with a neurologist or neurosurgeon.
- For Suspected Subclavian Steal Syndrome:
  - Initial imaging should be a carotid duplex
    - If initial duplex demonstrates high-grade stenosis or occlusion of the subclavian artery, advanced imaging is NOT indicated unless the individual is symptomatic with arm claudication or signs of hypo-perfusion of the vertebral artery with recurrent dizziness
  - Surveillance of subclavian arterial disease is NOT indicated if there has not been any intervention such as a carotid-subclavian bypass or subclavian stent
  - Advanced imaging, see <u>Subclavian Steal Syndrome General (CH-27)</u> in the Chest Imaging Guidelines
- Carotid ultrasound screening in asymptomatic individuals due only to risk factors is not indicated.
- Repeat imaging of the cervical vessels (regardless of when the previous carotid imaging was performed) is indicated for new signs and symptoms consistent with carotid artery disease (e.g., TIA, amaurosis fugax, change in nature of a carotid bruit) using one of the following:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 68 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
---	-----------

- Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral study or CPT<sup>®</sup> 93882 unilateral study)
   MRA Neck with contrast (CPT<sup>®</sup> 70548) or without and with contrast (CPT<sup>®</sup> 70549)
   CTA Neck (CPT<sup>®</sup> 70498)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 69 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# Surveillance Imaging with NO History of Carotid Surgery or Intervention (PVD-3.2)

PVD.CV.0003.2.A

v1.0.2024

- Surveillance imaging is indicated once a year for individuals with fibromuscular dysplasia of the extracranial internal carotid arteries.
- Reporting standards for carotid stenosis varies widely. The most commonly used criteria, however, is noted in the chart below published by the Society of Radiology in 2003

Primary parameters		Additional Parameters		
% Stenosis	ICA PSV (cm/sec)	Plaque estimate (%)	ICA/CCA PSV ratio	ICA/EDV (cm/sec)
Normal	< 125	None	< 2.0	< 40
< 50	< 125	< 50	< 2.0	< 40
50-69	125-230	≥ 50	2.0-4.0	40-100
≥ 70 but less than near occlusion	> 230	> 50	> 4.0	> 100
Near occlusion	High, low, or undetectable	Visible	Variable	Variable
Total occlusion	undetectable	Visible- no detectable lesion	Not applicable	Not applicable

- If normal study, no routine follow-up imaging is indicated
- If <50% internal carotid stenosis
  - Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) can be performed every **two** years
- Between 50% and 70% internal carotid stenosis

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 70 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc. Click Anywhere in the Header to Return to the Main Table of Contents

Cardiovascular and Radiology Imaging Guidelines

- Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) can be performed annually.
- A repeat duplex (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) may be performed in three to six months until stability is reached when **one** of the following occurs:
  - Change in the character of the bruit
  - Duplex demonstrates rapid progression, including:
    - Doubling of peak systolic velocities in the internal carotid arteries
    - Increase of the ICA/CCA ratio
    - Heavy calcification in the internal carotid arteries
    - Thrombus in the internal carotid arteries
    - Ulcerated plaque in the internal carotid arteries
    - Echolucent plaque in the internal carotid arteries
- A one-time CTA Neck (CPT<sup>®</sup> 70498) or MRA Neck (CPT<sup>®</sup> 70548) is indicated to confirm degree of stenosis in individuals with ulcerated plaque or heavy calcification of the internal carotid artery seen on duplex.
- Internal carotid stenosis ≥70% or ICA/CCA ratio >4
  - Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) or MRA Neck with contrast (CPT<sup>®</sup> 70548) or CTA Neck (CPT<sup>®</sup> 70498) can be performed at the following intervals:
    - Every 6 months until one of the following occurs:
      - Intervention is performed
      - Decision is made to not intervene
- MRA Neck with contrast (CPT<sup>®</sup> 70548) or CTA Neck (CPT<sup>®</sup> 70498) is indicated if duplex Ultrasound shows ≥70% occlusion/stenosis of the internal carotid artery or the ICA/CCA ratio is >4.0, even with a lower percentage of stenosis.
  - If carotid stent is planned
    - MRA Head (CPT<sup>®</sup> 70544, or CPT<sup>®</sup> 70545, or CPT<sup>®</sup> 70546) or CTA Head (CPT<sup>®</sup> 70496) can be added

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 71 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

#### V2.0.2024

# Surveillance Imaging WITH History of Carotid Surgery or Intervention (PVD-3.3)

### PVD.CV.0003.3.A

#### v1.0.2024

- Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) is indicated postcarotid surgery or intervention at the following intervals:
  - 1 month after procedure
  - Every 6 months for 2 years after procedure
  - Then annually
- If ≥70% residual internal carotid stenosis is seen on duplex at 1 month after procedure
  - Duplex ultrasound (CPT<sup>®</sup> 93880 bilateral or CPT<sup>®</sup> 93882 unilateral) or CTA Neck (CPT<sup>®</sup> 70498) or MRA Neck (CPT<sup>®</sup> 70548) is indicated at the following intervals:
    - Every 3-6 months for one year
    - Then annually or until decision is made to re-intervene.
- If ≥70% residual internal carotid stenosis is seen on duplex at any time postprocedure, then
  - CTA Neck (CPT<sup>®</sup> 70498) or MRA Neck (CPT<sup>®</sup> 70548) is indicated for further evaluation and at six-month intervals until decision is made to re-intervene.

### Background and Supporting Information

- Carotid intima-media thickness using duplex ultrasound imaging (Category III code 0126T) is not recommended in clinical practice for risk assessment for a first ASCVD event. Although outcomes data are lacking, Texas has adopted this method in Texas Heart Attack Preventive Screening Bill (HR 1290)
- Texas Heart Attack Preventive Screening Law (HR 1290) mandates that insurers in Texas cover either a calcium scoring study (CPT<sup>®</sup> 75571 or HCPCS S8092) or a carotid intima-media thickness study (ultrasound—Category III code 0126T) every five years for certain populations. To qualify, the following must apply:
  - Must be a member of a fully-insured Texas health plan.
  - Must be male sex assigned at birth age 45 to 75 or female sex assigned at birth age 55 to 75.
  - Must have either diabetes or a Framingham cardiac risk score of intermediate or higher.
  - Must not have had a calcium scoring study or a carotid intima-media thickness study within the past 5 years

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 72 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.
Cardiovascular and Radiology Imaging Guidelines
---

• MRA Neck (CPT<sup>®</sup> 70548) or CTA Neck (CPT<sup>®</sup> 70498) may be indicated if ultrasound is technically difficult or confirmation of the degree of stenosis on ultrasound is needed because an interventional procedure is being considered

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 73 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

	vascular and Radiology imaging Guidelines V2.0.20
	References
	v1.0.202
1. A P h	Aboyans V, Ricco J-B, Bartelink M-LEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Europea Heart Journal. 2017;39(9):763-816. doi:10.1093/eurheartj/ehx095.
2. A th u	CR–AIUM–SPR–SRU. AIUM Practice Parameter for the Performance of an Ultrasound Examination of ne Extracranial Cerebrovascular System. <i>Journal of Ultrasound in Medicine</i> . 2016;35(9):1-11. doi:10.7863/ ultra.35.9.1.
3. S	almela MB, Mortazavi S, Jagadeesan BD, et al. Expert Panel on Neurologic Imaging. ACR Appropriateness
C 4. B S D	Criteria <sup>®</sup> Cerebrovascular Disease. <i>J Am Coll Radiol</i> . 2017;14(5S):S34-S61. doi:10.1016/j.jacr.2017.01.051. Frott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/ SIR/SNIS/SVM/SVS Guideline on the Management of Patients with Extracranial Carotid and Vertebral Artery Disease. <i>J Am Coll Cardiol</i> . 2011;57(8). doi:10.1016/j.jacc.2010.11.006.
5. A c d	sburahma AF, Srivastava M, Aburahma Z, et al. The value and economic analysis of routine postoperative arotid duplex ultrasound surveillance after carotid endarterectomy. <i>J Vasc Surg</i> . 2015;62(2):378-384. loi:10.1016/j.jvs.2015.03.023.
6. D S S	Derdeyn CP, Zipfel GJ, Albuquerque FC, et al. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(8). doi:10.1161/str.000000000000134.
7. G L N	Serhard-Herman M, Gardin JM, Jaff M, Mohler E, Roman M, Naqvi TZ. Guidelines for Noninvasive Vascular aboratory Testing: A Report from the American Society of Echocardiography and the Society of Vascular <i>I</i> edicine and Biology. <i>J Am Soc Echocardiogr</i> . 2006;19(8):955-972. doi:10.1016/j.echo.2006.04.019.
8. G R	Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Circulation</i> . 2014;129(25 suppl 2):s49-s73. doi:10.1161/01.cir.0000437741.48606.98.
9. M S Tr d	Iohler ER, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE. ACCF/ACR/AIUM/ASE/ASN/ICAVL/ CAI/SCCT/SIR/SVM/SVS 2012 Appropriate Use Criteria for Peripheral Vascular Ultrasound and Physiologica Testing Part I: Arterial Ultrasound and Physiological Testing. J Am Coll Cardiol. 2012;60(3):242-276. Ioi:10.1016/i.jacc.2012.02.009.
10. M S	Noresoli P, Habib B, Reynier P, et al. Carotid Stenting versus Endarterectomy for Asymptomatic Carotid Artery Stenosis. Stroke. 2017;48(8):2150-2157. doi:10.1161/strokeaha.117.016824.
11. N A V	laylor A, Ricco J-B, Borst GD, et al. Editor's Choice – Management of Atherosclerotic Carotid and Vertebral artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). <i>Eur J</i> /asc Endovasc Surg. 2018;55(1):3-81. doi:10.1016/j.ejvs.2017.06.021.
12. H o j.j	lasan B, Farah M, Nayfeh T, et al. A systematic review supporting the Society for Vascular Surgery Guideline in the management of carotid artery disease. J Vasc Surg. 2022;75(1S):99S-108S.e42. doi:10.1016/ jvs.2021.06.001.
13. S	hakarchi JA, Lowry D, Nath J, et al. Duplex ultrasound surveillance after carotid artery endarterectomy. lournal of Vascular Surgery. 2016;63(6):1647-1650. doi:10.1016/j.jvs.2016.01.054.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 74 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# **Aortic Imaging**

#### Guideline

Aortic Disorders General Information (PVD-6.1) References Thoracic Aortic Aneurysm (TAA) (PVD-6.2) Abdominal Aortic Aneurysm (AAA) (PVD-6.3) Iliac Artery Aneurysm (IAA) (PVD-6.4) References Aortic and Arterial Dissection and Other Aortic Conditions (PVD-6.7) References Post Aortic Endovascular/Open Surgery Surveillance Studies (PVD-6.8) Large Vessel Vasculitis (PVD-6.9) References (PVD-6.9) Medium Vessel Vasculitis (PVD-6.10) Small Vessel Vasculitis (PVD-6.11)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 75 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Aortic Disorders General Information (PVD-6.1)

PVD.AD.0006.1.A

v1.0.2024

Duplex ultrasound for visceral vascular studies	CPT <sup>®</sup>
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study.	93975
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study.	93976
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study.	93978
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study.	93979
Ultrasound, abdominal aorta, real time, with image documentation, screening study for abdominal aortic aneurysm (AAA) for AAA screening	76706

- In clinical practice, CT, CTA, MRA are usually preferred to evaluate for stenosis of these vessels rather than ultrasound (Exception: Duplex ultrasound is indicated to rule out testicular or ovarian torsion or to evaluate an abdominal bruit or a pulsatile abdominal mass).
- Mesenteric Ischemia
  - See Mesenteric/Colonic Ischemia (AB-6) in the Abdomen Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 76 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

ard	iovascular and Radiology Imaging Guidelines V2.0.202
	References
	PVD.AD.0006.1.4 v1.0.2024
1.	Bonci G, Steigner ML, et al. ACR Appropriateness Criteria <sup>®</sup> Thoracic Aorta Interventional Planning and Follow- Up. <i>J Am Coll Radiol</i> . 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.
2.	Kalva SP, Dill KE, et al. ACR Appropriateness Criteria <sup>®</sup> nontraumatic aortic disease. <i>J Thorac Imaging</i> . 2014;29(5):W85-W88. doi:10.1097/RTI.0000000000000107.
3.	Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissectionsincidence, modes of inheritance, and phenotypic patterns. <i>Ann Thorac Surg.</i> 2006;82(4):1400-1405. doi:10.1016/j.athoracsur.2006.04.098.
4.	Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) <i>J Am Coll Cardiol</i> . 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
5.	Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. <i>J Am Coll Radiol.</i> 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
6.	Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm <i>.J Vasc Surg.</i> 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
7.	Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. <i>Ann Thorac Surg</i> 2002; 74: S1877-S1880.
8.	Erben Y, Brownstein AJ, Rajaee S. Natural History of and Management of Splanchnic Artery Aneurysms in a Single Tertiary Referral Center. <i>J Vasc Surg</i> 2018 Oct; 68(4): 1079-1087.
9.	Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. <i>J Vasc Surg.</i> 2020;72(1S):3S-39S. doi:10.1016/j.jvs.2020.01.039.
10.	Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria <sup>®</sup> Acute Chest Pain Suspected Aortic Dissection. <i>American College of Radiology (ACR</i> ); 2014.
11.	Collard M, Sutphin PD, Kalva SP, et al. Expert Panel on Vascular Imaging. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm Follow-up (without Repair). <i>J Am Coll Radiol</i> . 2019;16(5S):S2-S6. doi:10.1016/ j.jacr.2019.02.005.
12.	Corey MR, Ergul EA, Cambria RP. The Natural History of Sphlanchnic Aneurysms and Outcome after Operative Intervention. <i>J Vasc Surg.</i> 2016 April 63 (4):949-57.
13.	Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> . 2018;77(5):636-643. doi:10.1136/annrheumdis-2017-212649.
14.	Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients with suspected acute nontraumatic thoracic aortic dissection. <i>Ann Emerg Med.</i> 2015 Jan; 65 (1) :32-42.
15.	Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interventional
	Radiology. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. <i>J Am Coll Radiol.</i> 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.
16.	Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria <sup>®</sup> Renovascular Hypertension. <i>J Am Coll Radiol</i> . 2017;14(11). doi:10.1016/j.jacr.2017.08.040.
17.	Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. <i>J Am Coll Cardiol</i> . 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 77 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Card	iovascular and Radiology Imaging Guidelines	V2.0.202
18.	Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. <i>Radiol Clin North Am</i> . 2020;58(4): doi:10.1016/j.rcl.2020.02.009.	721-731.
19.	Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines and Management of Patients with Thoracic Aortic Disease. <i>Circulation</i> 2010; 121: e266-e369.	for the Diagnosis
20.	Masuda Y1, Yamada Z, Morooka N, Watanabe S, Inagaki Y.Prognosis of patients with medically dissections. <i>Circulation</i> . 1991 Nov;84(5 Suppl):III7-13.	/ treated aortic
21.	Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. <i>New England Journal of Med</i> 2006;355(4):385-392. doi:10.1056/nejmcp041698.	dicine.
22.	Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management o dysplasia. <i>Journal of Hypertension</i> . 2014;32(7):1367-1378.doi:10.1097/hjh.00000000000213	f fibromuscular
23.	Sakamoto I, Sueyoshi E, Hazama S, et al. Endovascular treatment of iliac artery aneurysms. <i>Ra</i> October 2005;25:S213-S227.	adiographics
24.	Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocar Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aort Systematic Review and Meta-analysis. <i>Arch Intern Med</i> 2006; 166 (13): 1350-1356.	diography, ic Dissection:
25.	Alcantara S, Yang CK, Sasson J, et al. The evidence for nonoperative management of visceral dissections: a single-center experience. <i>Ann Vasc Surg.</i> 2015;29(1):103-108. doi:10.1016/j.avsg	artery g.2014.09.004.
26.	Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneu <i>American Journal of Roentgenology</i> . 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.	rysm Repair.
27.	Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic v 2009; 119: 880-890.	alve. Circulation
28.	Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. <i>Contrast Mec Imaging</i> . 2019;2019:1-8. doi:10.1155/2019/9157637.	ne Diagnosis of lia & Molecular
29.	van Bogerijen GH, Tolenaar JL, Rampoldi V, et.al. Predictors of aortic growth in uncomplicated to dissection. <i>J Vasc Surg.</i> 2014 Apr;59(4):1134-43. doi: 10.1016/j.jvs.2014.01.042.	type B aortic
30.	Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pres A Report of the American College of Cardiology/American Heart Association Task Force on Clir Guidelines. <i>Hypertension</i> . 2018;71(6). doi:10.1161/hyp.000000000000065.	/ASPC/NMA/ ssure in Adults: lical Practice
31.	Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on for vascular surgery arterial procedures. <i>J Vasc Surg</i> . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.	llow-up after 04.018.1.
32.	Salim S, Machin M, Patterson BO, Bicknell C. The Management of Penetrating Aortic Ulcer. <i>He</i> 2020;1(1):5-13. doi:10.3390/hearts1010003.	arts.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 78 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Thoracic Aortic Aneurysm (TAA) (PVD-6.2)

PVD.AI.0006.2.A v1.0.2024

## Thoracic Aortic Aneurysm (TAA) (PVD-6.2)

- Advanced imaging with a CT or MR is preferred imaging for this diagnosis. Transesophageal echocardiogram (TEE) can also be indicated for initial imaging of ascending and descending thoracic aortic aneurysms. For repeat imaging or established thoracic aneurysms, TEE is indicated **only** when imaging with CT or MR is contraindicated.
- Given the diversity of studies, pathology, and provider preference, ONE of the imaging studies in the Table of Thoracic Aorta Imaging Options can be approved for Thoracic Aortic Aneurysm (TAA) as indicated in this section

Table of Thoracic Aorta Imaging Options	CPT <sup>®</sup>
CT Chest with contrast	71260
CT Chest without contrast	71250
CTA Chest	71275
MRA Chest	71555
TEE	93312-93314

- For TAA associated with a dissection, please see section <u>Aortic Dissection and</u> <u>Other Aortic Conditions (PVD-6.7)</u>
- For suspected TAA, any requested imaging from the Table of Thoracic Aorta Imaging Options above:
  - Abnormalities identified on chest x-ray (abnormality including widened mediastinum, suspicious calcifications) or other imaging studies (fluoroscopy, MRI Spine, etc.) abnormality.
- For known TAA accompanied with chest pain or back pain and suspicion of rupture, any requested imaging from the Table of Thoracic Aorta Imaging Options above.
- For planning for pre-thoracic endovascular repair (TEVAR) of thoracic aorta disease.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 79 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc. Click Anywhere in the Header to Return to the Main Table of Contents

Cardiovascular and Radiology Imaging Guidelines

- CTA Chest, and/or Abdomen, and/or Pelvis (CPT<sup>®</sup> 71275, CPT<sup>®</sup> 74175, CPT<sup>®</sup> 72191, CPT<sup>®</sup> 74174); or
- MRA Chest, and/or Abdomen, and/or Pelvis (CPT<sup>®</sup> 71555, CPT<sup>®</sup> 74185, CPT<sup>®</sup> 72198).
- For follow-up of ascending aortic aneurysms CTA Chest (CPT<sup>®</sup> 71275) or CT Chest (CPT<sup>®</sup> 71250 or CPT<sup>®</sup> 71260) or MRA chest (CPT<sup>®</sup> 71555)
  - Operative treatment is reasonable for asymptomatic individuals when the diameter of the arch exceeds 5.5 cm.
  - For individuals with ascending aortic aneurysms <4.0 cm in diameter
    - Repeat imaging annually
  - For individuals with ascending aortic aneurysms ≥4.0 cm
    - Repeat imaging 6 months.
  - TEE is indicated **only** when imaging with CT or MR is contraindicated
- For follow-up of descending aortic aneurysms, any requested imaging from the "Table of Thoracic Aorta Imaging Options" above for the following:
  - "Medically" treated/observation.
    - 3.5cm to 4.4 cm TAA can be followed annually.
    - ≥4.5 cm TAA can be followed every 6 months.
    - ≥3.0 cm TAA when there is concern for growth can have a one-time 3-month interval advanced imaging.
  - TEE is indicated **only** when imaging with CT or MR is contraindicated
- Screening in the presence of other aortic aneurysms.
  - In an individual with a known TAA, screening for AAA is indicated with an abdominal duplex. See **Abdominal Aortic Aneurysm (AAA) (PVD-6.3)**.
  - In an individual with a known AAA, screening for TAA is not supported by sufficient evidence.
- Screening in individuals with bicuspid aortic valve or familial TAA syndromes. See <u>Screening for TAA with bicuspid aortic valve (PVD-2.3)</u>. See <u>Screening for</u> <u>Vascular related genetic connective tissue Disorders (PVD-2.2)</u>

## Background and Supporting Information

The thoracic aorta is generally divided into two segments: the ascending aorta, which includes the aortic root, aortic arch and ends just distal to the left subclavian artery and the descending aorta, which starts just distal to the left subclavian artery to the level of the diaphragm.

## References

 Bonci G, Steigner ML, et al. ACR Appropriateness Criteria<sup>®</sup> Thoracic Aorta Interventional Planning and Follow-Up. J Am Coll Radiol. 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 80 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

ard	iovascular and Radiology Imaging Guidelines V2.0.202
2.	Kalva SP, Dill KE, et al. ACR Appropriateness Criteria <sup>®</sup> nontraumatic aortic disease. <i>J Thorac Imaging</i> . 2014:29(5):W85-W88. doi:10.1097/RTI.0000000000000107.
3.	Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissectionsincidence, modes of inheritance, and phenotypic patterns. <i>Ann Thorac Surg.</i> 2006;82(4):1400-1405. doi:10.1016/j.athoracsur.2006.04.098.
4.	Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) <i>J Am Coll Cardiol</i> . 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
5.	Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. <i>J Am Coll Radiol</i> . 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
6.	Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm <i>J Vasc Surg.</i> 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
7.	Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. <i>Ann Thorac Surg</i> 2002; 74: S1877-S1880.
8.	Erben Y, Brownstein AJ, Rajaee S. Natural History of and Management of Splanchnic Artery Aneurysms in a Single Tertiary Referral Center. <i>J Vasc Surg</i> 2018 Oct; 68(4): 1079-1087.
9.	Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. <i>J Vasc Surg.</i> 2020;72(1S):3S-39S. doi:10.1016/j.jvs.2020.01.039.
0.	Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria <sup>®</sup> Acute Chest Pain Suspected Aortic Dissection. <i>American College of Radiology (ACR)</i> ; 2014.
11.	Collard M, Sutphin PD, Kalva SP, et al. Expert Panel on Vascular Imaging. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm Follow-up (without Repair). <i>J Am Coll Radiol</i> . 2019;16(5S):S2-S6. doi:10.1016/ j.jacr.2019.02.005.
2.	Corey MR, Ergul EA, Cambria RP. The Natural History of Sphlanchnic Aneurysms and Outcome after Operative Intervention. <i>J Vasc Surg.</i> 2016 April 63 (4):949-57.
3.	Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> . 2018;77(5):636-643. doi:10.1136/annrheumdis-2017-212649.
4.	Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients with suspected acute nontraumatic thoracic aortic dissection. <i>Ann Emerg Med.</i> 2015 Jan; 65 (1) :32-42.
5.	Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interventional
	Radiology. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. <i>J Am Coll Radiol</i> . 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.
6.	Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria <sup>®</sup> Renovascular Hypertension. <i>J Am Coll Radiol</i> . 2017;14(11). doi:10.1016/j.jacr.2017.08.040.
7.	Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCA/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. <i>J Am Coll Cardiol</i> . 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015.
8.	Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. <i>Radiol Clin North Am</i> . 2020;58(4):721-731. doi:10.1016/j.rcl.2020.02.009.
9.	Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease. <i>Circulation</i> 2010; 121: e266-e369.
20.	Masuda Y1, Yamada Z, Morooka N, Watanabe S, Inagaki Y.Prognosis of patients with medically treated aortic dissections. <i>Circulation</i> . 1991 Nov;84(5 Suppl):III7-13.
21.	Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. New England Journal of Medicine.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 81 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- 22. Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. *Journal of Hypertension*. 2014;32(7):1367-1378.doi:10.1097/hjh.0000000000213.
- 23. Sakamoto I, Sueyoshi E, Hazama S, et al. Endovascular treatment of iliac artery aneurysms. *Radiographics* October 2005;25:S213-S227.
- 24. Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocardiography, Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aortic Dissection: Systematic Review and Meta-analysis. *Arch Intern Med* 2006; 166 (13): 1350-1356.
- 25. Alcantara S, Yang CK, Sasson J, et al. The evidence for nonoperative management of visceral artery dissections: a single-center experience. *Ann Vasc Surg.* 2015;29(1):103-108. doi:10.1016/j.avsg.2014.09.004.
- 26. Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneurysm Repair. American Journal of Roentgenology. 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.
- 27. Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic valve. *Circulation* 2009; 119: 880-890.
- Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. *Contrast Media & Molecular Imaging*. 2019;2019:1-8. doi:10.1155/2019/9157637.
- 29. van Bogerijen GH, Tolenaar JL, Rampoldi V, et.al. Predictors of aortic growth in uncomplicated type B aortic dissection. *J Vasc Surg.* 2014 Apr;59(4):1134-43. doi: 10.1016/j.jvs.2014.01.042.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6). doi:10.1161/hyp.0000000000000065.
- 31. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg*. 2018;68(1):256-284. doi:10.1016/j.jvs.2018.04.018.1.
- 32. Salim S, Machin M, Patterson BO, Bicknell C. The Management of Penetrating Aortic Ulcer. *Hearts*. 2020;1(1):5-13. doi:10.3390/hearts1010003.

V2.0.2024

## Abdominal Aortic Aneurysm (AAA) (PVD-6.3)

PVD.AD.0006.3.A v1.0.2024

## Screen for AAA

- Ultrasound abdominal aorta with any of the studies from the table of Duplex ultrasound for visceral vascular studies in <u>Aortic Disorders General Information</u> (<u>PVD-6.1</u>) is the preferred initial imaging study to screen for AAA.
- One-time screening recommendations for AAA (Ultrasound CPT<sup>®</sup> 76706)
  - Individuals 65 to 75 years of age with a history of tobacco use.
  - Individuals older than 75 years with a history of tobacco use and in otherwise good health who have not previously received a screening ultrasound examination.
  - All first-degree relatives of individuals who present with an AAA and are between 65 and 75, or in those older than 75 in good health.
- AAA screening is reasonable with ultrasound (CPT<sup>®</sup> 76706, 93975, 93976, 93978, or 93979) if there is a documented thoracic aortic aneurysm; however, there is insufficient evidence to support the use of advanced imaging to screen for a thoracic aortic aneurysm in individuals with known abdominal aortic aneurysm.

## Survey known AAA

- Ultrasound abdominal aorta with any of the studies from the table of Duplex ultrasound for visceral vascular studies in <u>Aortic Disorders General Information</u> (<u>PVD-6.1</u>) is the preferred initial imaging study to survey known AAA.
- Surveillance recommendations for AAA (CPT<sup>®</sup> 76706, 93975, 93976, 93978, 93979)
  - >2.5 cm but <3.0 cm: 10 years</li>
  - 3.0 cm to 3.9 cm: 3 year intervals
  - 4.0 cm to 4.9 cm: every 12 months
  - 5.0 cm to 5.4 cm: every 6 months
  - >5.4 cm or aortic diameter has increased in size by 0.5 cm in six months, or at least 1 cm in a year may undergo more frequent monitoring and should be evaluated by a Vascular Specialist
- Additional Imaging
  - CT Abdomen and Pelvis with contrast (CPT<sup>®</sup> 74177), CT Abdomen and Pelvis without contrast (CPT<sup>®</sup> 74176), or CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174), or CTA Abdomen (CPT<sup>®</sup> 74175), or CTA Pelvis (CPT<sup>®</sup> 72191).
    - Suspected or known AAA with recent-onset abdominal or back pain, particularly in the presence of a pulsatile epigastric mass or significant risk factors for AAA

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 83 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Pre-operative imaging for AAA repair

### Evaluate a pulsatile abdominal mass

- Ultrasound abdominal aorta with any of the studies from the table of Duplex ultrasound for visceral vascular studies in <u>Aortic Disorders General Information</u> (<u>PVD-6.1</u>) is the preferred initial imaging study to evaluate a pulsatile abdominal mass.
- Additional Imaging
  - CT Abdomen and Pelvis with contrast (CPT<sup>®</sup> 74177), CT Abdomen and Pelvis without contrast (CPT<sup>®</sup> 74176), or CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174), or CTA Abdomen (CPT<sup>®</sup> 74175), or CTA Pelvis (CPT<sup>®</sup> 72191).
    - Suspected or known AAA with recent-onset abdominal or back pain, particularly in the presence of a pulsatile epigastric mass or significant risk factors for AAA
    - Pre-operative imaging for AAA repair

### Obese Individual (BMI ≥35)

CT Abdomen and Pelvis with contrast (CPT<sup>®</sup> 74177) or without contrast (CPT<sup>®</sup> 74176) can be substituted for US using the same timeline as a non-obese individual. Ultrasound abdominal aorta should ideally first be attempted to see if the image quality is adequate.

## References

- Bonci G, Steigner ML, et al. ACR Appropriateness Criteria<sup>®</sup> Thoracic Aorta Interventional Planning and Follow-Up. *J Am Coll Radiol*. 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.
- Kalva SP, Dill KE, et al. ACR Appropriateness Criteria<sup>®</sup> nontraumatic aortic disease. J Thorac Imaging. 2014;29(5):W85-W88. doi:10.1097/RTI.00000000000107.
- Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns. *Ann Thorac Surg.* 2006;82(4):1400-1405. doi:10.1016/ j.athoracsur.2006.04.098.
- Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations). *J Am Coll Cardiol.* 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
- Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. J Am Coll Radiol. 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
- 6. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm *.J Vasc Surg.* 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
- 7. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. *Ann Thorac Surg* 2002; 74: S1877-S1880.
- 8. Erben Y, Brownstein AJ, Rajaee S. Natural History of and Management of Splanchnic Artery Aneurysms in a Single Tertiary Referral Center. *J Vasc Surg* 2018 Oct; 68(4): 1079-1087.
- 9. Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. *J Vasc Surg.* 2020;72(1S):3S-39S. doi:10.1016/j.jvs.2020.01.039.
- Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria<sup>®</sup> Acute Chest Pain -- Suspected Aortic Dissection. American College of Radiology (ACR); 2014.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 84 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Card	liovascular and Radiology Imaging Guidelines	V2.0.2024
11.	Collard M, Sutphin PD, Kalva SP, et al. Expert Panel on Vascular Imaging. ACR Appropriateness Abdominal Aortic Aneurysm Follow-up (without Repair). <i>J Am Coll Radiol</i> . 2019;16(5S):S2-S6. d j.jacr.2019.02.005.	s Criteria <sup>®</sup> oi:10.1016/
12.	Corey MR, Ergul EA, Cambria RP. The Natural History of Sphlanchnic Aneurysms and Outcome Intervention. <i>J Vasc Surg.</i> 2016 April 63 (4):949-57.	after Operative
13.	Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large v vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> . 2018;77(5):636-643. doi:10.113 annrheumdis-2017-212649.	ressel 96/
14.	Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy issues in the evaluation and management of adult patients with suspected acute nontraumatic the dissection. <i>Ann Emerg Med.</i> 2015 Jan; 65 (1):32-42.	y: critical noracic aortic
15.	Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interv	ventional
	Radiology. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning <i>J Am Coll Radiol</i> . 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.	and Follow-Up.
16.	Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria <sup>®</sup> Renovascular Hypertens <i>Radiol.</i> 2017;14(11). doi:10.1016/j.jacr.2017.08.040.	sion. J Am Coll
17.	Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCA/SIR/ST Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline Association for Thoracic Surgery, American College of Radiology,American Stroke Association, S Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Sc Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine [public appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. <i>J Am Coll Cardiol</i> . 2010;55(14):e27 doi:10.1016/j.jacc.2010.02.015.	S/SVM of the American s, American Society of ociety of shed correction -e129.
18.	Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. <i>Radiol Clin North Am</i> . 2020;58(4):7 doi:10.1016/j.rcl.2020.02.009.	21-731.
19.	Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines for and Management of Patients with Thoracic Aortic Disease. <i>Circulation</i> 2010; 121: e266-e369.	or the Diagnosis
20.	Masuda Y1, Yamada Z, Morooka N, Watanabe S, Inagaki Y.Prognosis of patients with medically dissections. <i>Circulation</i> . 1991 Nov;84(5 Suppl):III7-13.	treated aortic
21.	Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. <i>New England Journal of Med</i> 2006;355(4):385-392. doi:10.1056/nejmcp041698.	icine.
22.	Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of dysplasia. <i>Journal of Hypertension</i> . 2014;32(7):1367-1378.doi:10.1097/hjh.000000000000213.	fibromuscular
23.	Sakamoto I, Sueyoshi E, Hazama S, et al. Endovascular treatment of iliac artery aneurysms. <i>Ra</i> October 2005;25:S213-S227.	diographics
24.	Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocarc Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aortic Systematic Review and Meta-analysis. <i>Arch Intern Med</i> 2006; 166 (13): 1350-1356.	liography, c Dissection:
25.	Alcantara S, Yang CK, Sasson J, et al. The evidence for nonoperative management of visceral a dissections: a single-center experience. Ann Vasc Surg. 2015;29(1):103-108. doi:10.1016/j.avsg	artery .2014.09.004.
26.	Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneur American Journal of Roentgenology. 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.	ysm Repair.
27.	Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic va 2009; 119: 880-890.	lve. Circulation
28.	Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in th Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. <i>Contrast Medi Imaging</i> . 2019;2019:1-8. doi:10.1155/2019/9157637.	e Diagnosis of ia & Molecular
29.	van Bogerijen GH, Tolenaar JL, Rampoldi V, et.al. Predictors of aortic growth in uncomplicated ty dissection. J Vasc Surg. 2014 Apr;59(4):1134-43. doi: 10.1016/j.jvs.2014.01.042.	ype B aortic
30.	Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pres	ASPC/NMA/ sure in Adults:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 85 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

		Imaging		Inconstruct and	( 'ordiovoooul
uldelines	ing Guidell	imaging	Radiology	ascular and	ovascui

V2.0.2024

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6). doi:10.1161/hyp.00000000000065.

- 31. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg* . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.04.018.1.
- 32. Salim S, Machin M, Patterson BO, Bicknell C. The Management of Penetrating Aortic Ulcer. *Hearts*. 2020;1(1):5-13. doi:10.3390/hearts1010003.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 86 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Iliac Artery Aneurysm (IAA) (PVD-6.4)

## PVD.AD.0006.4.A

v1.0.2024

- Ultrasound (CPT<sup>®</sup> 76882 or CPT<sup>®</sup> 93925) for evaluation of a suspected IAA
  - CT Pelvis with contrast (CPT<sup>®</sup> 72193) if ultrasound is equivocal.
  - Outrasound for follow-up imaging annually if an aneurysm is ≥2cm
- Additional Imaging
  - CT Abdomen and Pelvis with contrast (CPT<sup>®</sup> 74177), CT Abdomen and Pelvis without and with contrast (CPT<sup>®</sup> 74178), or CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174) for preoperative imaging if endovascular or open repair is being considered

## Background and Supporting Information

- · Isolated IAA's are rare and are typically associated with AAA
- Approximately one third to one half of isolated IAA's are bilateral at time of presentation
- Abdominal Aortic aneurysm rupture usually occurs at a diameter of 5 cm or larger, whereas common iliac aneurysms that are less than 3 cm in diameter almost never rupture

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 87 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

ard	iovascular and Radiology Imaging Guidelines V2.0.202
	References
	PVD.AD.0006.4.4 v1.0.202
1.	Bonci G, Steigner ML, et al. ACR Appropriateness Criteria <sup>®</sup> Thoracic Aorta Interventional Planning and Follow- Up. <i>J Am Coll Radiol.</i> 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.
2.	Kalva SP, Dill KE, et al. ACR Appropriateness Criteria <sup>®</sup> nontraumatic aortic disease. <i>J Thorac Imaging</i> . 2014;29(5):W85-W88. doi:10.1097/RTI.000000000000107.
3.	Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissectionsincidence, modes of inheritance, and phenotypic patterns. <i>Ann Thorac Surg.</i> 2006;82(4):1400-1405. doi:10.1016/ j.athoracsur.2006.04.098.
4.	Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) <i>J Am Coll Cardiol.</i> 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
5.	Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. <i>J Am Coll Radiol</i> . 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
6.	Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm <i>.J Vasc Surg.</i> 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
7.	Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. <i>Ann Thorac Surg</i> 2002; 74: S1877-S1880.
8.	Erben Y, Brownstein AJ, Rajaee S. Natural History of and Management of Splanchnic Artery Aneurysms in a Single Tertiary Referral Center. <i>J Vasc Surg</i> 2018 Oct; 68(4): 1079-1087.
9.	Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. <i>J Vasc Surg.</i> 2020;72(1S):3S-39S. doi:10.1016/j.jvs.2020.01.039.
10.	Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria <sup>®</sup> Acute Chest Pain Suspected Aortic Dissection. <i>American College of Radiology (ACR</i> ); 2014.
11.	Collard M, Sutphin PD, Kalva SP, et al. Expert Panel on Vascular Imaging. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm Follow-up (without Repair). <i>J Am Coll Radiol</i> . 2019;16(5S):S2-S6. doi:10.1016/ j.jacr.2019.02.005.
12.	Corey MR, Ergul EA, Cambria RP. The Natural History of Sphlanchnic Aneurysms and Outcome after Operative Intervention. <i>J Vasc Surg.</i> 2016 April 63 (4):949-57.
13.	Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> . 2018;77(5):636-643. doi:10.1136/annrheumdis-2017-212649.
14.	Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients with suspected acute nontraumatic thoracic aortic dissection. <i>Ann Emerg Med</i> . 2015 Jan; 65 (1):32-42.
15.	Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interventional
	Radiology. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. <i>J Am Coll Radiol.</i> 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.
16.	Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria <sup>®</sup> Renovascular Hypertension. <i>J Am Coll Radiol.</i> 2017;14(11). doi:10.1016/j.jacr.2017.08.040.
17.	Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine [published correction appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. <i>J Am Coll Cardiol</i> . 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 88 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Card	iovascular and Radiology Imaging Guidelines	V2.0.202
18.	Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. <i>Radiol Clin North Am</i> . 2020;58(4): doi:10.1016/j.rcl.2020.02.009.	721-731.
19.	Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines and Management of Patients with Thoracic Aortic Disease. <i>Circulation</i> 2010; 121: e266-e369.	for the Diagnosis
20.	Masuda Y1, Yamada Z, Morooka N, Watanabe S, Inagaki Y.Prognosis of patients with medically dissections. <i>Circulation</i> . 1991 Nov;84(5 Suppl):III7-13.	/ treated aortic
21.	Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. <i>New England Journal of Med</i> 2006;355(4):385-392. doi:10.1056/nejmcp041698.	dicine.
22.	Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management o dysplasia. <i>Journal of Hypertension</i> . 2014;32(7):1367-1378.doi:10.1097/hjh.00000000000213	f fibromuscular
23.	Sakamoto I, Sueyoshi E, Hazama S, et al. Endovascular treatment of iliac artery aneurysms. <i>Ra</i> October 2005;25:S213-S227.	adiographics
24.	Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocar Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aort Systematic Review and Meta-analysis. <i>Arch Intern Med</i> 2006; 166 (13): 1350-1356.	diography, ic Dissection:
25.	Alcantara S, Yang CK, Sasson J, et al. The evidence for nonoperative management of visceral dissections: a single-center experience. <i>Ann Vasc Surg.</i> 2015;29(1):103-108. doi:10.1016/j.avsg	artery g.2014.09.004.
26.	Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneu <i>American Journal of Roentgenology</i> . 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.	rysm Repair.
27.	Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic v 2009; 119: 880-890.	alve. Circulation
28.	Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. <i>Contrast Mec Imaging</i> . 2019;2019:1-8. doi:10.1155/2019/9157637.	ne Diagnosis of <i>lia &amp; Molecular</i>
29.	van Bogerijen GH, Tolenaar JL, Rampoldi V, et.al. Predictors of aortic growth in uncomplicated to dissection. <i>J Vasc Surg.</i> 2014 Apr;59(4):1134-43. doi: 10.1016/j.jvs.2014.01.042.	type B aortic
30.	Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pres A Report of the American College of Cardiology/American Heart Association Task Force on Clir Guidelines. <i>Hypertension</i> . 2018;71(6). doi:10.1161/hyp.000000000000065.	/ASPC/NMA/ ssure in Adults: lical Practice
31.	Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on for vascular surgery arterial procedures. <i>J Vasc Surg</i> . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.	llow-up after 04.018.1.
32.	Salim S, Machin M, Patterson BO, Bicknell C. The Management of Penetrating Aortic Ulcer. <i>He</i> 2020;1(1):5-13. doi:10.3390/hearts1010003.	arts.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 89 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Aortic and Arterial Dissection and Other Aortic Conditions (PVD-6.7)

PVD.AD.0006.7.A

v1.0.2024

Imaging for Aortic conditions	CPT <sup>®</sup>
CT Chest, and/or Abdomen, and/or Pelvis	71260 74177 74160 72193
CTA Chest, and/or Abdomen, and/or Pelvis	71275 74175 72191 74174
MRA Chest, and/or Abdomen, and/or Pelvis	71555 74185 72198

- CTA or MRA of the entire aorta (including arch branches) and extending through the femoral arteries for suspected aortic dissection. Any of the following studies can be used if acute dissection is suspected:
  - CT Chest (CPT<sup>®</sup> 71260 or CPT<sup>®</sup> 71270) and/or one of the following:
    - CT Abdomen (CPT<sup>®</sup> 74160 or CPT<sup>®</sup> 74170) with or without and with contrast
    - CT Pelvis (CPT<sup>®</sup> 72193 or CPT<sup>®</sup> 72194) with or without and with contrast
    - CT Abdomen and Pelvis (CPT<sup>®</sup> 74177 or CPT<sup>®</sup> 74178) with or without and with contrast
  - CTA Chest (CPT<sup>®</sup> 71275) and/or **one** of the following:
    - CTA Abdomen (CPT<sup>®</sup> 74175)
    - CTA Pelvis (CPT<sup>®</sup> 72191)
    - CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 90 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- MRA Chest and/or Abdomen and/or Pelvis (CPT<sup>®</sup> 71555 and/or CPT<sup>®</sup> 74185 and/ or CPT<sup>®</sup> 72198)
- Chronic Aortic Dissections- 1/3 of individuals with chronic type B dissections that were not treated via open or endovascular repair will go on to develop aneurysmal disease requiring subsequent intervention.
  - Advanced imaging of the affected segment of the aorta with any of the studies in above table <u>Imaging for Aortic conditions</u> can be performed as follows:
    - In individuals with a persistent false lumen or initial aortic diameter of ≥4cm:
      - Every 6 months for two years until stability has been reached
      - Then annually
    - In individuals with initial aortic diameter of <4cm and/or a thrombosed false lumen:
      - Annually
    - Any time if the individual is symptomatic with chest pain, back pain or has any evidence of end organ ischemia: renal dysfunction, mesenteric ischemia or acute limb ischemia
- In individuals with Marfan syndrome/Loeys-Dietz/Ehlers-Danlos
  - As aneurysmal expansion within a dissection can occur rapidly, post-dissection imaging in these individuals is indicated as follows:
    - 1 month
    - 3 months
    - 6 months
    - 12 months
    - yearly thereafter
  - Depending on the location of the dissection the following may be approved:
    - CTA or MRA Head (CPT<sup>®</sup> 70496 or CPT<sup>®</sup> 70544)
    - Carotid duplex or CTA Neck or MRA Neck (CPT<sup>®</sup> 93980, CPT<sup>®</sup> 70498, or CPT<sup>®</sup> 70547)
    - CTA or MRA Chest (CPT<sup>®</sup> 71275 or CPT<sup>®</sup> 71555)
    - CTA Abdomen and Pelvis (CPT<sup>®</sup> 74174); or CTA or MRA Abdomen (CPT<sup>®</sup> 74175 or CPT<sup>®</sup> 74185); or CTA or MRA Pelvis (CPT<sup>®</sup> 72191 or CPT<sup>®</sup> 72198)
- Asymptomatic incidentally found arterial dissections not affecting the aorta including but not excluded to iliac arteries, visceral arteries, extracranial arteries can be imaged according to the general schedule:
  - Within one month of discovery
  - Six months
  - 12 months
  - No further imaging after 12 months if noted to be stable
- Asymptomatic penetrating aortic ulcers can be imaged according to the following time intervals:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 91 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- Within one month of discovery
- Three months
- Six months
- Twelve months
- Annually until decision made to intervene

## Background and Supporting Information

Classic symptoms of sharp, severe acute onset of retrosternal or interscapular chest pain is seen in 96% and is best adapted to the emergent setting. Chest x-ray is imprecise; any suspicion should be considered since up to 10% of individuals with aortic dissection present without classic symptoms.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 92 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

ard	iovascular and Radiology Imaging Guidelines V2.0.202
	References
	PVD.AD.0006.7./ v1.0.202
1.	Bonci G, Steigner ML, et al. ACR Appropriateness Criteria <sup>®</sup> Thoracic Aorta Interventional Planning and Follow- Up. <i>J Am Coll Radiol</i> . 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.
2.	Kalva SP, Dill KE, et al. ACR Appropriateness Criteria <sup>®</sup> nontraumatic aortic disease. <i>J Thorac Imaging</i> . 2014:29(5):W85-W88. doi:10.1097/RTI.000000000000107.
3.	Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissectionsincidence, modes of inheritance, and phenotypic patterns. <i>Ann Thorac Surg.</i> 2006;82(4):1400-1405. doi:10.1016/j.athoracsur.2006.04.098.
4.	Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations) <i>J Am Coll Cardiol</i> . 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
5.	Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. <i>J Am Coll Radiol</i> . 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
6.	Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm . <i>J Vasc Surg.</i> 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
7.	Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. <i>Ann Thorac Surg</i> 2002; 74: S1877-S1880.
8.	Erben Y, Brownstein AJ, Rajaee S. Natural History of and Management of Splanchnic Artery Aneurysms in a Single Tertiary Referral Center. <i>J Vasc Surg</i> 2018 Oct; 68(4): 1079-1087.
9.	Chaer RA, Abularrage CJ, Coleman DM, et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. <i>J Vasc Surg.</i> 2020;72(1S):3S-39S. doi:10.1016/j.jvs.2020.01.039.
10.	Expert Panel on Cardiac Imaging. ACR Appropriateness Criteria <sup>®</sup> Acute Chest Pain Suspected Aortic Dissection. <i>American College of Radiology (ACR</i> ); 2014.
11.	Collard M, Sutphin PD, Kalva SP, et al. Expert Panel on Vascular Imaging. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm Follow-up (without Repair). <i>J Am Coll Radiol</i> . 2019;16(5S):S2-S6. doi:10.1016/ j.jacr.2019.02.005.
12.	Corey MR, Ergul EA, Cambria RP. The Natural History of Sphlanchnic Aneurysms and Outcome after Operative Intervention. <i>J Vasc Surg.</i> 2016 April 63 (4):949-57.
13.	Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> . 2018;77(5):636-643. doi:10.1136/annrheumdis-2017-212649.
14.	Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients with suspected acute nontraumatic thoracic aortic dissection. <i>Ann Emerg Med</i> . 2015 Jan: 65 (1):32-42.
15.	Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interventional
	Radiology. ACR Appropriateness Criteria <sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. <i>J Am Coll Radiol.</i> 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.
16.	Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria <sup>®</sup> Renovascular Hypertension. <i>J Am Coll Radiol</i> . 2017;14(11). doi:10.1016/j.jacr.2017.08.040.
17.	Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. <i>J Am Coll Cardiol</i> . 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 93 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Card	iovascular and Radiology Imaging Guidelines	V2.0.202
18.	Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. <i>Radiol Clin North Am</i> . 2020;58(4): doi:10.1016/j.rcl.2020.02.009.	721-731.
19.	Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines and Management of Patients with Thoracic Aortic Disease. <i>Circulation</i> 2010; 121: e266-e369.	for the Diagnosis
20.	Masuda Y1, Yamada Z, Morooka N, Watanabe S, Inagaki Y.Prognosis of patients with medically dissections. <i>Circulation</i> . 1991 Nov;84(5 Suppl):III7-13.	/ treated aortic
21.	Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. <i>New England Journal of Med</i> 2006;355(4):385-392. doi:10.1056/nejmcp041698.	dicine.
22.	Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management o dysplasia. <i>Journal of Hypertension</i> . 2014;32(7):1367-1378.doi:10.1097/hjh.00000000000213	f fibromuscular
23.	Sakamoto I, Sueyoshi E, Hazama S, et al. Endovascular treatment of iliac artery aneurysms. <i>Ra</i> October 2005;25:S213-S227.	adiographics
24.	Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocar Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aort Systematic Review and Meta-analysis. <i>Arch Intern Med</i> 2006; 166 (13): 1350-1356.	diography, ic Dissection:
25.	Alcantara S, Yang CK, Sasson J, et al. The evidence for nonoperative management of visceral dissections: a single-center experience. <i>Ann Vasc Surg.</i> 2015;29(1):103-108. doi:10.1016/j.avsg	artery g.2014.09.004.
26.	Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneu <i>American Journal of Roentgenology</i> . 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.	rysm Repair.
27.	Tadros TM, Klein MD, Shapira OM. Ascending aortic dilatation associated with bicuspid aortic v 2009; 119: 880-890.	alve. Circulation
28.	Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. <i>Contrast Mec Imaging</i> . 2019;2019:1-8. doi:10.1155/2019/9157637.	ne Diagnosis of <i>lia &amp; Molecular</i>
29.	van Bogerijen GH, Tolenaar JL, Rampoldi V, et.al. Predictors of aortic growth in uncomplicated to dissection. <i>J Vasc Surg.</i> 2014 Apr;59(4):1134-43. doi: 10.1016/j.jvs.2014.01.042.	type B aortic
30.	Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pres A Report of the American College of Cardiology/American Heart Association Task Force on Clir Guidelines. <i>Hypertension</i> . 2018;71(6). doi:10.1161/hyp.000000000000065.	/ASPC/NMA/ ssure in Adults: lical Practice
31.	Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on for vascular surgery arterial procedures. <i>J Vasc Surg</i> . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.	llow-up after 04.018.1.
32.	Salim S, Machin M, Patterson BO, Bicknell C. The Management of Penetrating Aortic Ulcer. <i>He</i> 2020;1(1):5-13. doi:10.3390/hearts1010003.	arts.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 94 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Post Aortic Endovascular/Open Surgery Surveillance Studies (PVD-6.8)

## PVD.AD.0006.8.A

v1.0.2024

- Aortic root/ascending aortic aneurysm/aortic dissection repair post-operative echocardiography (TEE/TTE) is indicated:
  - Every three months for the first year
  - · Every six months during the second year
  - Annually thereafter
- Open descending thoracic aortic aneurysm repair One of the following postoperative studies [CT Chest with contrast (CPT<sup>®</sup> 71260) or CT Chest without contrast (CPT<sup>®</sup> 71250) or CTA Chest (CPT<sup>®</sup> 71275)], is indicated as follows:
  - 3-6 months post-procedure
  - 12 months post-procedure
  - Every two years thereafter
- Open Aortic Abdominal Aneurysm Repair contrast and non-contrast enhanced CT of the entire aorta (CPT<sup>®</sup>74176, CPT<sup>®</sup> 74177, CPT<sup>®</sup> 74174):
  - Every 5-years
  - As requested to assess for suspected infection of the graft (see <u>Nuclear Medicine</u> <u>Imaging indications (PVD-10.1)</u> for nuclear medicine imaging for vascular graft infection).

## Post-operative surveillance after TEVAR for any indication (PVD-6.8.1)

CPT <sup>®</sup>
71260
74177
74160
72193

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 95 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
---	-----------

Imaging for post-operative TEVAR	CPT®
CTA Chest, and/or Abdomen, and/or Pelvis	71275 74175 72191 74174
MRA Chest, and/or Abdomen, and/or Pelvis	71555 74185 72198

- ANY of the above studies listed in the table can be performed at one month, six months, twelve months and then annually
- Abdomen and Pelvis imaging is indicated only if TEVAR performed for a dissection that extends into the abdomen or pelvis

## Post-operative surveillance after abdominal EVAR (endovascular aneurysm repair) (PVD-6.8.2)

Imaging for post-operative abdominal EVAR	CPT®
	74160
CT Abdomen and/or Pelvis with contrast	72193
	74177
	74170
CT Abdomen and/or Pelvis without and with contrast	72194
	74178
	74175
CTA Abdomen and/or Pelvis	72191
	74174

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 96 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines
---

Imaging for post-operative abdominal EVAR	CPT <sup>®</sup>
MRA Abdomen and/or Pelvis	74185 72198

- CT as per above coding as requested and color duplex ultrasound (CPT<sup>®</sup> 93975, CPT<sup>®</sup> 93976, CPT<sup>®</sup> 93978, or CPT<sup>®</sup> 93979) one month after EVAR
- If no endoleak, or sac enlargement, repeat **either** preferred CT or duplex ultrasound (**but not both**) at 12 months
- If a type II endoleak is observed 1 month after EVAR, may approve BOTH at 6 months:
  - Any of the above CT with contrast
  - Color duplex US
- If no endoleak or AAA sac enlargement is detected at 1 year after EVAR annual surveillance with:
  - Color duplex US
  - If DGUS is not available, any of the above CT can be performed
- If a type II endoleak is associated with an aneurysm sac that is shrinking or stable in size:
  - Continue surveillance with color duplex US every 6 months for 2 years
  - Annually thereafter.
- If US detects a new endoleak, graft migration, or aneurysm sac growth > 5mm:
  - Any of the above CT scan as requested.
  - Non-contrast CT of the entire aorta at 5-year intervals (CPT<sup>®</sup>74176)

## Post-endoleak intervention surveillance imaging

Surveillance imaging after EVAR or any subsequent endoleak intervention is based on the most recent intervention unless it increases the frequency of interval imaging of prior established interval

For any subsequent interventions for endoleak repair, imaging can be obtained at 1 month with CT and then follow protocol as above.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 97 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	\/2 0 2024
Cardiovascular and Radiology inaging Guidelines	VZ.U.ZUZ4

## Endovascular (Stent) Iliac Repair (PVD-6.8.3)

Imaging for endovascular iliac repair (stent)	CPT®
	72193
	72194
CTA Pelvis	72191
MRA Pelvis	72198

- One of the above studies can be performed for endovascular iliac repair (stent)
- If performed in conjunction with EVAR, surveillance can follow the same schedule as EVAR.
- For isolated iliac artery aneurysm repair, surveillance can be performed with an arterial duplex (CPT<sup>®</sup> 93975, CPT<sup>®</sup> 93976, CPT<sup>®</sup> 93978, or CPT<sup>®</sup> 93979) or CT or MR as above if duplex unavailable:
  - Post-operatively within the first month
  - 6 months after endovascular treatment
  - Annually

## **References (PVD-6.8)**

- Bonci G, Steigner ML, et al. ACR Appropriateness Criteria<sup>®</sup> Thoracic Aorta Interventional Planning and Follow-Up. *J Am Coll Radiol*. 2017;14(11S):S570-S583. doi:10.1016/j.jacr.2017.08.042.
- Kalva SP, Dill KE, et al. ACR Appropriateness Criteria<sup>®</sup> nontraumatic aortic disease. J Thorac Imaging. 2014;29(5):W85-W88. doi:10.1097/RTI.00000000000107.
- Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns. *Ann Thorac Surg.* 2006;82(4):1400-1405. doi:10.1016/ j.athoracsur.2006.04.098.
- 4. Bennett SJ, Dill KE, Hanley M, et al. ACR Appropriateness Criteria <sup>®</sup> Suspected Thoracic Aortic Aneurysm. J Am Coll Radiol. 2018;15(5). doi:10.1016/j.jacr.2018.03.031.
- 5. Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm *.J Vasc Surg.* 2018;67(1). doi:10.1016/j.jvs.2017.10.044.
- 6. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. *Ann Thorac Surg* 2002; 74: S1877-S1880.
- 7. Diercks D, Promes S, Schuur J, et al. American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of adult patients with suspected acute nontraumatic thoracic aortic dissection. *Ann Emerg Med.* 2015 Jan; 65 (1) :32-42.
- Francois CJ, Skulborstad EP, Majdalany BS, et al. Expert Panels on Vascular Imaging and Interventional Radiology. ACR Appropriateness Criteria<sup>®</sup> Abdominal Aortic Aneurysm: Interventional Planning and Follow-Up. *J Am Coll Radiol*. 2018;15(5S):S2-S12. doi:10.1016/j.jacr.2018.03.008.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 98 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- 9. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in J Am Coll Cardiol. 2013 Sep 10;62(11):1039-40]. *J Am Coll Cardiol*. 2010;55(14):e27-e129. doi:10.1016/j.jacc.2010.02.015.
- 10. Kallianos KG, Burris NS. Imaging Thoracic Aortic Aneurysm. *Radiol Clin North Am.* 2020;58(4):721-731. doi:10.1016/j.rcl.2020.02.009.
- 11. Loren F. Hiratzka MD, et al, 2010 ACCF/AHA/AATS/ACR/ASA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease. *Circulation* 2010; 121: e266-e369.
- 12. Shiga T, Wajima Z, Apfel CC, InoueT, Ohe Y. Diagnostic Accuracy of Transesophageal Echocardiography, Helical Computed Tomography, and Magnetic Resonance Imaging for Suspected Thoracic Aortic Dissection: Systematic Review and Meta-analysis. *Arch Intern Med* 2006; 166 (13): 1350-1356.
- 13. Smith T, Quencer KB. Best Practice Guidelines: Imaging Surveillance After Endovascular Aneurysm Repair. *American Journal of Roentgenology*. 2020;214(5):1165-1174. doi:10.2214/ajr.19.22197.
- 14. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg*. 2018;68(1):256-284. doi:10.1016/j.jvs.2018.04.018.1.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 99 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

maging Guidelines (For Ohio Only): CSRAD013OH.C P

## Large Vessel Vasculitis (PVD-6.9)

## PVD.AD.0006.9.A

v1.0.2024

- Large vessel vasculitis is generally sub-grouped into three areas
  - Aortitis (Inflammatory Aortitis)
  - Giant Cell Vasculitis
  - Takayasu Arteritis

## Inflammatory Aortitis (PVD-6.9.1)

Imaging for Inflammatory Aortitis	CPT®
CTA Chest	71275
MRA Chest	71555
CTA Pelvis	72191
MRA Pelvis	72198
CTA Abdomen and Pelvis	74174
CTA Abdomen	74175
MRA Abdomen	74185

## Initial imaging

- Initial imaging with CTA or MRA of the affected body region is considered medically necessary after the following workup:
  - Lab studies: CBC, CMP, elevated inflammatory markers such as ESR or CRP
  - Clinical history suggestive of disease listed below in <u>Background and Supporting</u> information
  - PET/CT is considered **not medically necessary** for management of pediatric vasculitis at this time.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 100 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	
---	--

V2.0.2024

## **Repeat imaging**

- Follow-up imaging with CTA or MRA of the affected body region is considered medically necessary for:
  - Change in signs/symptoms
  - Known aneurysm monitoring
    - See Aneurysm and AVM (HD-12) in the Head Imaging Guidelines
    - See Thoracic Aortic Aneurysms (PVD-6.2)
    - See <u>Abdominal Aortic Aneurysms (PVD-6.3)</u>

## Background and Supporting Information

Aortitis may be congenital (Marfan's, Hypermobility Syndromes, others) or acquired, including traumatic, atherosclerotic (dissecting aneurysm, other), infectious (syphilis, tuberculosis, other), neoplastic or inflammatory (Ankylosing Spondylitis, Giant Cell Arteritis, Cogan's, Relapsing Polychondritis, Behcet's Syndrome, Polyarteritis Nodosa, Granulomatous Polyangiitis, Lupoid, idiopathic, other).

Imaging for Giant Cell Arteritis				
CTA Chest	71275			
MRA Chest				
CTA Pelvis				
MRA Pelvis	72198			
CTA Abdomen and Pelvis	74174			
CTA Abdomen	74175			
MRA Abdomen				
MRA Head without contrast	70544			
MRA Head with contrast	70545			
MRA Neck without contrast	70547			

## Giant Cell Arteritis (GCA) (PVD-6.9.2)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 101 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
Cardiovascular and radiology inlaging Caldelines	V2.0.2024

Imaging for Giant Cell Arteritis		
MRA Neck with contrast	70548	
CTA Neck	70498	
PET/CT skull base to mid-thigh	78815	

### **Initial imaging**

- GCA may be subdivided into two basic types; Cranial and Extra-cranial
  - **Cranial GCA** is the more common type with temporal artery involvement. For predominantly Cranial GCA:
    - US (CPT<sup>®</sup> 93880 or CPT<sup>®</sup> 93882) of the temporal (and or axillary) arteries is the preferred modality. Ultrasound should be considered prior to advanced imaging.
    - MRA Head and/or MRA Neck (CPT<sup>®</sup> 70544, or CPT<sup>®</sup> 70545, or CPT<sup>®</sup> 70547, or CPT<sup>®</sup> 70548) may be considered when:
      - Vascular trained ultrasonography is not available
      - US is negative or equivocal with a clinical suspicion of GCA
    - CT and PET are **not** currently recommended for the assessment of inflammation of cranial arteries.

### Note:

For suspected cerebral vasculitis in individuals with neurologic symptoms, see **<u>Cerebral Vasculitis (HD-22)</u>** in the Head Imaging Guidelines

- **Extra-cranial GCA:** less commonly encountered. None of the "classic" clinical signs or symptoms of cranial GCA are present initially but may develop later.
  - Extra-cranial GCA is characterized by at least two or more of the following:
    - Jaw and/or upper extremity claudication
    - Fever/weight loss or fever of unknown origin (FUO) symptoms
    - New murmurs
    - Pulse asymmetry
    - Abdominal pain
    - Pulsatile mass
    - High inflammatory markers such as CRP or ESR > 50 mm/h
  - Imaging for aortic root, arch or abdomen involvement:
    - MRA Chest (CPT<sup>®</sup> 71555), MRA Neck (CPT<sup>®</sup> 70547), MRA Abdomen (CPT<sup>®</sup> 74185), CTA Chest (CPT<sup>®</sup> 71275), CTA Neck (CPT<sup>®</sup> 70498) or CTA Abdomen (CPT<sup>®</sup> 74175)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 102 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines V2.0.202
--

- PET (CPT<sup>®</sup> 78815) is indicated if MRA or CTA are non-diagnostic and there is still suspicion for aortic root, arch or abdomen involvement

### **Repeat imaging**

- Follow-up imaging is indicated for **any** of the following:
  - One-time documentation of remission or disease control
  - Change in signs/symptoms suggesting progression of disease
  - Although individuals with GCA can develop aortic aneurysms over time screening in the absence of signs or symptoms is not medically necessary
  - In individuals with known thoracic or abdominal aortic aneurysm:
    - See <u>Thoracic Aortic Aneurysm (TAA) (PVD-6.2)</u> for thoracic aneurysm surveillance
    - See <u>Abdominal Aortic Aneurysm (AAA) (PVD-6.3)</u> for abdominal aneurysm surveillance.
- Follow-up imaging is not routinely recommended for individuals in clinical and biochemical remission or without aneurysm/complication.

### Background and supporting information

Giant Cell Arteritis is the most commonly encountered vasculitis in adults. Although classically thought of as a disease of the temporal arteries, aortic arch involvement is now recognized as a frequent complication (up to 50% of individuals) and responsible for many of the more serious morbidities encountered such as blindness.

## Takayasu Arteritis (PVD-6.9.3)

Imaging for Takayasu Arteritis	CPT®
CTA Chest	71275
CTA Pelvis	72191
CTA Abdomen and Pelvis	74174
CTA Abdomen	74175
MRA Chest	71555
MRA Pelvis	72198

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 103 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Imaging for Takayasu Arteritis	CPT <sup>®</sup>
MRA Abdomen	74185

### Initial imaging

- Initial imaging is indicated for signs and symptoms suggestive of disease such as absent radial pulse, difficulty obtaining BP in one arm, or unexplained hypertension.
- Any of the following modalities may be indicated for evaluation of Takayasu arteritis:
  - MRA of the affected body area(s) (contrast as requested)
  - CTA of the affected body area(s) (contrast as requested)
  - Ultrasound with Doppler of the affected body area(s)

### **Repeat imaging**

Repeat imaging is indicated at the following intervals:

- Every 3 months to monitor treatment response during active treatment with systemic therapy.
- Annually for surveillance of known involved body areas to detect progressive vascular damage that may require intervention



## **References (PVD-6.9)**

## PVD.AD.0006.9.A

#### v1.0.2024

- Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations). J Am Coll Cardiol. 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
- Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Annals of the Rheumatic Diseases*. 2018;77(5):636-643. doi:10.1136/ annrheumdis-2017-212649.
- 3. Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. *Journal of Hypertension*. 2014;32(7):1367-1378.doi:10.1097/hjh.0000000000213.
- Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. *Contrast Media & Molecular Imaging*. 2019;2019:1-8. doi:10.1155/2019/9157637.
- 5. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg* . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.04.018.1.
- 6. Muratore F, Pipitone N, Salvarani C, Schmidt WA. Imaging of vasculitis: State of the art. *Best Practice Research Clinical Rheumatology*. 2016;30(4):688-706. doi:10.1016/j.berh.2016.09.010.
- 7. Lensen KDF, Comans EFI, Voskuyl AE, et al. Large-Vessel Vasculitis: Interobserver Agreement and Diagnostic Accuracy of 18F-FDG-PET/CT. BioMed Research International. 2015;2015:1-8.doi:10.1155/2015/914692.
- 8. Soussan M, Nicolas P, Schramm C, et al. Management of Large-Vessel Vasculitis With FDG-PET. Medicine. 2015;94(14). doi:10.1097/md.00000000000622.
- Besson FL, Parienti J-J, Bienvenu B, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2011;38(9):1764-1772. doi:10.1007/s00259-011-1830-0.
- 10. Sivaraman V, Fels EC, and Ardoin SP. Vasculitis syndromes. Nelson Textbook of Pediatrics, Chapter 192. eds Kliegman RM, St. Geme JW III, Blum NJ, et al. 21st ed. Philadelphia, PA: Elsevier; 2020:1317-1327.
- 11. Soliman M, Laxer R, Manson D, et. al. Imaging of systemic vasculitis in childhood. *Pediatric Radiology.* 2015;45(8):1110-1125. doi:10.1007/s00247-015-3339-3.
- 12. Sharma AM, Singh S, Lewis JE. Diagnostic Approach in Patients With Suspected Vasculitis. *Techniques in Vascular and Interventional Radiology*. 2014;17(4):226-233. doi:10.1053/j.tvir.2014.11.002.
- 13. Ammirati E, Moroni F, Pedrotti P, et al. Non-Invasive Imaging of Vascular Inflammation. *Frontiers in Immunology*. 2014;5:1-15. doi:10.3389/fimmu.2014.00399.
- 14. Granata C, Damasio MB, Zaottini F, et al. Imaging of Childhood Vasculitis. *Radiologic Clinics of North America*. 2017;55(5):1131-1143. doi:10.1016/j.rcl.2017.05.001.
- 15. Broncano J, Vargas D, Bhalla S, Cummings KW, Raptis CA, Luna A. CT and MR Imaging of Cardiothoracic Vasculitis. *RadioGraphics*. 2018;38(4):997-1021. doi:10.1148/rg.2018170136.
- 16. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis & Rheumatism*. 2012;65(1):1-11. doi:10.1002/art.37715.
- Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. *Annals of the Rheumatic Diseases*. 2010;69(5):798-806. doi:10.1136/ ard.2009.116657
- 18. Cui J, Huang LY, Guo J, Wu CR, Zhang B. Diagnosis and treatment of adult mixed-type Henoch-Schönlein purpura. *Cent Eur J Immunol*. 2019;44(2):138-143. doi:10.5114/ceji.2019.87064.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 105 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Medium Vessel Vasculitis (PVD-6.10)

PVD.AD.0006.10.A

v1.0.2024

- There are two main types of medium-size vessel vasculitis:
  - Polyarteritis nodosa
  - Kawasaki disease

### Kawasaki disease

- Imaging guidelines for Kawasaki Disease are addressed in <u>Kawasaki Disease</u> (<u>PEDCD-6</u>) in the Pediatric Cardiac imaging guideline
- Long-term routine surveillance imaging in asymptomatic Kawasaki disease is indicated as follows:

AHA risk level	Largest Aneurysm At Any Point	Largest Current Aneurysm	Routine Echo	Routine Stress Imaging	Routine Coronary Imaging
All			All risk levels 4-6 weeks after acute illness		
1	Normal	Normal	One echo 2-12 months after acute illness	none	none
2	Dilation	Dilation	6 months One year If dilation remains echo every 2-5 years until resolves	None	None
		Normal	After acute illness: 2-12 months One echocardiogram at one year No echocardiogram after one year		

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 106 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

AHA risk level	Largest Aneurysm At Any Point	Largest Current Aneurysm	Routine Echo	Routine Stress Imaging	Routine Coronary Imaging
3.1	Small	Small	6 months 12 months then yearly	2-3 years	3-5 years
3.2	Small	Normal or dilated	6 months 12 months Then yearly	3-5 years	none
4.1	Medium	Medium	3 months 6 months 12 months Every 6-12 months after that	1-3 years	2-5 years
4.2	Medium	Small	6 months and 12 months, every 1 year	2-3 years	3-5 years
4.3	Medium	Normal Or Dilated	Every 1-2 years	2-4 years	none
5.1	Large	Large	1 month 3 months 6 months 9 months 12 months Then every 3-6 months	6-12 months	at 2-6 months, every 1-5 years
5.2	Large	Medium	Every 6-12 months	yearly	2-5 years
5.3	Large	Small	6-12 month	1-2 years	2-5 years

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 107 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

AHA risk level	Largest Aneurysm At Any Point	Largest Current Aneurysm	Routine Echo	Routine Stress Imaging	Routine Coronary Imaging
5.4	Large	Normal Or Dilation	1-2 years	2-5 years	none

## Polyarteritis Nodosa Initial imaging

Any **ONE** of the following modalities is indicated for documented clinical suspicion of Polyarteritis Nodosa:

- MRA of the affected body area(s) (contrast as requested)
- CTA of the affected body area(s) (contrast as requested)
- Ultrasound (US) with Doppler of the affected body area(s)

## Repeat imaging

Imaging with MRA, CTA, or US with Doppler of the affected body area(s) is indicated for established Polyarteritis Nodosa as follows:

- Every 3 months during active treatment with systemic therapy to evaluate treatment response
- Annually for surveillance of known involved body areas to detect progressive vascular damage that may require intervention

## Background and supporting information

- Based on AHA recommendations, the following classifications are used in risk stratification of coronary artery abnormalities<sup>4</sup>
  - Z-Score classification accounts for the effects of body size and age through use of baseline coronary dimensions adjusted for body surface area. The Z score value represents the number of standard deviation above the mean. (e.g., z=0 pt. has coronary artery dimension value equal to mean, z=2 person has value 2 standard deviation above the mean, based on age, gender, BSA).
  - Coronary Artery Abnormalities Risk Classification based on Z-Score:
    - 1 No involvement at any time point (Z score always <2)</li>
    - 2 Dilation only (Z score 2 to <2.5)
    - 3 Small aneurysm (Z score ≥2.5 to <5)
      - 3.1 Current or persistent

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 108 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

<sup>&</sup>lt;sup>4</sup> Mccrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation. 2017;135(17). doi:10.1161/cir.00000000000484.
V2.0.2024

#### Cardiovascular and Radiology Imaging Guidelines

- 3.2 Decreased to dilation only or normal luminal dimension
- 4 Medium aneurysm (Z score ≥5 to <10, and absolute dimension <8 mm)
  - 4.1 Current or persistent
  - 4.2 Decreased to small aneurysm
  - 4.3 Decreased to dilation only or normal luminal dimension
- 5 Large and giant aneurysm (Z score ≥10, or absolute dimension ≥8 mm)
  - 5.1 Current or persistent
  - 5.2 Decreased to medium aneurysm
  - 5.3 Decreased to small aneurysm
  - 5.4 Decreased to dilation only or normal luminal dimension
- Additional clinical features that may increase the long-term risk of myocardial ischemia
  - Greater length and distal location of aneurysms that increase the risk of flow stasis
  - Greater total number of aneurysms
  - Greater number of branches affected
  - Presence of luminal irregularities
  - Abnormal characterization of the vessel walls (calcification, luminal myofibroblastic proliferation)
  - Presence of functional abnormalities (impaired vasodilation, impaired flow reserve)
  - Absence or poor quality of collateral vessels
  - Previous revascularization performed
  - Previous coronary artery thrombosis
  - Previous myocardial infarction
  - Presence of ventricular dysfunction

## Small Vessel Vasculitis (PVD-6.11)

## PVD.AD.0006.11.A

#### v1.0.2024

- Advanced imaging is not sensitive enough to detect changes in small vessels, and is not indicated for primary assessment of any small vessel vasculitis.
- End-organ damage occurs with several of the small vessel vasculitides. Advanced imaging indicated for the following:
  - Henoch-Schönlein Purpura (HSP)
  - Granulomatosis with polyangiitis (GPA, formerly known as Wegener's granulomatosis)
  - Eosinophilic granulomatosis with polyangiitis (EGPA, formerly known as ChurgStrauss Syndrome)
  - Immune complex associated small-vessel vasculitis [immunoglobulin A– associated vasculitis (IgAV)]

## **References (PVD-6.9)**

- 1. Anderson JL, Halperin JL, Albert N, et al. Management of Patients with Peripheral Artery Disease (Compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations). *J Am Coll Cardiol*. 2013;61(14):1555-1570. doi:10.1016/j.jacc.2013.01.004.
- 2. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. *Annals of the Rheumatic Diseases*. 2018;77(5):636-643. doi:10.1136/ annrheumdis-2017-212649.
- 3. Persu A, Giavarini A, Touzé E, et al. European consensus on the diagnosis and management of fibromuscular dysplasia. *Journal of Hypertension*. 2014;32(7):1367-1378.doi:10.1097/hjh.0000000000213.
- Taimen K, Salomäki SP, Hohenthal U, et al. The Clinical Impact of Using 18F-FDG-PET/CT in the Diagnosis of Suspected Vasculitis: The Effect of Dose and Timing of Glucocorticoid Treatment. *Contrast Media & Molecular Imaging*. 2019;2019:1-8. doi:10.1155/2019/9157637.
- 5. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg* . 2018;68(1):256-284. doi:10.1016/j.jvs.2018.04.018.1.
- 6. Muratore F, Pipitone N, Salvarani C, Schmidt WA. Imaging of vasculitis: State of the art. *Best Practice Research Clinical Rheumatology.* 2016;30(4):688-706. doi:10.1016/j.berh.2016.09.010.
- 7. Lensen KDF, Comans EFI, Voskuyl AE, et al. Large-Vessel Vasculitis: Interobserver Agreement and Diagnostic Accuracy of 18F-FDG-PET/CT. BioMed Research International. 2015;2015:1-8.doi:10.1155/2015/914692.
- 8. Soussan M, Nicolas P, Schramm C, et al. Management of Large-Vessel Vasculitis With FDG-PET. Medicine. 2015;94(14). doi:10.1097/md.00000000000622.
- Besson FL, Parienti J-J, Bienvenu B, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2011;38(9):1764-1772. doi:10.1007/s00259-011-1830-0.
- 10. Sivaraman V, Fels EC, and Ardoin SP. Vasculitis syndromes. Nelson Textbook of Pediatrics, Chapter 192. eds Kliegman RM, St. Geme JW III, Blum NJ, et al. 21st ed. Philadelphia, PA: Elsevier; 2020:1317-1327.
- 11. Soliman M, Laxer R, Manson D, et. al. Imaging of systemic vasculitis in childhood. *Pediatric Radiology.* 2015;45(8):1110-1125. doi:10.1007/s00247-015-3339-3.
- 12. Sharma AM, Singh S, Lewis JE. Diagnostic Approach in Patients With Suspected Vasculitis. *Techniques in Vascular and Interventional Radiology*. 2014;17(4):226-233. doi:10.1053/j.tvir.2014.11.002.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 110 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- 13. Ammirati E, Moroni F, Pedrotti P, et al. Non-Invasive Imaging of Vascular Inflammation. *Frontiers in Immunology*. 2014;5:1-15. doi:10.3389/fimmu.2014.00399.
- 14. Granata C, Damasio MB, Zaottini F, et al. Imaging of Childhood Vasculitis. *Radiologic Clinics of North America*. 2017;55(5):1131-1143. doi:10.1016/j.rcl.2017.05.001.
- 15. Broncano J, Vargas D, Bhalla S, Cummings KW, Raptis CA, Luna A. CT and MR Imaging of Cardiothoracic Vasculitis. *RadioGraphics*. 2018;38(4):997-1021. doi:10.1148/rg.2018170136.
- 16. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis & Rheumatism*. 2012;65(1):1-11. doi:10.1002/art.37715.
- Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. *Annals of the Rheumatic Diseases*. 2010;69(5):798-806. doi:10.1136/ ard.2009.116657
- 18. Cui J, Huang LY, Guo J, Wu CR, Zhang B. Diagnosis and treatment of adult mixed-type Henoch-Schönlein purpura. *Cent Eur J Immunol*. 2019;44(2):138-143. doi:10.5114/ceji.2019.87064 .

## IgA vasculitis Henoch-Schönlein Purpura (HSP)

#### **Initial imaging**

Ultrasound (US) Abdomen (CPT<sup>®</sup> 76700) is indicated to evaluate possible gastrointestinal complications of known or suspected HSP including **any** of the following:

- Bowel wall edema and hemorrhage
- Intussusception

CT Abdomen with contrast (CPT<sup>®</sup> 74160) if additional information is needed after ultrasound for management

#### **Repeat imaging**

US Abdomen (CPT<sup>®</sup> 76700) is indicated for known HSP to evaluate new or worsening gastrointestinal symptoms

### Background and Supporting Information

Henoch-Schönlein Purpura (HSP) is the most common vasculitis of childhood, mainly involving small blood vessels.

## Granulomatosis with polyangiitis (GPA) formerly Wegener's granulomatosis

### **Initial imaging**

CT Sinuses (CPT<sup>®</sup> 70486) and/or CT Chest without contrast (CPT<sup>®</sup> 71250) or with contrast (CPT<sup>®</sup> 71260) is indicated to evaluate the extent of the disease

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 111 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **Repeat imaging**

CT Sinuses (CPT<sup>®</sup> 70486) and/or CT Chest without contrast (CPT<sup>®</sup> 71250) or CT Chest with contrast (CPT<sup>®</sup> 71260) is indicated for **any** following:

- New or worsening clinical symptoms affecting the body area requested
- Assess response to medical therapy when a change in treatment regimen is being considered
- · Annually-to evaluate the extent of disease

## Eosinophilic granulomatosis with polyangiitis (EGPA) formerly Churg-Strauss Syndrome

## Initial imaging

CT Chest without contrast (CPT<sup>®</sup> 71250) or CT Chest with contrast (CPT<sup>®</sup> 71260) is indicated in the initial evaluation of Eosinophilic granulomatosis with polyangiitis (EGPA) formerly known as Churg-Strauss Syndrome.

## **Repeat imaging**

- CT Chest without contrast (CPT<sup>®</sup> 71250) or CT Chest with contrast (CPT<sup>®</sup> 71260) is indicated for any of the following:
  - New or worsening clinical symptoms affecting the body area requested
  - Assess response to medical therapy when a change in treatment regimen is being considered
  - Annually-to evaluate the extent of disease

## Immune complex associated small-vessel vasculitis

## Initial imaging

 Doppler ultrasound (US) of the affected body part (most commonly abdomen) is indicated in the initial evaluation of immune complex associated small-vessel vasculitis

## **Repeat imaging**

- Doppler ultrasound (US) of the affected body part (most commonly abdomen) is indicated in the following circumstances
  - New or worsening clinical symptoms affecting the body area requested
  - To assess response to medical therapy when a change in treatment is being considered

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 112 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovasoular and Badiology Imaging Cuidolines	1/2 0 2024
Calulovasculai allu Raulology Illagilig Gulueilles	VZ.U.ZUZ4

• Annually-to evaluate the extent of disease

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 113 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Peripheral Arterial Imaging

#### Guideline

Upper Extremity PVD – Imaging (PVD-4.1) References (PVD-4) Renovascular Hypertension/Renal Artery Stenosis (PVD-6.6) Visceral Artery Aneurysm (PVD-6.5) Median Arcuate Ligament Syndrome, Nutcracker Syndrome and other Abdominal Vascular Compression Syndromes (PVD-18) Lower Extremity Artery Aneurysms (PVD-7.4) Claudication and Critical Limb Ischemia (PVD-7.1) Popliteal Artery Entrapment Syndrome (PVD-7.2) Post-Procedure Surveillance Studies (PVD-7.3) Arterial Imaging for Free Flaps in Reconstructive Surgery (PVD-7.5) Arteriovenous Malformations (AVMs) (PVD-9.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 114 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Upper Extremity PVD – Imaging (PVD-4.1)

PVD.AI.0004.1.A v1.0.2024

### **Initial Imaging**

- Arterial ultrasound upper extremities (CPT<sup>®</sup> 93930 or CPT<sup>®</sup> 93931) for signs and symptoms of arterial insufficiency including:
  - Arm or hand claudication, cramping or fatigue of the unilateral extremity with use or with raising limb overhead that is relieved with rest and is reproducible. See <u>Subclavian Steal Syndrome (CH-27)</u> in the Chest Imaging Guidelines
  - Systolic blood pressure differential between arms of >15mmHg. See <u>Subclavian</u> <u>Steal Syndrome (CH-27)</u> in the Chest Imaging Guidelines
  - Bluish discoloration of the hand or fingers
  - Unilateral cold, painful, pulseless hand
  - Non-healing wound (>2 weeks with no healing or evidence of healing) or frank gangrene
- CTA Upper extremity (CPT<sup>®</sup> 73206) or MRA of Upper extremity (CPT<sup>®</sup> 73225), and/ or CTA Chest (CPT<sup>®</sup> 71275) or MRA Chest (CPT<sup>®</sup> 71555) for:
  - Abnormal results
  - Equivocal results
  - Pre-operative planning
- For suspected Fibromuscular Dysplasia of the brachial artery, appropriate studies include:
  - MRA Upper extremity (CPT<sup>®</sup> 73225)
  - CTA Upper extremity (CPT<sup>®</sup> 73206)
  - Arterial Ultrasound (CPT<sup>®</sup> 93930 bilateral study or CPT<sup>®</sup> 93931 unilateral study)

## Post-revascularization

- Arterial Duplex (CPT<sup>®</sup> 93931) can be obtained following upper extremity arterial revascularization at:
  - Baseline (within one month)
  - 6 months
  - Then annually if stable
  - Anytime for new or worsening symptoms of arterial insufficiency

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 115 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **References (PVD-4)**

## PVD.AI.0004.1.A

v1.0.2024

- 1. Skeik N, Soo-Hoo SS, Porten BR, et al. Arterial Embolisms and Thrombosis in Upper Extremity Ischemia. *Vascular and Endovascular Surgery*. 2015;49(5-6):100-109. doi:10.1177/1538574415596740.
- Desjardins B, Rybicki FJ, Kim HS, et al. ACR Appropriateness Criteria<sup>®</sup> Suspected Upper Extremity Deep Vein Thrombosis. J Am Coll Radiol 2012;9(9):613-619. doi:10.1016/j.jacr.2012.05.021.
- Kraaijpoel N, Es NV, Porreca E, Büller HR, Nisio MD. The diagnostic management of upper extremity deep vein thrombosis: A review of the literature. *Thrombosis Research*. 2017;156:54-59. doi:10.1016/ j.thromres.2017.05.035.
- Hughes K, Cubangbang M, Blackman K, et al. Upper Extremity Bypass for Chronic Ischemia—A National Surgical Quality Improvement Program Study Database Study. *Vascular and Endovascular Surgery*. 2013;47(3):192-194. doi:10.1177/1538574413478472.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 116 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Renovascular Hypertension/Renal Artery Stenosis (PVD-6.6)

PVD.Al.0006.6.A v1.0.2024

### **Initial imaging**

- MRA Abdomen (CPT<sup>®</sup> 74185) or CTA Abdomen (CPT<sup>®</sup> 74175) or US kidney retroperitoneal (CPT<sup>®</sup> 76775) and/or Doppler (CPT<sup>®</sup> 93975, 93976, 93978, or 93979 if expertise is available) are indicated when there is documentation of **any** of the following:
  - Individual is adherent to full doses of three blood pressure medications (including a diuretic) yet has still not achieved goal
  - Sudden and persistent worsening of previously controlled hypertension
  - Onset of hypertension younger than 30 years of age
  - Malignant hypertension with coexistent evidence of acute end-organ damage (acute renal failure, new visual or neurological disturbance and/or advanced retinopathy) or flash pulmonary edema
  - Individuals who develop hypertension (≥140/90) within the first 20 weeks of pregnancy when hypertension persists >12 weeks post-partum
  - New or worsening renal function/increasing creatinine (especially after the administration of an ACE inhibitor or with angiotensin receptor blocking agent)
- Carotid duplex (CPT<sup>®</sup> 93880) is reasonable to screen for carotid involvement in individuals with documented or highly suspicious renal artery stenosis due to fibromuscular dysplasia (mostly women between 15 and 50 years of age).

## Screening

CTA Abdomen (CPT<sup>®</sup> 74175) or MRA Abdomen (CPT<sup>®</sup> 74185) to screen for renovascular fibromuscular dysplasia in hypertensive individuals with documented cervicocephalic fibromuscular dysplasia. The assessment of other vascular beds should be considered if supported by suggestive symptoms or medical history.

Carotid duplex (CPT<sup>®</sup> 93880) is reasonable to screen for carotid involvement in individuals with documented or highly suspicious renal artery stenosis due to fibromuscular dysplasia (mostly women between 15 and 50 years of age)

## Repeat imaging post revascularization

CTA Abdomen (CPT<sup>®</sup> 74175), or MRA Abdomen (CPT<sup>®</sup> 74185), or CT Abdomen with contrast (CPT<sup>®</sup> 74160) is indicated after stent placement at the following intervals:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 117 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- 1 month post-procedure
- 6 months post-procedure
- 12 months post-procedure
- Then annually

#### Background and Supporting Information

Renal artery revascularization has **not** been shown to be more effective than medical therapy in most situations and should not be pursued except in extreme cases, or if there is concern for Takayasu arteritis or fibromuscular dysplasia.

Gadolinium agents may be contraindicated in individuals with severe renal disease or on dialysis due to the risk of developing nephrogenic systemic sclerosis

## **References (PVD-6.6)**

- 1. Harvin HJ, Verma N, Nikolaidis P, et al. ACR Appropriateness Criteria ® Renovascular Hypertension. *J Am Coll Radiol*. 2017;14(11). doi:10.1016/j.jacr.2017.08.040..
- Moser M, Setaro JF. Resistant or Difficult-to-Control Hypertension. N Engl J Med. 2006;355(4):385-392. doi:10.1056/nejmcp041698.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6). doi:10.1161/hyp.0000000000000065.
- Hicks CW, Clark TWI, Cooper CJ, et al. Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. Am J Kidney Dis. 2022;79(2):289-301. doi:10.1053/ j.ajkd.2021.06.025.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 118 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **Visceral Artery Aneurysm (PVD-6.5)**

PVD.AD.0006.5.A v1.0.2024

- Treatment is generally indicated for visceral aneurysms ≥2cm.
- Workup for suspected visceral artery aneurysm (spleen, kidney, liver or intestines) if calcifications seen on plain film imaging can include:
  - Ultrasound (CPT<sup>®</sup> 76700, 76705, 93975, 93976, 93978, or 93979), or
  - CTA Abdomen (CPT<sup>®</sup> 74175), or
  - CT Abdomen with contrast (CPT<sup>®</sup> 74160).
- Ultrasound (CPT<sup>®</sup> 76700,76705, 93975, 93976, 93978, or 93979) or CTA Abdomen (CPT<sup>®</sup> 74175) or CT Abdomen with contrast (CPT<sup>®</sup> 74160) for further monitoring based on the intervals below or as determined by a vascular specialist or any provider in consultation with a vascular specialist:
  - Splenic artery aneurysms:
    - <20mm can be imaged every three years</li>
    - 20mm to 29mm can be imaged annually
    - If ≥30mm, they should be referred for treatment, either stent, excision or splenectomy
  - For all other visceral artery aneurysms:
    - Initial evaluation with six-month follow-up for one year
    - Further follow-up annually if no significant enlargement is seen
- CTA Abdomen (CPT<sup>®</sup> 74175), MRA Abdomen (CPT<sup>®</sup> 74185), or CT Abdomen with contrast (CPT<sup>®</sup> 74160) are indicated following stent placement at:
  - 1 month
  - 6 months
  - 12 months
  - Then every year

## Background and Supporting Information

- Splenic artery aneurysms, the most common (60%), tend to exhibit very slow rates of growth, while the other visceral artery aneurysms are more unpredictable in their rate of growth with a greater tendency to rupture.
- Visceral Artery Aneurysms are defined by an increase of more than 50% of the original arterial diameter and include hepatic, renal and intestinal artery aneurysms.
- Vascular specialty consultation is beneficial in order to determine the time-frame to intervention.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 119 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **References (PVD-6.5)**

- 1. Alcantara S, Yank CK. The evidence for nonperative management of visceral arterial dissections. A single center experience. *Annals of Vasc Surg* 2015; 29: 103–108.
- 2. Chaer R, Abularrage C, Coleman D et al. The Society for Vascular Surgery clinical practice guidelines on the management of visceral aneurysms. *Journal of Vasc Surg* 2020;72:3S-39S.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 120 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Median Arcuate Ligament Syndrome, Nutcracker Syndrome and other Abdominal Vascular Compression Syndromes (PVD-18)

PVD.AI.0018.A v1.0.2024

## Median Arcuate Ligament Syndrome

### **Codes included**

CPT®	Description
74175	Computed tomographic angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image postprocessing
74185	Magnetic resonance angiography, abdomen, with or without contrast material(s)
93975	Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study
93976	Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study

### Initial Imaging

- Duplex Doppler Ultrasound of Mesenteric Arteries (CPT<sup>®</sup> 93975 or 93976) is indicated as the initial imaging
- CTA or MRA Abdomen ( $\widetilde{CPT}^{\mathbb{R}}$  74175 or 74185) is indicated for **either**:
  - US results are equivocal
  - Preoperative planning

## **Repeat imaging**

Surveillance imaging is not indicated post-operatively in the absence of abdominal symptoms.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 121 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

### Background and supporting information

A non-atherosclerotic cause of chronic mesenteric ischemia.

Patients are typically younger with an average age range of 30-50 years old and a female to male ratio of 4:1

Patients may have symptoms of postprandial abdominal pain, nausea, vomiting, food aversion, weight loss. Symptoms are nonspecific, so MALS may be considered a diagnosis of exclusion.

Imaging will demonstrate compression of the celiac artery by fibers of the median arcuate ligament, but this is a nonspecific finding and may be seen in the asymptomatic population.

Pathophysiologically related to foregut ischemic from compression of the celiac artery; may also be related to neuropathic pain secondary to compression of the celiac ganglion.

Treatment is generally surgical, via a variety of approaches.

#### References

- 1. Columbo JA, Trus T, Nolan B, et al. Contemporary management of median arcuate ligament syndrome provides early symptom improvement. *J Vasc Surg.* 2015;62(1):151-156. doi:10.1016/j.jvs.2015.01.050.
- 2. Goodall R, Langridge B, Onida S, Ellis M, Lane T, Davies AH. Median arcuate ligament syndrome. *J Vasc Surg.* 2020;71(6):2170-2176. doi:10.1016/j.jvs.2019.11.012.
- 3. Kim EN, Lamb K, Relles D, Moudgill N, DiMuzio PJ, Eisenberg JA. Median Arcuate Ligament Syndrome-Review of This Rare Disease. *JAMA Surg.* 2016;151(5):471-477. doi:10.1001/jamasurg.2016.0002.
- Björck M, Koelemay M, Acosta S, et al. Editor's Choice Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg.* 2017;53(4):460-510. doi:10.1016/j.ejvs.2017.01.010.
- Expert Panels on Vascular Imaging and Gastrointestinal Imaging:, Ginsburg M, Obara P, et al. ACR Appropriateness Criteria<sup>®</sup> Imaging of Mesenteric Ischemia. *J Am Coll Radiol.* 2018;15(11S):S332-S340. doi:10.1016/j.jacr.2018.09.018.

## Left Renal Vein Compression ("Nutcracker") Syndrome

### **Codes included**

CPT®	description
93975	Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study
93976	Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 122 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

CPT®	description
74174	Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing
72198	Magnetic resonance angiography, pelvis, with or without contrast material(s)
74185	Magnetic resonance angiography, abdomen, with or without contrast material(s)

### **Initial Imaging**

- Abdominal duplex (CPT® 93975 or 93976) is indicated as the initial imaging to confirm left renal vein compression syndrome.
- CTV or MRV Abdomen and Pelvis (CPT® 74174) or (CPT® 74185 and 72198) is indicated for preoperative planning when left renal vein compression syndrome is confirmed by duplex ultrasound.

### **Repeat imaging**

• Postoperative follow up imaging is not indicated in the absence of symptomatology.

## Background and supporting information

Patients may present with symptoms related to compression of the left renal vein between the aorta and superior mesenteric artery. A less common presentation ("posterior nutcracker syndrome") is related to compression of a retroaortic (or circumaortic) left renal vein between the aorta and vertebral body.

The radiologic finding may be asymptomatic or considered a normal variant.

Signs/symptoms may include hematuria, proteinuria, flank pain, pelvic congestion/ associated pain in females, varicocele in males.

There may be an overlap in symptom complex with patients who have pelvic congestion syndrome, iliac vein compression (May-Thurner).

There is no single accepted treatment modality. Approaches will range from conservative/medical (esp in younger patients), to endovascular, to open/laparoscopic/ robotic surgical.

### References

1. Velasquez CA, Saeyeldin A, Zafar MA, Brownstein AJ, Erben Y. A systematic review on management of nutcracker syndrome. *J Vasc Surg Venous Lymphat Disord*. 2018;6(2):271-278. doi:10.1016/j.jvsv.2017.11.005.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 123 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- 2. Ananthan K, Onida S, Davies AH. Nutcracker Syndrome: An Update on Current Diagnostic Criteria and Management Guidelines. *Eur J Vasc Endovasc Surg.* 2017;53(6):886-894. doi:10.1016/j.ejvs.2017.02.015.
- 3. Meissner MH, Khilnani NM, Labropoulos N, Gasparis AP, Gibson K, Greiner M, et al. The Symptoms-Varices-Pathophysiology classification of pelvic venous disorders: A report of the American Vein & Lymphatic Society International Working Group on Pelvic Venous Disorders. *J Vasc Surg Venous Lymphat Disord* 2021;9:568-84.
- De Maeseneer MG, Kakkos SK, Aherne T, et al. Editor's Choice European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs [published correction appears in Eur J Vasc Endovasc Surg. 2022 Aug-Sep;64(2-3):284-285]. Eur J Vasc Endovasc Surg. 2022;63(2):184-267. doi:10.1016/j.ejvs.2021.12.024.
- Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg.* 2011;53(5 Suppl):2S-48S. doi:10.1016/j.jvs.2011.01.079.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 124 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Lower Extremity Artery Aneurysms (PVD-7.4)

PVD.AI.0007.4.A

v1.0.2024

- For Iliac artery aneurysm see <u>Iliac Artery Aneurysm (IAA) (PVD-6.4)</u>
- Femoral artery aneurysm
  - Initial imaging
    - Ultrasound (CPT<sup>®</sup> 93925 bilateral study or CPT<sup>®</sup> 93926 unilateral study).
  - Surveillance imaging
    - Symptomatic true femoral aneurysms smaller than 2.5 cm in diameter
      - Ultrasound (CPT<sup>®</sup> 93926 unilateral study) annually
    - Symptomatic true femoral aneurysms larger than 2.5 cm
      - Ultrasound (CPT<sup>®</sup> 93926 unilateral study) every 6 months
  - Other imaging
    - CTA or MRA Lower extremity (CPT<sup>®</sup> 73706 or 73725 or 74198 or 75635):
      - Preoperative study for individuals with no plans for invasive angiography
      - Technically limited or abnormal ultrasound results
- Popliteal artery aneurysm
  - Initial imaging
    - Ultrasound (CPT<sup>®</sup> 93925 bilateral study or CPT<sup>®</sup> 93926 unilateral study) and Ultrasound to assess for a contralateral popliteal aneurysm and abdominal aortic aneurysm (CPT<sup>®</sup> 76770 or CPT<sup>®</sup> 76775)
  - Surveillance imaging
    - Ultrasound (CPT<sup>®</sup> 93926 unilateral study) annually
    - Post-interventional functional testing (ABI) (CPT<sup>®</sup> 93922) may be useful as clinically indicated
  - Other imaging
    - CTA or MRA (CPT<sup>®</sup> 73706 or 73725 or 74185 or 75635) for:
      - Preoperative study
      - Technically limited or abnormal ultrasound results

## **References (PVD-7.4)**

- 1. Hall HA, Minc S, Babrowski T. Peripheral artery aneurysm. *Surg Clin North Am*. 2013;93(4):911-ix. doi:10.1016/ j.suc.2013.04.008.
- von Stumm M, Teufelsbauer H, Reichenspurner H, Debus ES. Two Decades of Endovascular Repair of Popliteal Artery Aneurysm--A Meta-analysis. *Eur J Vasc Endovasc Surg.* 2015;50(3):351-359. doi:10.1016/ j.ejvs.2015.04.036

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 125 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
<ol> <li>Kim TI, Sumpio BE. Management of Asymptomatic Popliteal Artery Aneurysms. Int J Angiol. 20 doi:10.1055/s-0038-1676792.</li> </ol>	19;28(1):5-10.
<ol> <li>Corriere MA, Guzman RJ. True and false aneurysms of the femoral artery. Semin Vasc Surg. 2005;18(4):216-223. doi:10.1053/j.semvascsurg.2005.09.008</li> </ol>	

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 126 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Claudication and Critical Limb Ischemia (PVD-7.1)

## PVD.AI.0007.1.A

### v1.0.2024

- Resting ABI for initial evaluation of suspected PAD. This can be accomplished at the bedside as part of the physical examination or requested as CPT<sup>®</sup> 93922 (limited Doppler ultrasound) or CPT<sup>®</sup> 93923 (multi-level complete Doppler ultrasound)
  - CPT<sup>®</sup> 93923 may be performed once
  - Follow-up studies may be performed with CPT<sup>®</sup> 93922
  - Post-exercise ABI (CPT<sup>®</sup> 93924) can be performed if the resting ABI is >0.89 and PAD is still highly suspected clinically.
- History and physical suggestive of PAD include:
  - History
    - Claudication- reproducible calf or thigh cramping with exertion that is relieved completely with rest
    - Critical limb ischemia
    - Rest pain suggestive of ischemia-pain in the ball of foot when the leg is in an elevated position particularly at night
    - Distal non-healing wound or punched out ulcer with sharply demarcated edges present for >2 weeks with no evidence of healing, i.e. presence of granulation tissue
  - Physical Examination
    - Abnormal lower extremity pulse examination
    - Vascular bruit
    - Non-healing lower extremity wound
    - Lower extremity gangrene
    - Other suggestive lower extremity physical findings (e.g., elevation pallor/ dependent rubor)
    - Atrophic nails, hair loss, shiny skin
- If resting ABI (CPT<sup>®</sup> 93922) is normal (0.9 to 1.3) and disease is still suspected:
  - Differentiate from "pseuodoclaudication". See <u>Lumbar Spinal Stenosis (SP-9)</u> in the Spine Imaging Guidelines
  - Re-measure ABI after exercise (CPT<sup>®</sup> 93924)
  - A TBI (toe-brachial index) may be used as further screening in individuals with ABI's ≥1.4
  - Advanced imaging is necessary only if there is consideration for invasive therapy not to confirm diagnosis

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 127 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines V2.0.2024	-
<ul> <li>Duplex ultrasound (CPT<sup>®</sup> 93925 bilateral study or CPT<sup>®</sup> 93926 unilateral study) and Doppler studies are adjuncts to abnormal ABI that may be used to identify location and extent of disease once there has been a decision for revascularization.</li> <li>MRA Aorta and Pelvic vessels, and Lower extremities (CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725 and CPT<sup>®</sup> 73725), or CTA with run-off (CPT<sup>®</sup> 75635) to further evaluate the lower extremity arteries for ANY of the following: <ul> <li>Potentially limb-threatening vascular disease evidenced by:</li> <li>Skin breakdown</li> <li>Non-healing ischemic ulcers</li> <li>Resting leg pain</li> <li>Gangrene</li> </ul> </li> <li>Blue Toe Syndrome: <ul> <li>Emboli from aortic plague or mural thrombus</li> </ul> </li> </ul>	
<ul> <li>Emboli nom aortic plaque or mutar thrombus</li> <li>Hyperviscosity syndrome</li> </ul>	
<ul> <li>Hyperviscosity syndrome</li> <li>Hypercoagulable states</li> </ul>	
<ul> <li>Type: coagulable states</li> <li>Vasculitis</li> </ul>	
<ul> <li>Preoperative planning for Intermittent claudication (i.e., non-limb threatening</li> </ul>	

- ischemia) **AND** there is documentation of both of the following:
- Failed 3-months' conservative medical therapy (physician supervised walking/ exercise program plus medical therapy)
- Functional disability (e.g., exercise impairment sufficient to threaten the individual's employment or to require significant alterations in the individual's lifestyle)
- CTA lower extremity (CPT<sup>®</sup> 73706) OR MRA lower extremity (CPT<sup>®</sup> 73725) can be approved for evaluation of PVD when aortoiliac disease is not a concern or the state of the aorta and iliac arteries is already known as documented in the clinical history

### Note:

MRA Pelvis (CPT<sup>®</sup> 72198) should not be requested/billed with CPT<sup>®</sup> 74185, CPT<sup>®</sup> 73725 and CPT<sup>®</sup> 73725

## Background and Supporting Information

Claudication symptoms usually remain stable (70% to 80% of individuals) and do not worsen or improve at rapid rates. Repeat studies to assess the efficacy of medical therapy are not indicated unless there is a negative change in clinical status for the purpose of preoperative planning such as worsening claudication or progression to critical limb ischemia.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 128 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **References (PVD-7)**

- 1. Dick F, Ricco J-B, Davies A.H, Cao P, et. al. Chapter VI: Follow-up after Revascularization. *European Journal of Vascular and Endovascular Surgery*, Volume 42, Supplement 2, 2011 pp.S75-90.
- 2. Lane TRA et al. Post-Operative Surveillance after Open Peripheral Arterial Surgery. *Eur J Vasc Endovasc Surg.* Volume 42, Issue 1, July 2011. Pages 59-77.
- Brooke BS, Beck AW, Kraiss LW, et al. Association of Quality Improvement Registry Participation with Appropriate Follow-up after Vascular Procedures. *JAMA Surgery*. 2018;153(3):216. doi:10.1001/ jamasurg.2017.3942.
- 4. Rooke TW, Hirsch AT, Misra S, Sidawy AN, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. American College of Cardiology Foundation/American Task Force on Practice Guidelines., Society for Cardiology Foundation/American Heart Association Task Force on Practice Guidelines., Society for Cardiology Foundation/American Heart Association Task Force on Practice Guidelines., Society for Cardiovascular Angiography and Interventions., Society of Interventional Radiology., Society for Vascular Medicine., Society for Vascular Surgery. *J Vasc Surg.* 2011 Nov; 54(5):e32-58
- Conte MS, Pomposelli FB, and Clair DG. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. March 2015;61(3):2S-41S.e1
- Bui TD, Mills JL Sr, Inhnat DM et al. The natural history of duplex-detected stenosis after femoropopliteal endovascular therapy suggests questionable clinical utility of routine duplex surveillance. J Vasc Surg. 2012 Feb 55:2:346-352
- Troutman DA, Madden NJ, Dougherty MJ, et al. Duplex Ultrasound Diagnosis of Failing Stent Grafts Placed for Occlusive Disease. J Vasc Surg 2014;70:1–5.
- 8. Humphries MD, Pevec WC, Laird JR, et.al. Early Duplex Scanning after Infrainguinal Endovascular Therapy. *J Vasc Surg* 2011; 53:353–8.
- 9. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg.* 2018 Jul;68(1):256-284. doi: 10.1016/j.jvs.2018.04.018.
- Cooper K, Majdalany BS, Kalva SP, et al. ACR Appropriateness Criteria <sup>®</sup> Lower Extremity Arterial Revascularization—Post-Therapy Imaging. *J Am Coll Radiol*. 2018;15:S104-S115.
- 11. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017; 135: e726-e779.
- Ahmed O, Hanley M, Bennett SJ, et al. ACR Appropriateness Criteria<sup>®</sup> Vascular claudication -Assessment for Revascularization. J Am Coll Radiol. 2017 May;14(5S):S372-S379. doi: 10.1016/j.jacr.2017.02.037.
- 13. Macedo TA, Johnson M, Hallett Jr JW, and Breen JF. Popliteal artery entrapment syndrome: role of imaging in the diagnosis. *AJR Am J Roentgen*. 2003 Nov;181(5):1259-1265. doi:10.2214/ajr.181.5.1811259.
- 14. Ahmed O, Hanley M, Bennett SJ, et al. ACR <sup>®</sup> Appropriateness Criteria Vascular Claudication-Assessment for Revascularization. J Am Coll Radiol. 2017;14(5):S372-S379. doi:10.1016/j.jacr.2017.02.037.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 129 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## Popliteal Artery Entrapment Syndrome (PVD-7.2)

PVD.AI.0007.2.A

#### v1.0.2024

- Diagnosis of popliteal artery stenosis or occlusion due to compression by adjacent muscle and tendons:
  - Ultrasound (CPT<sup>®</sup> 93926 unilateral study), CTA Lower extremity (CPT<sup>®</sup> 73706), or MRA Lower extremity (CPT<sup>®</sup> 73725).
  - CT or MRI Lower Extremity (contrast as requested) if requested by the operating surgeon

### Background and Supporting Information

Popliteal Artery Entrapment Syndrome is typically seen in young men (ages 20 to 40) but is not exclusive to this gender or age group.

## References (PVD-7.2)

- 1. Hall HA, Minc S, Babrowski T. Peripheral artery aneurysm. *Surg Clin North Am*. 2013;93(4):911-ix. doi:10.1016/ j.suc.2013.04.008.
- von Stumm M, Teufelsbauer H, Reichenspurner H, Debus ES. Two Decades of Endovascular Repair of Popliteal Artery Aneurysm--A Meta-analysis. *Eur J Vasc Endovasc Surg.* 2015;50(3):351-359. doi:10.1016/ j.ejvs.2015.04.036
- 3. Kim TI, Sumpio BE. Management of Asymptomatic Popliteal Artery Aneurysms. *Int J Angiol.* 2019;28(1):5-10. doi:10.1055/s-0038-1676792.
- 4. Corriere MA, Guzman RJ. True and false aneurysms of the femoral artery. *Semin Vasc Surg.* 2005;18(4):216-223. doi:10.1053/j.semvascsurg.2005.09.008

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 130 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## **Post-Procedure Surveillance Studies** (PVD-7.3)

PVD.AI.0007.3.A v1.0.2024

- Scheduled Interval

  - ABI (CPT<sup>®</sup> 93922) following any revascularization procedure
     ABI (CPT<sup>®</sup> 93922) or Duplex ultrasound (CPT<sup>®</sup> 93926 unilateral study) at each routine follow up is indicated generally after a history/physical has been performed
    - Further imaging studies such as CTA or MRA are indicated for worsening symptoms, an abnormal duplex or a significant reduction (>0.15) in the ABI

Indication	Imaging
Suprainguinal Revascularization, both open and endovascular therapy, including Aortobifem/iliofem/fem-fem bypass/iliac angioplasty/stent	<ul> <li>Clinical examination and ABI (CPT<sup>®</sup> 93922) with arterial duplex (CPT<sup>®</sup> 93978 or CPT<sup>®</sup> 93979) at:         <ul> <li>Within 1 month</li> <li>6 months</li> <li>12 months</li> <li>Then annually</li> </ul> </li> </ul>
Infrainguinal Open Revascularization (Femoral-popliteal, femoral-tibial, femoral- distal bypass)	
With vein or autologous conduit	<ul> <li>Clinical exam and ABI (CPT<sup>®</sup> 93922) with arterial duplex (CPT<sup>®</sup> 93978 or CPT<sup>®</sup> 93979)</li> <li>Post-operatively</li> <li>3 months</li> <li>6 months</li> <li>12 months</li> <li>Then annually</li> </ul>

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 131 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

Indication	Imaging
With Prosthetic conduit (PTFE/Dacron)	<ul> <li>Clinical exam and ABI (CPT<sup>®</sup> 93922) with arterial duplex (CPT<sup>®</sup> 93978 or CPT<sup>®</sup> 93979)</li> <li>Post-operatively</li> <li>6 months</li> <li>12 months</li> <li>Then annually</li> </ul>
Infrainguinal Endovascular Revascularization Femoropopliteal angioplasty/stent	<ul> <li>Clinical exam and ABI (CPT<sup>®</sup> 93922) with arterial duplex (CPT<sup>®</sup> 93978 or CPT<sup>®</sup> 93979):</li> <li>Within 1 month</li> <li>3 month</li> <li>Every 6 months for two years</li> <li>Then annually</li> </ul>

## After suprainguinal intervention (PVD-7.3.1)

- One of the following studies: Arterial duplex, CTA Abdomen and Pelvis, CT Abdomen and Pelvis with contrast, CTA Aorta with lower extremity runoff, MRI Abdomen and Pelvis, MRA Abdomen and Pelvis, or MRA Aorta with lower extremity runoff for any one of the following:
  - Worsening signs or symptoms
  - Reduction of ABI >0.15
  - Peak systolic velocities or PSV ratio suggestive of high grade stenosis or in-stent re-stenosis

## After infrainguinal intervention (PVD-7.3.2)

- CTA Lower Extremity (CPT<sup>®</sup> 73706) or MRA Lower Extremity (CPT<sup>®</sup> 73725) or CTA aorta with lower extremity runoff CPT<sup>®</sup> 75635) for any one of the following:
  - Worsening signs or symptoms
  - Reduction of ABI >0.15
  - Duplex suggestive of threatened graft
- If intervention was performed for a non-healing wound and wound has gone on to heal, no additional imaging is recommended for surveillance.
- Repeat arterial duplex imaging can be obtained for worsening clinical signs and symptoms such as the presence of a new wound or rest pain

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 132 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

## **References (PVD-7.3)**

- 1. Dick F, Ricco J-B, Davies A.H, Cao P, et. al. Chapter VI: Follow-up after Revascularization. *European Journal of Vascular and Endovascular Surgery*, Volume 42, Supplement 2, 2011 pp.S75-90.
- 2. Lane TRA et al. Post-Operative Surveillance after Open Peripheral Arterial Surgery. *Eur J Vasc Endovasc Surg.* Volume 42, Issue 1, July 2011. Pages 59-77.
- Brooke BS, Beck AW, Kraiss LW, et al. Association of Quality Improvement Registry Participation with Appropriate Follow-up after Vascular Procedures. JAMA Surgery. 2018;153(3):216. doi:10.1001/ jamasurg.2017.3942.
- 4. Rooke TW, Hirsch AT, Misra S, Sidawy AN, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. American College of Cardiology Foundation/American Task Force on Practice Guidelines., Society for Cardiology Foundation/American Heart Association Task Force on Practice Guidelines., Society for Cardiology Foundation/American Heart Association Task Force on Practice Guidelines., Society for Cardiovascular Angiography and Interventions., Society of Interventional Radiology., Society for Vascular Medicine., Society for Vascular Surgery. *J Vasc Surg.* 2011 Nov; 54(5):e32-58
- Conte MS, Pomposelli FB, and Clair DG. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: Management of asymptomatic disease and claudication. J Vasc Surg. March 2015;61(3):2S-41S.e1
- Bui TD, Mills JL Sr, Inhnat DM et al. The natural history of duplex-detected stenosis after femoropopliteal endovascular therapy suggests questionable clinical utility of routine duplex surveillance. J Vasc Surg. 2012 Feb 55:2:346-352
- 7. Troutman DA, Madden NJ, Dougherty MJ, et al. Duplex Ultrasound Diagnosis of Failing Stent Grafts Placed for Occlusive Disease. *J Vasc Surg* 2014;70:1–5.
- 8. Humphries MD, Pevec WC, Laird JR, et.al. Early Duplex Scanning after Infrainguinal Endovascular Therapy. *J Vasc Surg* 2011; 53:353–8.
- 9. Zierler RE, Jordan WD, Lal BK, et al. The Society for Vascular Surgery practice guidelines on follow-up after vascular surgery arterial procedures. *J Vasc Surg.* 2018 Jul;68(1):256-284. doi: 10.1016/j.jvs.2018.04.018.
- Cooper K, Majdalany BS, Kalva SP, et al. ACR Appropriateness Criteria<sup>®</sup> Lower Extremity Arterial Revascularization—Post-Therapy Imaging. *J Am Coll Radiol*. 2018;15:S104-S115.
- 11. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017; 135: e726-e779.
- Ahmed O, Hanley M, Bennett SJ, et al. ACR Appropriateness Criteria<sup>®</sup> Vascular claudication -Assessment for Revascularization. J Am Coll Radiol. 2017 May;14(5S):S372-S379. doi: 10.1016/j.jacr.2017.02.037.
- 13. Macedo TA, Johnson M, Hallett Jr JW, and Breen JF. Popliteal artery entrapment syndrome: role of imaging in the diagnosis. *AJR Am J Roentgen*. 2003 Nov;181(5):1259-1265. doi:10.2214/ajr.181.5.1811259.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 133 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Arterial Imaging for Free Flaps in Reconstructive Surgery (PVD-7.5)

## PVD.AI.0007.5.A

v1.0.2024

- For breast reconstruction preoperative planning. See <u>Breast Reconstruction (BR-3)</u> in the Breast Imaging Guidelines
- For head and neck reconstruction, CTA or MRA unilateral lower extremity (CPT<sup>®</sup> 73706 or 73725) of the harvest site is indicated for evaluation of perforator anatomy for planned fibular flap

## References (PVD-7.4)

- 1. Hall HA, Minc S, Babrowski T. Peripheral artery aneurysm. *Surg Clin North Am*. 2013;93(4):911-ix. doi:10.1016/j.suc.2013.04.008.
- von Stumm M, Teufelsbauer H, Reichenspurner H, Debus ES. Two Decades of Endovascular Repair of Popliteal Artery Aneurysm--A Meta-analysis. *Eur J Vasc Endovasc Surg.* 2015;50(3):351-359. doi:10.1016/ j.ejvs.2015.04.036
- 3. Kim TI, Sumpio BE. Management of Asymptomatic Popliteal Artery Aneurysms. *Int J Angiol*. 2019;28(1):5-10. doi:10.1055/s-0038-1676792.
- 4. Corriere MA, Guzman RJ. True and false aneurysms of the femoral artery. *Semin Vasc Surg.* 2005;18(4):216-223. doi:10.1053/j.semvascsurg.2005.09.008

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 134 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Arteriovenous Malformations (AVMs) (PVD-9.1)

PVD.AI.0009.1.A

v1.0.2024

- See Pulmonary AVMs (CH-24.1) in the Chest Imaging Guidelines
- See <u>Arteriovenous Malformations (AVMs) and Related Lesions (HD 12.2)</u> in the Head Imaging Guidelines
- See <u>Arteriovenous Malformations (AVMs) and Fistulas (PEDPVD-2.5)</u> in the Pediatric Peripheral Vascular Disease Imaging Guidelines
- See Pelvic Pain/Dyspareunia, Female (PV-11.1) in the Pelvis Imaging Guidelines

### **Initial imaging**

- Ultrasound with Doppler is indicated as an initial examination for superficial lesions in the limbs.
  - Large lesion characterization may be limited by ultrasound imaging window.
  - Ultrasound is also limited in evaluating AVM relationship to airway or bony structures.

## **Evaluation and surveillance**

- MRI without contrast or without and with contrast of the affected body part is the study of choice for abdominal AVMs and deep tissue (below the skin) AVM's in the limbs.
- MRA (contrast as requested) of the affected body part can be approved for evaluation and surveillance of known AVMs.
- It is unusual for both MRI and MRA to be necessary for routine treatment response or surveillance imaging of AVMs, but both may be approved for preoperative planning.
- CT and CTA can also be used to characterize AVMs and their relationship to normal structures but is generally not better than MRI and has associated radiation risks.
  - CT with contrast and/or CTA (contrast as requested) of the affected body part can be approved when MRI and/or MRA is inconclusive or contraindicated.

## **Post-embolization**

- Advanced imaging can be approved one-time post-embolization to evaluate for successful resolution of the AVM.
- Additional imaging (same study performed pre-procedure or as requested by the treating provider) can be approved for treatment planning purposes if resolution of the AVM was not achieved.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 135 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

#### Background and Supporting Information

Arteriovenous malformations are characterized by a network of multiple abnormal vascular channels interposed between enlarged feeding arteries and draining veins. The arteriovenous fistula has a single communication interposed between a feeding artery and a draining vein. The normal capillary bed is absent in both lesions. Both lesions may have an aggressive clinical course and are characterized by a reddish pulsatile mass which has a thrill or bruit. Though often recognized at birth, these lesions may grow and present near adolescence.

## References

- Pizzo PA, Poplack DG, Krishnamurthy R, Daldrup-Link HE, Jones JY, et. al. Imaging studies in the diagnosis and management of pediatric malignancies. In: Principles and Practice of Pediatric Oncology. Vol 7. Philadelphia: Wolters Kluwer; 2016:185-234.
- 2. Martin KL. Vascular disorders. *Nelson Textbook of Pediatrics*, Chapter 669. eds Kliegman R, St. Geme JW III, Blum NJ, et al. 21st ed. Philadelphia, PA: Elsevier; 2020:3461-3469.
- 3. Blei F, Guarini A. Current workup and therapy of infantile hemangiomas. Clinics in Dermatology. 2014;32(4):459-470. doi:10.1016/j.clindermatol.2014.02.001.
- Cahill AM, Nijs ELF. Pediatric Vascular Malformations: Pathophysiology, Diagnosis, and the Role of Interventional Radiology. *CardioVascular and Interventional Radiology*. 2011;34(4):691-704. doi:10.1007/ s00270-011-0123-0.
- 5. Bagrodia N, Defnet AM, Kandel JJ. Management of lymphatic malformations in children. *Current Opinion in Pediatrics*. 2015;27(3):356-363. doi:10.1097/mop.000000000000209.
- Wassef M, Blei F, Adams D, et al. Vascular Anomalies Classification: Recommendations from the International Society for the Study of Vascular Anomalies. *Pediatrics*. 2015;136(1):e203-e214. doi:10.1542/peds.2014-3673.
- Kutz AM, Aranibar L, Lobos N, Wortsman X. Color Doppler Ultrasound Follow-Up of Infantile Hemangiomas and Peripheral Vascularity in Patients Treated with Propranolol. *Pediatric Dermatology*. 2015;32(4):468-475. doi:10.1111/pde.12596.
- 8. Adams DM, Trenor CC, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. *Pediatrics*. 2016;137(2). doi:10.1542/peds.2015-3257.
- Snyder E, Puttgen K, Mitchell S, Ahlawat S, Tekes A. Magnetic Resonance Imaging of the Soft Tissue Vascular Anomalies in Torso and Extremities in Children: An Update with 2014 International Society for the Study of Vascular Anomalies Classification. *Journal of Computer Assisted Tomography*. 2017;42(2):167-177. doi:10.1097/rct.00000000000675.
- Merrow AC, Gupta A, Patel MN, Adams DM. 2014 Revised Classification of Vascular Lesions from the International Society for the Study of Vascular Anomalies: Radiologic-Pathologic Update. *RadioGraphics*. 2016;36(5):1494-1516. doi:10.1148/rg.2016150197.
- Johnson CM, Navarro OM. Clinical and sonographic features of pediatric soft-tissue vascular anomalies part 1: classification, sonographic approach and vascular tumors. *Pediatric Radiology*. 2017;47(9):1184-1195. doi:10.1007/s00247-017-3885-y.
- 12. Johnson CM, Navarro OM. Clinical and sonographic features of pediatric soft-tissue vascular anomalies part 2: vascular malformations. *Pediatric Radiology*. 2017;47(9):1196-1208. doi:10.1007/s00247-017-3906-x.
- Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth W. Vascular Anomalies (Part I): Classification and Diagnostics of Vascular Anomalies. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2018;190(09):825-835. doi:10.1055/a-0620-8925.
- Olivieri B, White CL, Restrepo R, et. al. Low-Flow Vascular Malformation Pitfalls: From Clinical Examination to Practical Imaging Evaluation—Part 2, Venous Malformation Mimickers. *American Journal of Roentgenology*. 2016;206(5):952-962. doi:10.2214/ajr.15.15794.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 136 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
---	-----------

 White CL, Olivieri B, Restrepo R, et.al. Low-Flow Vascular Malformation Pitfalls: From Clinical Examination to Practical Imaging Evaluation—Part 1, Lymphatic Malformation Mimickers. *American Journal of Roentgenology*. 2016;206(5):940-951. doi:10.2214/ajr.15.15793.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 137 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.



# **Venous Imaging**

#### Guideline

Venous Imaging General Information (PVD-11) Upper Extremity Venous – Imaging (PVD-4.2) Acute Limb Swelling (PVD-12) Chronic limb swelling due to chronic deep venous thrombosis (DVT)/May-Thurner syndrome (PVD-13) Chronic limb swelling due to venous insufficiency/Venous stasis changes/Varicose veins (PVD-14) Imaging for Hemodialysis Access (PVD-8) IVC filters – Treatment (PVD-16.2) Post iliac vein stenting/angioplasty (PVD-17.1)

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 138 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Venous Imaging General Information (PVD-11)

PVD.VI.0011.A v1.0.2024

## Abbreviations and glossary (PVD-11.1)

Abbreviation	Definition
СТV	Computed Tomography Venography
DVT	Deep Venous Thrombosis
EVA	Endovenous ablation – a minimally invasive procedure using heat to obliterate the saphenous vein for the treatment of venous reflux
IVC	Inferior vena cava
May-Thurner's	Syndrome of compression of the left iliac vein via an overlying right common iliac artery. The pulsations of the artery into the vein against the 5 <sup>th</sup> lumbar vertebrae can predispose to DVT
MRV	Magnetic Resonance Venography
Phlebectomy	Removal of a vein usually through a small incision
Post-thrombotic syndrome	Constellation of symptoms including chronic edema and pain that develops after a DVT
Sclerotherapy	Injection of an irritant into a vein to obliterate it
SEPS	Sub-fascial endoscopic perforator surgery
SVT	Superficial venous thrombosis

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 139 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Abbreviation	Definition
VVI	Venous Valvular Insufficiency – a study utilizing ultrasound to assess for the presence of reflux within the superficial and deep veins of the lower extremity.

## Venous imaging - General guidelines (PVD-11.2)

- A current clinical evaluation (within 60 days), including medical treatments, are required prior to considering advanced imaging, which includes:
  - Relevant history and physical examination including:
    - The affected limb(s), the extent of the edema (calf and/or thigh), pitting or non-pitting. With regard to venous insufficiency, presence or absence of hyperpigmentation or other skin changes, ulcerations if applicable, size of varicosities if present as well as distribution
    - Arterial examination to rule out phlegmasia alba/cerulea dolens which is comprised arterial flow secondary to extensive DVT if applicable
    - Appropriate laboratory studies, for example d-dimer, if applicable
    - Non-advanced imaging modalities, such as a venous duplex or venous valvular insufficiency study (VVI) after symptoms started or worsened
  - Other meaningful contact (telephone call, electronic mail or messaging) by an established patient can substitute for a face-to-face clinical evaluation.

## • General Guidelines-Imaging (PVD-11.4)

- Venous duplex (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) of the limb is the initial imaging of choice
  - Follow-up duplex imaging (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) is not generally indicated to document resolution and should only be obtained for new signs/symptoms or for concerns of propagation of thrombus when the treatment plan would change (Insertion of IVC filter, change of anticoagulation, etc.)
- Imaging studies
  - Venous duplex (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) should visualize the veins, with demonstration of the presence or absence of compressibility and venous flow.
  - Venous valvular insufficiency studies (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) visualize the veins of the lower extremity, assess for reflux (reversal of venous antegrade flow after valve closure) and measure its duration.
  - CTV or MRV Abdomen and Pelvis (CPT<sup>®</sup> 74174) or (CPT<sup>®</sup> 74185 and 72198) images with contrast involves taking images from the diaphragm to just below the inguinal ligament after a delay of a few minutes after IV contrast

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 140 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

is administered to optimize filling and therefore visualization of the venous vasculature

### Background and Supporting Information

Venous disease can be classified into three categories:

### Veno-occlusive disease

- Types of thrombotic disease
  - Superficial venous thrombosis
  - Deep venous thrombosis
  - Iliac vein obstruction, unilateral or bilateral
  - May-Thurner's syndrome
- Signs/Symptoms of veno-occlusive disease is generally sudden onset of pain and edema in the limb.
- Risk factors include age >40, obesity, pregnancy, prolonged immobility, postsurgery, and malignancy among others.
- Procedures related to veno-occlusive disease include:
  - Thrombolysis
  - Thrombectomy
  - Post-iliac vein stent/angioplasty

## Venous insufficiency

- Types of venous insufficiency:
  - Superficial and deep venous reflux
  - Varicose veins
  - Reticular and spider veins.
- Signs/symptoms of venous insufficiency include:
  - Chronic swelling in the leg that is relieved with elevation
  - Chronic swelling in the leg that is worse in the evenings
  - Aching or sense of heaviness in the leg
  - Hyperpigmentation of the calf particularly around the ankle
  - Itchy skin on legs and feet
  - Leather appearance of the skin of the calves
  - Skin ulcers in the calf particularly around the medial malleolus
  - Varicose veins
  - Spider veins/reticular veins/telangiectasias
- Procedures related to the venous insufficiency include:
  - Endovenous laser ablation utilizing either chemical, laser or radio-frequency
  - Saphenous vein high ligation and stripping

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 141 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- Phlebectomy, stab or powered
- Sclerotherapy, liquid or foam

## Venous malformations

- Types of venous malformations include:
  - Arterio-venous malformations which can occur throughout the body
  - See Pulmonary AVM (CH-24) in the Chest imaging guidelines
  - See Aneurysm and AVM (HD-12) in the Head imaging guidelines
  - See <u>Pelvic Pain/Dyspareunia, Female (PV-11)</u> in the Pelvic imaging guidelines
  - Klippel-Trenaunay which affects primarily the lower extremity venous circulation and is characterized by varicose veins, limb size discrepancies, and port-wine stains.
- Treatment includes:
  - Primarily embolization
  - Sclerotherapy
    - Klippel-Trenaunay: treatment can include phlebectomy and sclerotherapy of symptomatic varicose veins provided they meet the criteria for intervention.

## Procedure Coding (PVD-11.3)

Venous Studies – Extremities	CPT®
CTV Abdomen and Pelvis involves obtaining images from the diaphragm to just below the inguinal ligament after a delay of a few minutes after IV contrast is administered to optimize filling and therefore visualization of the venous vasculature.	74174
CTV Pelvis involves obtaining images from the top of the pelvic brim to the upper thighs or just below the inguinal ligament. The venogram portion is performed by obtaining images after a delay of a few minutes after IV contrast is administered to optimize filling and therefore visualization of the venous vasculature.	72191
MRV Abdomen and Pelvis involves taking images from the diaphragm to just below the inguinal ligament after a delay of a few minutes after IV contrast is administered to optimize filling and therefore visualization of the venous vasculature.	74185 and 72198

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 142 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines V2.0.2
--

Venous Studies – Extremities	CPT®
MRV Pelvis involves obtaining images from the top of the pelvic brim to the upper thighs or just below the inguinal ligament. The venogram portion is performed by obtaining images after a delay of a few minutes after IV contrast is administered to optimize filling and therefore visualization of the venous vasculature.	72198
Duplex scan of extremity veins, including responses to compression and other maneuvers; complete bilateral study.	93970
Duplex scan of extremity veins, including responses to compression and other maneuvers; unilateral or limited study.	93971
<ul> <li>These codes are used to report studies of lower <i>or</i> upper extremity veins.</li> <li>A complete bilateral study of the lower extremity veins includes examination of the external iliac veins, common femoral, proximal deep femoral, great saphenous and popliteal veins. Calf veins may also be included.</li> <li>A complete bilateral study of upper extremity veins includes examination of the subclavian, jugular, axillary, brachial, basilic, and cephalic veins. Forearm veins may also be included.</li> </ul>	
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	93978
Duplex scan of extremity veins, including responses to compression and other maneuvers; unilateral or limited study.	93979

## References

- 1. Ageno W, Haas S, Weitz JI, et al. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. *Thromb Haemost.* 2019;119(2):319-327. doi:10.1055/s-0038-1676611.
- 2. Jones WS, Vemulapalli S, Parikh KS et al. Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD. Agency for Healthcare Research and Quality (US); 2017 Apr.
- Gloviczki P, Comerota AJ, Dalsing MD, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg.* 2011. 53(16S):1-47. doi:10.1016/j.jvs.2011.01.079.
- Wolpert L, Rahmani O, Stein B, et al. Magnetic Resonance Venography in the Diagnosis and Management of May-Thurner syndrome. *Vasc Endovascular Surg.* 2002 Jan-Feb;36(1):51-7. doi:10.1177/153857440203600109.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 143 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

## Upper Extremity Venous – Imaging (PVD-4.2)

## PVD.AI.0004.1.A

#### v1.0.2024

- For symptoms of venous insufficiency including but not limited to unilateral pain and swelling of the upper extremity
  - Venous duplex upper extremities (CPT<sup>®</sup> 93970 or CPT<sup>®</sup> 93971) should be performed initially
  - If duplex ultrasound is non-diagnostic:
    - MRV Upper extremity (CPT<sup>®</sup> 73225) and/or MRV Chest (CPT<sup>®</sup> 71555), or
    - CTV Upper extremity (CPT<sup>®</sup> 73206) and/or CTV Chest (CPT<sup>®</sup> 71275)
      - CTV Upper extremity (CPT<sup>®</sup> 73206) or MRV Upper extremity (CPT<sup>®</sup> 73225), and/or CTV Chest (CPT<sup>®</sup> 71275) or MRV Chest (CPT<sup>®</sup> 71555) can be performed if there is a history of exertion with the limb such as with weight lifting or in the presence of central venous access (port, PICC line, to name a few) with a negative venous duplex. See <u>Thoracic Outlet Syndrome</u> (CH-31.1) in the Chest Imaging Guidelines.
- For Superior Vena Cava Syndrome (upper extremity and facial symptoms) **one** of the following can be approved when stenting of the SVC is being considered:
  - CT Chest with contrast (CPT<sup>®</sup> 71260)
  - MRV Chest (CPT<sup>®</sup> 71555)
  - CTV Chest (CPT<sup>®</sup> 71275)

## **References (PVD-4)**

- 1. Skeik N, Soo-Hoo SS, Porten BR, et al. Arterial Embolisms and Thrombosis in Upper Extremity Ischemia. *Vascular and Endovascular Surgery*. 2015;49(5-6):100-109. doi:10.1177/1538574415596740.
- Desjardins B, Rybicki FJ, Kim HS, et al. ACR Appropriateness Criteria<sup>®</sup> Suspected Upper Extremity Deep Vein Thrombosis. *J Am Coll Radiol* 2012;9(9):613-619. doi:10.1016/j.jacr.2012.05.021.
- Kraaijpoel N, Es NV, Porreca E, Büller HR, Nisio MD. The diagnostic management of upper extremity deep vein thrombosis: A review of the literature. *Thrombosis Research*. 2017;156:54-59. doi:10.1016/ j.thromres.2017.05.035.
- Hughes K, Cubangbang M, Blackman K, et al. Upper Extremity Bypass for Chronic Ischemia—A National Surgical Quality Improvement Program Study Database Study. *Vascular and Endovascular Surgery*. 2013;47(3):192-194. doi:10.1177/1538574413478472.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 144 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.
# Acute Limb Swelling (PVD-12)

PVD.VI.0012.A v1.0.2024

# Superficial venous thrombosis (SVT) (PVD-12.1)

- The diagnosis of superficial venous thrombosis is generally made on the basis of physical examination.
  - Duplex ultrasound (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) is the initial imaging if the diagnosis is equivocal
  - Follow-up duplex ultrasound (CPT<sup>®</sup> 93970, CPT<sup>®</sup> 93971) is indicated only if thrombus in the superficial systems is encroaching onto the deep venous system (saphenofemoral or saphenopopliteal junction)

#### Background and Supporting Information

Superficial venous thrombosis (SVT) refers to acute or chronic thrombosis of the superficial veins in both the upper (cephalic and basilic veins) and lower extremities (greater [great] saphenous vein, lesser [small] saphenous vein, gastrocnemius and soleal veins). Treatment: Elevation and warm compresses until pain and swelling subsides.

# Acute deep venous thrombosis (DVT) (PVD-12.2)

- Duplex ultrasound (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study) is the initial imaging study for any suspected DVT
  - Deep venous thrombosis can present as
    - Symptomatic
      - Swelling
      - Pain
      - Warmth
      - Erythema
      - Pain with dorsiflexion of the foot (Homan's Sign)
      - Or with progression, such as phlegmasia cerulean dolens
      - Risk factors for DVT include age >40, obesity, malignancy, prolonged immobilization, hypercoagulability as well as those outlined in <u>Pulmonary</u> <u>Embolism (PE) (CH-25)</u> in Chest Imaging Guidelines.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 145 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- CTA/CTV Abdomen and pelvis with contrast can be performed to rule out IVC thrombus secondary to the filter when there is acute bilateral lower extremity swelling in an individual with a history of an IVC filter in place.
- When there is concern for proximal DVT (iliofemoral):
  - Focused abdominal duplex can generally visualize the iliac veins and IVC to determine the absence or presence of iliac vein thrombus in an individual. If the results are equivocal or indeterminate:
    - CTV or MRV Abdomen and Pelvis with contrast (CPT<sup>®</sup> 74174 or CPT<sup>®</sup> 74185 and CPT<sup>®</sup> 73725) can be performed.
- For request concerning abdominal vein thrombosis, see <u>Abdominal Veins other</u> <u>than Hepatic and Portal Veins (AB-43.2)</u> in the Abdomen Imaging Guidelines
- For proximal DVT's (iliac vein DVT's or in cases of phlegmasia (extensive DVT compromising arterial inflow), thrombectomy (rarely performed) or thrombolysis can be performed.
- If the cause of the DVT is found to be due to May-Thurner, iliac vein angioplasty followed by stenting of the left iliac vein is generally performed. See <u>May-Thurner</u> <u>Syndrome (PVD-13.3)</u>

#### Background and Supporting Information

Deep venous thrombosis is characterized by thrombosis of a deep vein in either the upper (brachial, axillary, subclavian veins) or the lower extremity (peroneal, posterior tibial, popliteal, femoral or iliac veins).

# Follow-up imaging of known DVT (PVD-12.3)

- Duplex ultrasound (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study) can be repeated in order to rule out proximal extension of a calf vein DVT in those individuals who cannot be anticoagulated, most commonly after recent surgery. Time interval for follow-up study includes:
  - One week after the initial diagnosis.
  - Serial imaging (up to 3 studies) over the first three weeks if calf DVT is not treated.
- Imaging during or to terminate long-term anticoagulation therapy to determine venous recanalization is not supported by evidence. Repeat imaging to make decisions on whether or not to continue or terminate anticoagulation is not indicated.

# Follow-up imaging after venous surgery (PVD-12.4)

- Venous duplex (CPT<sup>®</sup> 93971 unilateral study) of the treated limb is indicated to rule out a DVT within seven days of endovenous ablation.
- Follow-up routine imaging is not indicated after other venous procedures including:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 146 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- Saphenous vein ligation and stripping
- Phlebectomy
- Sclerotherapy

### Generalized bilateral lower extremity edema (PVD-12.5)

Bilateral lower extremity edema is multifactorial. Prior to any request for advanced imaging, a workup for causes of the edema should be instituted including echocardiogram to rule out congestive heart failure and laboratory studies to exclude renal insufficiency and liver disease. The following imaging is indicated based on the suspected cause of the edema:

- Suspected abdominal or pelvic pathology
  - · Abdominal ultrasound or duplex is the initial imaging
  - CT Abdomen and Pelvis or CT pelvis either with or without constrast can be performed if abdominal US is equivocal or indeterminate
- Suspected chronic venous insufficiency
  - A venous duplex CPT<sup>®</sup> 93970 (bilateral) or CPT<sup>®</sup> 93971 (unilateral) is indicated to evaluate for venous reflux.
- Suspected lymphedema
  - When initial noninvasive studies, such as ultrasound, are negative for venous valvular insufficiency either of the following advanced imaging studies is indicated:
    - Lymphoscintigraphy (CPT<sup>®</sup> 78195)
    - MRI lymphaniography (CPT<sup>®</sup> 73718)

# References

- Lim W, Gal GL, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. *Blood Advances*. 2018;2(22):3226-3256. doi:10.1182/bloodadvances.2018024828.
- 2. American College of Phlebology. Treatment of Superficial Venous Disease of the Lower Leg Guidelines. American Vein & Lymphatic Society. http://www.phlebology.org/member-resources/publications/treatmentsuperficial-venous-disease-lower-leg-guidelines. Published 2016.
- 3. American College of Phlebology. Duplex Ultrasound Imaging of Lower Extremity Veins in Chronic Venous Disease. American Vein & Lymphatic Society. http://www.phlebology.org/member-resources/publications/ duplex-ultrasound-imaging-lower-extremity-veins-chronic-venous-disease. Published 2012.
- 4. Healy DA, Kimura S, Power D, et al. A Systematic Review and Meta-analysis of Thrombotic Events Following Endovenous Thermal Ablation of the Great Saphenous Vein. *European Journal of Vascular and Endovascular Surgery*. 2018;56(3):410-424. doi:10.1016/j.ejvs.2018.05.008.
- Jacobs CE, Pinzon MM, Orozco J, et al. Deep Venous Thrombosis after Saphenous Endovenous Radiofrequency Ablation: Is it Predictable? *Annals of Vascular Surgery*. 2014;28(3):679-685. doi:10.1016/ j.avsg.2013.08.012.
- Liu N, Wang C, Sun M. Noncontrast three-dimensional magnetic resonance imaging vs lymphoscintigraphy in the evaluation of lymph circulation disorders: A comparative study. *J Vasc Surg.* 2005;41(1):69-75. doi:10.1016/ j.jvs.2004.11.013.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 147 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Chronic limb swelling due to chronic deep venous thrombosis (DVT)/May-Thurner syndrome (PVD-13)

PVD.VI.0013.A v1.0.2024

# Chronic DVT with incompletely lysed or residual DVT (PVD-13.1)

Individuals with incompletely lysed or residual DVT can develop post-thrombotic syndrome that can be characterized as chronic edema, venous stasis changes, pain and in advanced cases venous stasis ulceration.

- Imaging is indicated to evaluate for iliac venous obstruction from incompletely lysed thrombus in individuals with a history of proximal (iliofemoral) DVT who have developed post thrombotic syndrome.
  - Initial imaging is duplex (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study)
  - Either a CTV or MRV Abdomen and Pelvis (CPT<sup>®</sup> 74174) or (CPT<sup>®</sup> 74185 and 72198) OR CTV Pelvis (CPT<sup>®</sup> 72191) or MRV Pelvis (CPT<sup>®</sup> 72198), or venography for treatment planning purposes.
- Imaging for post-thrombotic syndrome is only indicated for either:
  - Signs and symptoms suggestive of a new acute DVT
  - Preoperative planning for iliac vein/stenting for suspected iliac vein stenosis or occlusion

#### Background and Supporting Information

- Chronic deep venous thrombosis is defined as an acute DVT that is greater than 14 days old.
- Incompletely lysed DVT can cause luminal narrowing of the vein restricting venous outflow leading to stenosis or occlusion and /or can lead to valve dysfunction resulting in reflux of venous blood retrograde towards gravity. Both pathologies ultimately lead to chronic edema which can cause chronic pain and venous stasis disease.
  - The mainstay of treatment for chronic deep venous thrombosis is compression stockings
  - Selected individuals may be a candidate for iliac vein angioplasty/stenting.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 148 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Post-thrombotic syndrome (PVD-13.2)

- Imaging for post-thrombotic syndrome is indicated when:
  - There are signs and symptoms suggestive of a new acute DVT
  - For preoperative planning for iliac vein/stenting in the setting of known iliac venous obstruction in those with a history of a proximal (iliofemoral) DVT.
- Imaging for post-thrombotic syndrome is NOT indicated for chronic swelling that has not changed in severity or character

# May-Thurner syndrome (PVD-13.3)

- CTV or MRV Abdomen and Pelvis (CPT<sup>®</sup> 74174, or 74185 and 72198) OR CTV Pelvis or MRV Pelvis (CPT<sup>®</sup> 72191 or 72198) can be approved in individuals with a history of **one** of the following:
  - Left lower extremity iliac DVT
  - Persistent left lower extremity edema OR varicose veins OR venous stasis ulcer despite treatment of superficial venous disease in that extremity
  - Persistent left lower extremity edema OR varicose vein OR venous stasis ulcer in the absence of saphenous vein reflux.
- Imaging and/or prophylactic treatment of May-Thurner syndrome, in the absence of acute or chronic DVT OR chronic left lower extremity edema and its sequelae such as varicose veins or venous stasis ulcers, is NOT considered medically necessary

#### Background and Supporting Information

In approximately 25% of people, the right iliac artery overlies the left iliac vein over the fifth lumbar vertebrae and its pulsations can compress the vein increasing the risk of DVT in the left extremity.

• Treatment is with iliac vein angioplasty/stenting

### Pelvic congestion syndrome (PVD-13.4)

- Signs and symptoms of pelvic congestion syndrome include:
  - Chronic pelvic pain OR post-coital discomfort >6 months.
  - Associated symptoms can include the presence of labial varicosities OR heavy menstrual periods.
- Initial imaging is via transvaginal or pelvic ultrasound to exclude other pathologies of chronic pelvic pain
- CT Venogram of the abdomen/pelvis or MRA of the abdomen/pelvis is indicated if initial ultrasound is inconclusive or non-diagnostic.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 149 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

#### References

- 1. Eberhardt RT and Raffetto JD. Chronic Venous Insufficiency. Circulation. 2005; 111: 2398-2409.
- 2. Partsch H, Flour M, Smith PC, et al. Indications for compression therapy in venous and lymphatic disease. Consensus based on experimental data and scientific evidence. *Int Angiol.* 2008;27:193-219.
- 3. Nayak L, Vedantham S. Multifaceted Management of the Postthrombotic Syndrome. *Seminars in Interventional Radiology*. 2012: 29:1.
- 4. Christof T, Kaltenmeier, Erben Y, et al. Systematic review of May-Thurner syndrome with emphasis on gender differences. *J Vasc Surg Venous Lymphat Disord*. 2018;6(3):399-407.
- 5. Rossi FH, Kambara AM, Izukawa NM, et al. Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. *J Vasc Surg Venous Lymphat Disord*. 2018;6(2):183-191.
- Sermsathanasawadi N, Pruekprasert K, Pitaksantayothin W, et al. Prevalence, risk factors, and evaluation of iliocaval obstruction in advanced chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2019 May;7(3):441-447.
- 7. Vedantham S, Kahn SR, Goldhaber SZ, Comerota AJ, et al. Endovascular therapy for advanced postthrombotic syndrome: Proceedings from a multidisciplinary consensus panel. *Vasc Med.* 2016 Aug;21(4):400-7.
- 8. O'Brian M and Gillespie B. Diagnosis and treatment of the pelvic congestion syndrome. Journal of Vascular Surgery. *Venos and Lympathic Disorders*. 2015. 3(1):96-106.
- 9. Brown CL, Rizer M et al. Pelvic Congestion Syndrome: Systematic Review of Treatment Success. Semin Intervent Radiol. 2018 Mar;35(1):35-40.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 150 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Chronic limb swelling due to venous insufficiency/Venous stasis changes/ Varicose veins (PVD-14)

PVD.VI.0014.A v1.0.2024

# Venous Reflux (PVD-14.2)

- Diagnosis is made with a venous valvular insufficiency study (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study) which documents the presence of reflux (>500ms) in the greater saphenous vein as well as the size of the refluxing vein (3-15mm).
- Treatment of superficial venous reflux is amenable to intervention in selected individuals who are symptomatic and have failed conservative therapy. A duplex ultrasound (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study) demonstrating the presence of pathologic reflux within the greater and lesser saphenous veins should be undertaken within the last six months. Vein size should be documented.
- A post-ablation venous ultrasound (CPT<sup>®</sup> 93970 bilateral study or CPT<sup>®</sup> 93971 unilateral study) is indicated within seven days post-procedure. If thrombus is noted within the saphenofemoral junction, repeat imaging can be performed within seven days to assess for propagation into the deep system.
- Ultrasound mapping or monitoring techniques are considered medically necessary only to initially determine the extent and configuration of symptomatic varicosities or valvular insufficiency. Post-procedure assessment by imaging techniques is inappropriate to confirm efficacy or outcome of the procedure.

#### Background and Supporting Information

Venous insufficiency --- General information

- Venous insufficiency is characterized by failure of the venous blood to flow in its normal antegrade path of flow and instead reflux backwards by the force of gravity usually secondary to malfunction of the venous valves.
- Risk factors include previous DVT, obesity, female sex assigned at birth, hereditary, and environmental factors such as prolonged standing on a hard surface.
- Venous insufficiency loosely includes the diagnosis of venous reflux, varicose veins, venous stasis ulcers and spider/reticular veins.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 151 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

#### Venous reflux

- Symptoms of venous reflux include chronic edema, pain, and venous stasis ulcerations. Symptoms of venous reflux can be ameliorated with compression therapy with graded compression stockings, elevation, avoidance of prolonged standing and weight loss. Venous reflux can be seen in both the deep and superficial venous systems. Reflux within the deep system is not amenable to intervention.
- Treatment of deep venous reflux is via active compression with compression stocks, pneumatic pumps or specialized dressings such as Unna boots.
- Treatment of symptomatic superficial venous reflux is via endovenous laser radiofrequency ablation of the greater or lesser saphenous vein resulting in closure of the vein allowing for venous blood to be rerouted to the deep venous system.
- Treatment of symptomatic superficial venous reflux can also be treated via saphenous vein ligation and stripping which has fallen out of favor but can be performed for a tortuous or enlarged (>15mm) greater or lesser saphenous vein. One complication of endovenous ablation is deep venous thrombosis.

#### Varicose Veins

- If the varicosities remain symptomatic despite conservative therapy, varicose veins are treated with sclerotherapy or phlebectomy generally on the basis of size.
- Varicose veins are defined as enlarged, tortuous veins visible under the skin. Symptoms associated with varicose veins include achiness and heaviness of the legs and pain/discomfort over the varicosities. Varicose veins can exist both in the absence and presence of venous reflux.
- Treatment involves conservative therapy such as compression stockings, avoidance of prolonged standing, intermittent elevation, weight loss (if applicable) and exercise which relieves the distention of the varicose veins ameliorating the symptoms.

Spider veins/reticular veins

- Spider veins are formed by the dilation of a cluster of blood vessels within the dermis

   generally <3mm in diameter. Diagnosis is via physical examination. Spider veins
   are usually asymptomatic but can cause aching, burning and tenderness in the area
   overlying the abnormal veins. Spider veins can exist in the absence or presence of
   venous reflux. The presence of spider veins should not be an indication for treatment
   of venous reflux.</li>
- Treatment of spider veins is generally cosmetic except in certain cases and can be treated with sclerotherapy.

### References

 Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. *J Vasc Surg.* 2011;53(5 Suppl):2S-48S. doi:10.1016/j.jvs.2011.01.079.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 152 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

- 2. Wittens C, Davies A, Bækgaard N, et al. Editor's Choice Management of Chronic Venous Disease. *Eur J Vasc Endovasc Surg.* 2015;49(6):678-737. doi:10.1016/j.ejvs.2015.02.007.
- 3. Piazza G. Varicose veins. Circulation. 2014;130(7):582-587. doi:10.1161/CIRCULATIONAHA.113.008331.
- Jones WS, Vemulapalli S, Parikh KS, et al. Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD). Technology Assessment Program. Project ID: DVTT0515. (Prepared by the Duke University Evidence-based Practice Center under Contract No. 290-2015-00004-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2017.
- National Institute for Health and Care Excellence (NICE). Varicose veins in the legs: the diagnosis and management of varicose veins. NICE Clinical Guideline: Methods, evidence and recommendations. London: National Institute for Health and Care Excellence (UK). July, 2013.
- Kahn SR, M'lan CE, Lamping DL, et al. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: results from an international cohort study. *J Vasc Surg.* 2004;39(4):823-828. doi:10.1016/j.jvs.2003.12.007.
- 7. Khilnani NM. Duplex ultrasound evaluation of patients with chronic venous disease of the lower extremities. *AJR Am J Roentgenol*. 2014;202(3):633-642. doi:10.2214/AJR.13.11465.
- 8. King T, Coulomb G, Goldman A, et al. Experience with concomitant ultrasound guided foam sclerotherapy and endovenous laser treatment in chronic venous disorder and its influence on Health Related Quality of Life: interim analysis of more than 1000 consecutive procedures. *International Angiology*. 2009:28 (4):289 -297.
- Lurie F, Kistner RL. Trends in patient reported outcomes of conservative and surgical treatment of primary chronic venous disease contradict current practices. *Annals of Surgery*. 2011 Aug;254(2):363-367. DOI: 10.1097/sla.0b013e31821d4a5f.
- 10. Meissner MH, Moneta G, Burnand K, et al. The hemodynamics and diagnosis of venous disease. *J Vasc Surg.* 2007;46 Suppl S:4S-24S. doi:10.1016/j.jvs.2007.09.043.
- 11. Smith JJ, Garratt AM, Guest M, Greenhalgh RM, Davies AH. Evaluating and improving health-related quality of life in patients with varicose veins. *J Vasc Surg.* 1999;30(4):710-719. doi:10.1016/s0741-5214(99)70110-2.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 153 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Imaging for Hemodialysis Access (PVD-8)

PVD.AI.0008.0.A v1.0.2024

### Arterial Evaluation and Venous Mapping Prior to AV Fistula (PVD-8.1)

- Imaging prior to AV fistula creation:
  - For vessel mapping CPT<sup>®</sup> 93985 or 93986
  - MRA Upper Extremity (CPT<sup>®</sup> 73225) may be needed if duplex imaging is equivocal
- Arterial evaluation to assess arterial suitability (size, degree of stenosis and calcification) prior to AV fistula creation may be indicated
  - CPT<sup>®</sup> 93930 or CPT<sup>®</sup> 93931 can be used to report upper extremity arterial evaluation
- Venous mapping (CPT<sup>®</sup> 93970 or CPT<sup>®</sup> 93971) to assess venous suitability prior to AV fistula creation may be indicated

# Hemodialysis access imaging (PVD-8.2)

- Indications for Duplex ultrasound (CPT<sup>®</sup> 93990) of hemodialysis access include but are not limited to:
  - Individuals with decreased flow rates during hemodialysis.
  - Development of arm swelling or discomfort after access placement surgery or a hemodialysis session.
  - Prolonged immaturity of a surgically created AV fistula.
  - Suspected pseudoaneurysm.
  - Suspected AV fistula or graft stenosis.
  - Known or suspected fluid collection adjacent to an AV fistula or graft.
  - One Duplex US (CPT<sup>®</sup> 93990) can be performed after a surgically created AV fistula for assessment, although it is not generally needed.
- Central venous stenosis can cause new dialysis access to fail to mature or cause the premature failure of existing fistulas/grafts.
- CT Chest with contrast (CPT<sup>®</sup>71260), or CTA Chest (CPT<sup>®</sup> 71275), or MRA Chest (CPT<sup>®</sup>71555) is indicated when there is documentation of either:
  - Signs and symptoms of central venous stenosis including:
    - Arm swelling
    - Presence of numerous collateral veins

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 154 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and F	Radiology Imaging	Guidelines
----------------------	-------------------	------------

- Prolonged bleeding from dialysis puncture sites
- A history of pacemaker placement or previous tunneled dialysis graft, regardless of signs and symptoms.

# **References (PVD-8)**

- Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. *J Vasc Surg.* 2008;48(5). doi:10.1016/j.jvs.2008.08.042.
- Schmidli J, Widmer MK, Basile C, et al. Editor's Choice Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg*. 2018;55(6):757-818. doi:10.1016/j.ejvs.2018.02.001
- 3. Kundu S. Central venous disease in hemodialysis patients: prevalence, etiology and treatment. *Journal of Vascular Access*. 2010;11(1):1-7.

# IVC filters – Treatment (PVD-16.2)

PVD.VI.0016.A v1.0.2024

- IVC filter insertion
  - An initial venous duplex can be performed to assess for the presence of thrombus in the femoral vein which would affect the approach (transjugular or transfermoral)
  - Advanced imaging is not indicated
- CT Abdomen and Pelvis with contrast CPT<sup>®</sup> 74177 for ANY of the following:
  - · A KUB demonstrates tilting of the filter or malposition of one of the filter thongs
  - New bilateral lower extremity swelling (venous duplex should be performed first)
  - Filter present for >12 months, with documentation stating intent to remove

#### Background and Supporting Information

- IVC filters are placed in individuals with known DVT that cannot be anti-coagulated, individuals with poor pulmonary reserve and high risk for DVT, or prophylaxis in trauma and surgical individuals.
- Most IVC filters inserted are retrievable and should be removed as soon as clinically feasible. After 12 months, removal of IVC filters can become technically more difficult.

# References

- Abdul-Haqq R, Almaroof B, Chen BL, Panneton JM, Parent FN. Endovenous Laser Ablation of Great Saphenous Vein and Perforator Veins Improves Venous Stasis Ulcer Healing. *Annals of Vascular Surgery*. 2013;27(7):932-939. doi:10.1016/j.avsg.2012.09.014.
- Ageno W, Haas S, Weitz JI, et al. Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. *Thromb Haemost*. 2019;119(2):319-327. doi:10.1055/s-0038-1676611.
- American College of Phlebology. Duplex Ultrasound Imaging of Lower Extremity Veins in Chronic Venous Disease. American Vein & Lymphatic Society. http://www.phlebology.org/member-resources/publications/ duplex-ultrasound-imaging-lower-extremity-veins-chronic-venous-disease. Published 2012.
- 4. American College of Phlebology. Treatment of Superficial Venous Disease of the Lower Leg Guidelines. American Vein & Lymphatic Society. http://www.phlebology.org/member-resources/publications/treatmentsuperficial-venous-disease-lower-leg-guidelines. Published 2016.
- 5. Biemans AA, Kockaert M, Akkersdijk GP, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. *J Vasc Surg.* 2013;58(3):727-34.e1. doi:10.1016/j.jvs.2012.12.074.
- Brittenden J, Cotton SC, Elders A, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. *Health Technol Assess*. 2015;19(27):1-342. doi:10.3310/hta19270.
- 7. Christof T, Kaltenmeier, Erben Y, et al. Systematic review of May-Thurner syndrome with emphasis on gender differences. *J Vasc Surg Venous Lymphat Disord*. 2018;6(3):399-407.
- 8. Eberhardt RT and Raffetto JD. Chronic Venous Insufficiency. Circulation. 2005; 111: 2398-2409.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 156 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Card	iovascular and Radiology Imaging Guidelines	V2.0.2024
9.	Gloviczki P, Comerota AJ, Dalsing MD, et al. The care of patients with varicose veins and associat venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Forum. <i>J Vasc Surg.</i> 2011. 53(16S):1-47. doi:10.1016/j.jvs.2011.01.079.	ted chronic n Venous
10.	Harlander-Locke M, Lawrence PF, Alktaifi A, Jimenez JC, Rigberg D, Derubertis B. The impact of a of incompetent superficial and perforator veins on ulcer healing rates. <i>J Vasc Surg.</i> 2012;55(2):458 doi:10.1016/j.jvs.2011.08.054.	ablation 3-464.
11.	Healy DA, Kimura S, Power D, et al. A Systematic Review and Meta-analysis of Thrombotic Event Endovenous Thermal Ablation of the Great Saphenous Vein. <i>European Journal of Vascular and Eu</i> <i>Surgery</i> . 2018;56(3):410-424. doi:10.1016/j.ejvs.2018.05.008.	s Following ndovascular
12.	Jacobs CE, Pinzon MM, Orozco J, et al. Deep Venous Thrombosis after Saphenous Endovenous Radiofrequency Ablation: Is it Predictable? <i>Annals of Vascular Surgery</i> . 2014;28(3):679-685. doi:1 j.avsg.2013.08.012.	0.1016/
13.	Jones WS, Vemulapalli S, Parikh KS et al. Treatment Strategies for Patients with Lower Extremity Venous Disease (LECVD. Agency for Healthcare Research and Quality (US); 2017 Apr.	Chronic
14.	Jones WS, Vemulapalli S, Parikh KS, et al. Treatment Strategies for Patients with Lower Extremity Venous Disease (LECVD). Technology Assessment Program. Project ID: DVTT0515. (Prepared b University Evidence-based Practice Center under Contract No. 290-2015-00004-I). Rockville, MD: Healthcare Research and Quality; April 2017.	r Chronic y the Duke Agency for
15.	Kahn SR, M'lan CE, Lamping DL, et al. Relationship between clinical classification of chronic vence and patient-reported quality of life: results from an international cohort study. <i>J Vasc Surg.</i> 2004;39 doi:10.1016/j.jvs.2003.12.007.	ous disease 9(4):823-828.
16.	Khilnani NM. Duplex ultrasound evaluation of patients with chronic venous disease of the lower ex <i>Am J Roentgenol</i> . 2014;202(3):633-642. doi:10.2214/AJR.13.11465.	tremities. AJR
17.	King T, Coulomb G, Goldman A, et al. Experience with concomitant ultrasound guided foam sclerc endovenous laser treatment in chronic venous disorder and its influence on Health Related Quality interim analysis of more than 1000 consecutive procedures. <i>International Angiology</i> . 2009:28 (4):2	otherapy and y of Life: 289 -297.
18.	Lawrence PF, Alktaifi A, Rigberg D, Derubertis B, Gelabert H, Jimenez JC. Endovenous ablation of perforating veins is effective treatment for recalcitrant venous ulcers. <i>J Vasc Surg.</i> 2011;54(3):737-doi:10.1016/j.jvs.2011.02.068.	f incompetent -742.
19.	Lim W, Gal GL, Bates SM, et al. American Society of Hematology 2018 guidelines for managemer venous thromboembolism: diagnosis of venous thromboembolism. <i>Blood Advances</i> . 2018;2(22):3: doi:10.1182/bloodadvances.2018024828.	nt of 226-3256.
20.	Liu N, Wang C, Sun M. Noncontrast three-dimensional magnetic resonance imaging vs lymphosci the evaluation of lymph circulation disorders: A comparative study. <i>J Vasc Surg.</i> 2005;41(1):69-75 j.jvs.2004.11.013.	ntigraphy in . doi:10.1016/
21.	Lurie F, Kistner RL. Trends in patient reported outcomes of conservative and surgical treatment of chronic venous disease contradict current practices. <i>Annals of Surgery</i> . 2011 Aug;254(2):363-367 10.1097/sla.0b013e31821d4a5f.	primary . DOI:
22.	Meissner MH, Moneta G, Burnand K, et al. The hemodynamics and diagnosis of venous disease. 2007;46 Suppl S:4S-24S. doi:10.1016/j.jvs.2007.09.043.	J Vasc Surg.
23.	National Institute for Health and Care Excellence (NICE). Varicose veins in the legs: the diagnosis management of varicose veins. NICE Clinical Guideline: Methods, evidence and recommendation: National Institute for Health and Care Excellence (UK). July, 2013.	and s. London:
24.	Nayak L, Vedantham S. Multifaceted Management of the Postthrombotic Syndrome. Seminars in I Radiology. 2012: 29:1.	nterventional
25.	Partsch H, Flour M, Smith PC, et al. Indications for compression therapy in venous and lymphatic Consensus based on experimental data and scientific evidence. <i>Int Angiol.</i> 2008;27:193-219.	disease.
26.	Piazza G. Varicose veins. Circulation. 2014;130(7):582-587. doi:10.1161/CIRCULATIONAHA.113.	008331.
27.	Poblete H, Elias S. Venous Ulcers: New Options in Treatment: Minimally Invasive Vein Surgery. <i>The American College of Certified Wound Specialists</i> . 2009;1(1):12-19. doi:10.1016/j.jcws.2008.10	ne Journal of .004.
28.	Proebstle TM, Alm BJ, Göckeritz, et al. Five-year results from the prospective European multicente study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. <i>BJS</i> . 212-218. doi:10.1002/bjs.9679.	er cohort 2015; 102:

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 157 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

- 29. Rossi FH, Kambara AM, Izukawa NM, et al. Randomized double-blinded study comparing medical treatment versus iliac vein stenting in chronic venous disease. *J Vasc Surg Venous Lymphat Disord*. 2018;6(2):183-191.
- Sermsathanasawadi N, Pruekprasert K, Pitaksantayothin W, et al. Prevalence, risk factors, and evaluation of iliocaval obstruction in advanced chronic venous insufficiency. *J Vasc Surg Venous Lymphat Disord*. 2019 May;7(3):441-447.
- 31. Smith JJ, Garratt AM, Guest M, Greenhalgh RM, Davies AH. Evaluating and improving health-related quality of life in patients with varicose veins. *J Vasc Surg.* 1999;30(4):710-719. doi:10.1016/s0741-5214(99)70110-2.
- 32. van der Velden SK, Biemans AA, De Maeseneer MG, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. *Br J Surg.* 2015;102(10):1184-1194.
- 33. Vedantham S, Kahn SR, Goldhaber SZ, Comerota AJ, et al. Endovascular therapy for advanced postthrombotic syndrome: Proceedings from a multidisciplinary consensus panel. *Vasc Med.* 2016 Aug;21(4):400-7.
- 34. Washington State Health Care Authority. Selected Treatments for Varicose Veins, A Health Technology Assessment. Prepared by Hayes, Inc. Final Report: April 2017.
- 35. Weiss RA, Weiss MA, Eimpunth S, et al. Comparative Outcomes of Different Endovenous Thermal Ablation Systems on Great and Small Saphenous Vein Insufficiency: Long-Term Results. *Lasers in Surgery and Medicine*. 2015; 47: 156-160. Aortic Disorders General Information.
- 36. Wittens C, Davies A, Bækgaard N, et al. Editor's Choice Management of Chronic Venous Disease. *Eur J Vasc Endovasc Surg.* 2015;49(6):678-737. doi:10.1016/j.ejvs.2015.02.007.
- Wolpert L, Rahmani O, Stein B, et al. Magnetic Resonance Venography in the Diagnosis and Management of May-Thurner syndrome. *Vasc Endovascular Surg.* 2002 Jan-Feb;36(1):51-7. doi:10.1177/153857440203600109.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 158 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Post iliac vein stenting/angioplasty (PVD-17.1)

PVD.VI.0017.A v1.0.2024

Iliac venous stents can be placed after thrombolysis for DVT associated with May-Thurner's syndrome, DVT associated with extrinsic compression or for post thrombotic iliac obstruction.

- Arterial duplex (CPT<sup>®</sup> 93975, 93976, 93978, 93979) can be obtained for:
  - Surveillance of iliac venous stents
  - Worsening signs or symptoms including increased edema when stent malfunction is suspected
  - Postoperatively within the first month, at six months, twelve months and then annually
- CTV or MRV Abdomen and Pelvis can be obtained for an abnormal or indeterminate duplex

### References

- 1. Washington State Health Care Authority. Selected Treatments for Varicose Veins, A Health Technology Assessment. Prepared by Hayes, Inc. Final Report: April 2017.
- Proebstle TM, Alm BJ, Göckeritz, et al. Five-year results from the prospective European multicenter cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. *BJS*. 2015; 102: 212-218. doi:10.1002/bjs.9679.
- 3. Weiss RA, Weiss MA, Eimpunth S, et al. Comparative Outcomes of Different Endovenous Thermal Ablation Systems on Great and Small Saphenous Vein Insufficiency: Long-Term Results. *Lasers in Surgery and Medicine*. 2015; 47: 156-160. Aortic Disorders General Information.
- 4. Brittenden J, Cotton SC, Elders A, et al. Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial. *Health Technol Assess*. 2015;19(27):1-342. doi:10.3310/hta19270.
- Biemans AA, Kockaert M, Akkersdijk GP, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. *J Vasc Surg.* 2013;58(3):727-34.e1. doi:10.1016/ j.jvs.2012.12.074.
- van der Velden SK, Biemans AA, De Maeseneer MG, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. *Br J Surg.* 2015;102(10):1184-1194. doi:10.1002/bjs.9867.
- 7. Rasmussen L, Lawaetz M, Serup J, et al. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy, and surgical stripping for great saphenous varicose veins with 3-year follow-up. *J Vasc Surg Venous Lymphat Disord*. 2013;1(4):349-356. doi:10.1016/j.jvsv.2013.04.008.
- 8. Brittenden J, Cotton SC, Elders A, et al. A randomized trial comparing treatments for varicose veins. *N Engl J Med*. 2014; 371(13): 1218-1227. doi:10.1056/NEJMoa1400781.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 159 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

Cardiovascular and Radiology Imaging Guidelines	V2.0.2024
---	-----------

 Venermo M, Saarinen J, Eskelinen E, et al. Randomized clinical trial comparing surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy for the treatment of great saphenous varicose veins. *Br J Surg.* 2016;103(11):1438-1444. doi:10.1002/bjs.10260.

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 160 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

V2.0.2024

# Policy History and Instructions for Use

#### Guideline

Policy History and Instructions for Use

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 161 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.

# **Policy History and Instructions for Use**

Policy History and Instructions for Use v2.0.2024

#### Instructions for Use

This Medical Policy provides assistance in interpreting United HealthCare Services, Inc. standard benefit plans. When deciding coverage, the federal, state (Ohio Administrative Code [OAC]) or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state (OAC) or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state (OAC) or contractual requirements for benefit plan coverage govern.

Before using this policy, please check the federal, state (OAC) or contractual requirements for benefit plan coverage. United HealthCare Services, Inc. reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

United HealthCare Services, Inc. uses InterQual<sup>®</sup> for the primary medical/surgical criteria, and the American Society of Addiction Medicine (ASAM) for substance use, in administering health benefits. If InterQual<sup>®</sup> does not have applicable criteria, United HealthCare Services, Inc. may also use United HealthCare Services, Inc.'s Medical Policies, Coverage Determination Guidelines, and/or Utilization Review Guidelines that have been approved by the Ohio Department for Medicaid Services. The United HealthCare Services, Inc.'s Medical Policies, Coverage Determination Guidelines, and Utilization Review Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

#### **Policy History/Revision Information**

Date	Summary of Changes
02/01/2024	Annual evidence-based updates
07/01/2024	Interim evidence-based updates

Adult Peripheral Vascular Disease (PVD) Imaging Guidelines (For Ohio Only): CSRAD013OH.C Page 162 of 162 UnitedHealthcare Community Plan Coverage Determination Guideline Effective: November 15, 2024 Proprietary Information of United Healthcare. Copyright© 2024 United Healthcare Services, Inc.